






Retrotransposons in chronic pain: 





Thesis submitted in accordance with the requirements of the 
University of Liverpool for the degree of Doctor in Philosophy  
by 
 







The biggest thank you goes to my PhD supervisors, Prof John Quinn and Dr Jill Bubb. This PhD 
has taught me to have confidence in my own ideas and to be resilient. Your support and 
guidance, both professional and personal, has helped me beyond words and I can’t thank you 
enough. Thanks also go to my supervisor Dr Bernhard Frank for his clinical insight and 
contribution to the project. 
Thank you to everybody who has contributed to my training and provided resources 
to enable the success of this work including; Zsuzsanna Helyes, Eva Szoke, Maja Payrits, 
Angela Kecskes, József Kun, Lynn McLaughlin, Anne McArdle, Sarah Roper, staff at the 
Biomedical Services Unit, Neil Pendleton, Antony Payton, Daniel Carr, Felicity Lumb, Jenny 
Crowe, Margaret Harnett and Paddy Harrison. Thanks also go to others who made this work 
possible and kept us happy in the lab, including technical staff, cleaning staff, building 
managers and of course the staff in Gregg’s. Big thanks also go to all my other previous 
teachers, tutors and mentors, especially Luciane Mello, who played their part in getting me 
here.  
On a personal note, a huge thanks goes to all my colleagues in Quinn lab, past and 
present, but especially my lab family; Kimberley Billingsley, Jack Marshall, Olympia 
Gianfrancesco, Ben Middlehurst, Ana Illera, Ashley Hall and Li Li. I appreciate you all so much 
for the help with experiments, writing up, and emergency trips to the AJ. Jack, you have made 
me smile every single day, helped me through the hardest times and this PhD wouldn’t have 
been as half as fun if it wasn’t for you. Kim, you inspire me all the time and have given me 
the courage to go for it!  And now for my amazing family… To my Nan and Grandad, thanks 
for letting me stay up late and watch forensic science documentaries. Without that, I 
wouldn’t have become obsessed with DNA. To Gran and Grandad, thanks for your constant 
encouragement over the years, I hope I’ve done you proud. And to the rest of my wonderful 
family… Mum, thanks for being my listener of new theories and number one fan! Dad, for 
being my absolute rock. Claire, for the drive you have given me to succeed. And to my sibs; 
Jack, Lara, Megan and Libby – thanks for supporting me always, helping me achieve my goals, 
and keeping me sane.  
Finally, thank you to the Pain Relief Foundation (registered charity number: 1156227) who 











For my Aunty Ness and my Granny Anne, who were and will forever be the most 





Pain has evolved as a protective mechanism to signal danger, threat, injury and inflammation 
to an organism; however, this becomes problematic and detrimental to human physiological 
and psychological wellbeing when it persists without a noxious cause. Preclinical rodent 
models are frequently and successfully used to identify the molecular components of pain 
however novel therapeutics that are developed from these findings often fail to translate 
into human clinical intervention. Recent RNA-seq studies have identified transcriptomic 
differences in the dorsal root ganglia (DRG) of humans and mice that likely contribute to this 
lack of translational research. Transposable elements (TEs) are functional components of 
genomes that contribute to species specific gene expression patterns; therefore, we explored 
the role of TEs in the context of pain gene expression. This work focuses on non-LTR 
retrotransposons as they remain the major active class of autonomous TEs in the human 
genome.  
We first present a proof of principle study using CRISPR that demonstrates the effect 
of a human specific retrotransposon SINE-VNTR-Alu (SVA) insertion as a contributor to 
human specific gene regulation at the locus encoding pain genes TRPV1 and TRPV3. TEs also 
supply a vast source of genetic variation to individual genomes. Chronic pain is difficult to 
manage due to its heterogeneity in underlying cause, severity and response to therapeutics. 
Modern genetic approaches such as genome-wide association studies and candidate gene 
studies often do not identify causal variants responsible for these interpersonal differences. 
Here, we show that the SVA at TRPV1 and TRPV3 has regulatory properties and we further 
demonstrate its polymorphic nature and highlight potential links to pain phenotypes. An 
improved understanding of mechanisms that contribute to the development and 
maintenance of chronic pain are required to address the ever-increasing socio-economic 
burden it creates, which is amplified by the increasing ageing population and a lack of 
effective therapeutics.  
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 Recent work has identified that expression of the retrotransposon LINE-1 (L1) is a 
pathogenic contributor to neurodegenerative disease in the central nervous system and an 
inducer of inflammation in non-pathological ageing. Chronic pain is an age associated 
disorder and is driven by the onset of neuroinflammation in the peripheral nervous system. 
To assess whether L1 expression contributes to this mechanism associated with chronic pain, 
we present another proof of principle experiment in which we demonstrate increased L1 
expression in ageing DRG. Furthermore, we explored L1 expression in response to a novel 
anti-inflammatory drug and found unexpected increases in expression. The data from this 
study implies a strong case for further investigation and a potential role in 
neuroinflammation in the peripheral nervous system.  
To summarise, the work presented in this thesis describes the first studies to 
investigate the role of retrotransposons in several contexts that may contribute to the 
development of chronic pain and modulation of pain phenotype. This provides the basis for 
a wide range of future studies that can further explore the role of retrotransposons in chronic 
pain which could aid our understanding of species differences, age associated molecular 




ADRs  adverse drug reaction 
AGS  Aicardi-Goutières syndrome 
ALS  amyotrophic lateral sclerosis 
ASD  autism spectrum disorder 
CHO  Chinese hamster ovary 
CIP  congenital insensitivity to pain 
CNS  central nervous system 
CRE  cis-regulatory element 
DNMT1  DNA methyltransferase 
DRG  dorsal root ganglia 
ERV  endogenous retrovirus 
ETn  early transposons 
gDNA  genomic DNA 
GWAS  genome wide association study 
HERV  human endogenous retrovirus 
IAP  intracisternal-A particles 
IFN  interferon 
KAP1  KRAB-associated protein 1 
KRAB  Kruppel-associated box 
LCA  last common ancestor 
LD  linkage disequilibrium 
LINE  long interspersed nuclear element 
LTR  long terminal repeat 
L1  long interspersed nuclear element 1 
M1  metabolite O-desmethyltramadol  
MeCP2  methyl CpG binding protein 2 
MELT  mobile element locator tool 
MIR  mammalian interspersed repeat 
MND  motor neuron disease 
MS  multiple sclerosis 
Myrs  million years 
6 
 
NGF  nerve growth factor 
NHEJ  non-homologous end joining 
ORF  open reading frame 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PNS  peripheral nervous system 
RC-seq  retrotransposon capture sequencing 
RIP  retrotransposon insertion polymorphism 
RNP  ribonucleoprotein particle 
SEM  standard error from the mean 
SINE  short interspersed nuclear element 
siRNA  small interfering RNA 
SLE  system lupus erythematosus 
SVA  SINE-VNTR-Alu 
TE  transposable element 
TDP-43   transactive response DNA binding protein 43 kDa 
TFBS  transcription factor binding site 
TG  trigeminal ganglia 
TIR  two inverted tandem repeats 
TNFα  tumour necrosis factor α 
TPRT  target primed reverse transcription  
TRPV1  transient receptor potential vanilloid 1 
TRPV3  transient receptor potential vanilloid 3 
TSD  target site duplication 
TSS  transcriptional start site 
UTR  untranslated region 
UV  ultraviolet 
VAS  visual analogue scale 
VNTR  variable number tandem repeat 
XDP  X-linked dystonia parkinsonism 
YFP   yellow fluorescent protein 
ZFP  zinc finger protein 
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1.1 General introduction 
1.1.1 Thesis overview 
The requirement for a better understanding of chronic pain mechanisms and the 
development of effective and safe therapeutics is rapidly increasing due to an ageing 
population1,2, the large socio-economic burden placed on the workplace/healthcare systems 
and increasing rates of addiction to opioid based medication3,4. Genetic studies have focused 
mainly on protein coding candidate gene studies and genome-wide association studies 
(GWAS)5. This has led to an increase in understanding of pain mechanisms and highlighted 
hundreds of associated genetic variants, however this has also demonstrated the 
heterogeneity of this condition5. Other attempts to identify novel pain targets have used 
RNA-seq based methods in the peripheral nervous system, with a focus on the dorsal root 
ganglia (DRG), which have highlighted species specific gene expression differences6. Due to 
a lack of translational research and heterogeneity of the disease, there has been little success 
in treating chronic pain in the clinic. Therefore, a better understanding of genetic and 
epigenetic factors that contribute to these challenges in required. 
In this thesis, we address the potential role of transposable elements (TEs), 
specifically non-LTR retrotransposon subfamilies SVA and L1 in biological contexts relevant 
to pain. TEs play a fundamental role in shaping and regulating the genomes of individual 
species and provide a large source of genetic variation in the general population7,8. The role 
of TEs is an area of pain research that has not yet been explored. First, we focused on the 
role of a human specific retrotransposon insertion, termed SVA, at the genomic locus 
encoding pain genes TRPV1 and TRPV3. TRPV3 is expressed in DRG of humans but not the 
DRG of mice, highlighting species specific differences in gene regulation at this locus6,9,10. TEs, 
especially those that are lineage specific, can function as drivers of species-specific 
expression patterns; therefore, the SVA insertion was highlighted as a human specific 




insertion and demonstrated its regulatory properties; our results suggest it contributes to 
the species differences in gene expression documented in the literature. We further 
characterised genetic and epigenetic variation encoded within this element and revealed 
associations with pain phenotypes.   
In contrast to their role in pain, the pathogenic role for TE activity in 
neurodegenerative disorders that affect the central nervous system has been established in 
recent years. Increased levels of retrotransposon activity, specifically increased L1 
expression, has been demonstrated in ageing and as a cause of age-associated inflammation. 
An underlying cause of chronic pain is neuroinflammation which can occur in response to 
injury and trauma. Neuroinflammation results in epigenetic changes contributing to central 
and peripheral sensitisation, which causes the transition from acute to chronic pain. 
However, the prevalence of chronic pain is largely associated with increasing age. 
Neuroinflammation is a hallmark of ageing and therefore may be causative of spontaneous 
chronic pain without the requirement of nerve or tissue damage. We suspected that L1 
expression also plays a fundamental role in age associated neuroinflammation in the DRG 






1.1.2 Thesis structure 
This body of work ultimately aims to raise the profile of TEs in the field of chronic pain 
research. The work undertaken in this thesis has explored several key themes (listed below) 
of transposable element biology that may address some of the problems currently facing 
research in chronic pain.  
1. TEs contribute to species specific gene regulation – chapter 3 focuses on the role of 
a human specific SVA insertion at the locus encoding pain genes TRPV1 and TRPV3 
as a candidate regulatory domain to explain species differences in gene regulation.  
2. TEs are polymorphic in the general population – chapter 4 focuses on characterising 
polymorphism within the SVA at the TRPV1 and TRPV3 locus and explores the 
potential utility of SVA polymorphism as a genetic variant associated with pain 
phenotypes.  
3. TEs contribute to tissue specific gene regulation – chapter 4 also focuses on profiling 
the epigenetic status of the SVA at TRPV1 and TRPV3 between individuals, and 
between blood and brain in the same individuals to address variability and potential 
tissue specific function.  
4. TE activity increases during ageing and induces inflammation – chapter 5 focuses 
on profiling L1 mRNA in ageing mouse DRG, as a first look into whether L1 associated 
inflammation present in central nervous system (CNS) neurodegenerative disorders 
may also be a potential mechanism underlying age associated inflammation in the 
peripheral nervous system (PNS). L1 expression was further explored in the brains of 
mice with high fat diet (HFD) induced inflammation to assess if L1 expression could 
be modulated by diet with ageing. L1 expression was also measured in this HFD 
model in response to treatment with a novel anti-inflammatory drug ES-62 to assess 





1.2 Retrotransposons: drivers of ageing and neuroinflammation 
1.2.1 Overview of transposable elements in the human genome 
Transposable elements (TEs), commonly referred to as “jumping genes”, are DNA sequences 
that can transpose (move) to new locations in the genome11. Since the time of their discovery 
in 1956 by Barbara McClintock in maize, DNA sequencing has revealed that an estimated 45% 
of the human genome is derived from TE sequences12,13 (Figure 1.1). This, however, is likely 
to be an underestimation, due to ancient TEs undergoing sequence divergence throughout 
evolution, making them difficult to identify14. It is predicted that the current estimate of TEs 
in the human genome will increase in coming years with improvements to the reference 
human genome and bioinformatic TE detection tools15.  
All TEs in the human genome can be classified based on their mechanism of 
transposition and sequence structure16 (Figure 1.2.). Class I TEs transpose via a copy and 
paste mechanism involving an RNA intermediate (Figure 1.3) and are therefore referred to 
as retrotransposons. One subclass of retrotransposons are the LTR retrotransposons, which 
have acquired their name due to the presence of long terminal repeats (LTRs) at each end of 
their sequence14. LTR retrotransposons constitute approximately 8% of the human genome 
(Figure 1.1). LTR retrotransposons and all other transposon subclasses, can be further divided 
into families. The main family of LTR retrotransposons are human endogenous retroviruses 
(HERVs) (Figure 1.4B). HERVs have integrated into the human genome throughout evolution 
caused by repeated infection of germline cells by exogenous retroviruses17. HERVs (e.g. 
HERV-K) contain sequences for gag (group-specific antigen), pol (polymerase) and env 
(envelope) genes (Figure 1.4B). In modern humans, the majority of HERVs have accumulated 
mutations (which were acquired throughout evolution) and are now unable to replicate 
(transpose), thus are referred to as “fossil viruses”17. HERVs have recently been implicated in 
the pathology of autoimmune and neurodegenerative diseases including multiple sclerosis 




Amyotrophic Lateral Sclerosis; ALS)18. HERV insertional polymorphisms have been identified 
in the human genome, suggesting some may still undergo transposition – however the 
mechanism responsible has not been identified19. Class I TEs also consist of non-LTR 
retrotransposons and include the families; LINE-1, Alu and SVA (Figure 1.2.). Together, non-
LTR retrotransposons account for approximately one third of the human genome (Figure 1.1). 
These elements form the basis of the work presented in this thesis therefore are discussed 
in detail in the next section (1.2.2).  
Class II TEs are DNA transposons that transpose via a cut and paste mechanism 
(Figure 1.3), and include elements such as hAT, MuDR, piggyBAC and Tc1/Mariner elements 
(Figure 1.2.)16. Class II DNA transposons account for only 3% of the human genome (Figure 
1.1) as they no longer actively transpose due to an accumulation of mutations acquired 
throughout evolution that have rendered them inactive, however some examples remain 
active in  other organisms , e.g. the P element in Drosophila20,21. A hallmark of transposition 
is the generation of target site duplications (TSDs) (Figure 1.4), which are generated when 
target site sticky ends (created during transposition) are filled in, generating direct repeats 





Figure 1.1. Transposable element content in the human genome. Transposable elements constitute 
approximately 45% of the human genome. Non LTR-retrotransposons constitute 33.7% including L1s (21%), Alus 






Figure 1.2. Classification of transposable elements in the human genome. Non-LTR retrotransposons including 
L1, Alu and SVA are still actively mobilising in the human genome via a copy and paste mechanism. L1 mobilises 
its own RNA in cis therefore classed as autonomous. Alu and SVA RNA are mobilised in trans via L1 machinery 
therefore classed as nonautonomous. Adapted from Misiak et al16.  
 
 
Figure 1.3. Schematic of type I and type II transposition mechanisms. (Above) Type I copy and paste mechanism. 
The source TE is transcribed into an RNA intermediate, which is then reverse transcribed into cDNA by a reverse 
transcriptase encoded by the TE sequence. The cDNA copy is then integrated back into the genome in a new 
location. (Below) Type II cut and paste mechanism. The source TE is excised from the genome and reintegrated 





Figure 1.4. Structure of transposable elements in the human genome. (A) Example of a DNA transposon Hsmar-
1 (a mariner like element) containing the sequence encoding a transposase, which is flanked by two inverted 
tandem repeats (TIR) and target site duplications (TSD) following transposition. (B) Example of an LTR 
retrotransposon; HERV, encoding gag, pol and env. This is flanked by LTRs and TSD. (C) Examples of non-LTR 
retrotransposons; L1, Alu and SVA. L1 contains a 5’ untranslated region (UTR) which contains an internal 
promoter. It encodes ORF1 and ORF2 followed by a 3’UTR and a poly A tail. This is flanked by TSD. The Alu contains 
two monomers derived from the 7SL RNA gene, separated by an AT-rich sequence. This contains a poly A tail at 
the 3’ end and is flanked by TSD. SVA contains a CT-rich domain at the 5’ end followed by an alu-like region, a 
variable number tandem repeat (VNTR) domain, a SINE-R region and a poly A tail at the 3’ end. This is flanked by 





1.2.2 Active transposable elements: non-LTR retrotransposons 
The large proportion of TEs in the human genome (approximately 45%) is mainly attributed 
to non-LTR retrotransposons (33.7%) (Figure 1.1)14. The non-LTR retrotransposon families; 
L1, Alu and SVA have proliferated and accumulated throughout the past 80 million years of 
primate evolution14. These elements are considered to be the only TEs capable of 
transposition in the human genome.  
1.2.2.1 L1 
Long interspersed nuclear element 1 (LINE-1, often further abbreviated to L1) 
accounts for approximately 21% of the human genome (Figure 1.1)14. A full length L1 element 
is approximately 6 kb in length and consists of a 5’ untranslated region (UTR) which contains 
an internal promoter, two open reading frames named ORF1 and ORF2, a 3’UTR and a poly 
adenylation signal, followed by a poly A tail (Figure 1.4C)22. ORF1 encodes a 40kDa protein 
with RNA binding and nucleic acid chaperone activity. ORF2 encodes a 150kDa protein with 
endonuclease (EN) and reverse transcription (RT) activity. These proteins function as the 
machinery which transposes the mRNA molecule from which they were translated. This is 
referred to as cis-mobilisation.  
L1 mobilisation (Figure 1.5A) occurs via a process called target-primed reverse 
transcription (TPRT) (Figure 1.5B)22. In brief, L1 is transcribed by RNA polymerase II from the 
promoter in the 5’UTR. The mRNA is exported into the cytoplasm were ORF1 and ORF2 are 
then translated by ribosomes. ORF1p, ORF2p and the L1 mRNA then form a 
ribonucleoprotein (RNP) complex (Figure 1.5A). The L1 RNP is then transported back into the 
nucleus where ORF2p (EN) creates a nick on a DNA strand containing the sequence 3’-
AA/TTTT-5’ (Figure 1.5B). This exposes a 3’ hydroxyl group which enables the ORF2p (RT) to 
initiate TPRT from the associated L1 mRNA and reverse transcribe it into the site (Figure 




however the mechanisms behind this are at present unclear (Figure 1.5B). New genomic 
insertions that are mobilised by L1 machinery and TPRT are flanked by short genomic 
sequences called target site duplications (TSDs), which are carried over from the original site 
of the source element (Figure 1.4C).  
L1 are referred to as “autonomous” as they encode the machinery necessary to 
retrotranspose, which is a feature unique to this retrotransposon family. There are over 
500,000 copies of L1 in the genome, however the majority are neither full length or able to 
mobilise further, due to accumulation of mutations acquired throughout evolution, or 
truncations and structural rearrangements that can occur during the mobilisation process. It 
is estimated that there are approximately 80 – 100 full length L1 copies that are capable of 
facilitating mobilisation in the human genome. These are referred to as “hot L1s”23.  
1.2.2.2 Alu 
Alu retrotransposons are primate specific short interspersed nuclear elements 
(SINEs) that account for 11% of the human genome24 (Figure 1.1). Alu elements are 
approximately 280 bp in length and consist of two dimers derived from the 7SL RNA gene, 
which are separated by a short adenine rich region and contain a poly A region at the 3’ end22 
(Figure 1.4C). Within the first monomer is an RNA polymerase III promoter.  
Whilst they do not contribute as much DNA sequence in terms of base pairs as L1, 
they are the most abundant TE in the human genome by copy number (estimated >1 million 
copies)24. These elements do not encode the functional proteins required for mobilisation, 
instead they depend upon association with L1 encoded ORF2 in trans for their reverse 
transcription and reintegration into the genome, therefore are referred to as 





SINE-VNTR-Alu (SVA) retrotransposons are another primate specific non-LTR 
retrotransposon family (like Alu) (Figure 1.2)25. These elements account for only 0.2% of the 
human genome and consist of relatively few copies (estimated 3000), when compared to Alu. 
SVAs are derived from multiple composite sequences (Figure 1.4C). At the 5’ end there is 
typically a (CCCTCT)n hexamer repeat region, an Alu-like region comprised of two Alu 
fragments in the antisense orientation, a central variable number tandem repeat (VNTR, 
typically 30 – 50 bp in length) with a high CG content, a SINE-R region derived from a HERV-
K10 element and poly A tail at the 3’ end26 (Figure 1.4C).  
SVAs do not contain an internal promoter, unlike L1 and Alu, however they are 
transcribed by RNA pol II, likely as a result from nearby promoters in flanking regions and 
transcriptional readthrough25. An average SVA is approximately 2 kb in length but their actual 
length can range from 700 bp to 4 kb. The majority of SVAs are full length (63%) but they can 
be subject to truncations, internal rearrangements and inversions, resulting from the 
mobilisation process. Similar to Alu, SVA do not encode the machinery required for its 
transposition, and are hypothesised to retrotranspose via L1 machinery, therefore are also 
referred to as “nonautonomous”26.  
Interrogation of primate whole genome sequencing data and qPCR validation using 
primate genomic DNA has identified SVA copies in hominoid genomes including; human, 
chimpanzee, gorilla and orangutan25. No copies have been identified in old world primate 
genomes e.g. rhesus macaque. As a result, SVAs are classed as hominoid-specific 
retrotransposons and are thus considered to be the youngest subfamily of TEs currently 
identified in the human genome25. SVAs can be further assigned different subfamilies, based 
on evolutionary age which is calculated by sequence divergence in the Alu-like region25. There 
are currently six recognised SVA subfamilies in the human genome that are designated by 




(10.88 Myrs), SVA D (9.55 Myrs), SVA E, (3.46 Myrs), SVA F (3.18 Myrs)25. There is also an SVA 
F1 subfamily, distinguished by the inclusion of the MAST2 exon 1, which account for 3% of all 
SVAs26. SVA subfamilies A, B and C are conserved with other primates including chimpanzee, 
gorilla, and orangutan. Some SVA D are conserved with chimpanzee only, and some SVA D 
are human specific due to continued mobilisation following divergence with the last common 
ancestor shared with chimpanzee. SVA E and F are human specific as these subfamilies 
emerged after this divergence event15,25. SVA D is the most frequent SVA subfamily in the 
human genome comprising 42.7% of all SVAs, followed by SVA B (15%), SVA F (9.5%), SVA C 
(7.3%), SVA A (5.8%) and SVA E (4.4%). Approximately 15% of SVAs are difficult to designate 





Figure 1.5. Overview of L1 mediated mobilisation and target primed reverse transcription. (A) An overview of 
mobilisation. The L1 source element is transcribed in the nucleus. This mRNA then moves into the cytoplasm 
where it is translated by ribosomes, producing ORF1 and ORF2 proteins. ORF1 and ORF2 associate in cis with the 
mRNA from which is was transcribed, forming a ribonucleoprotein complex (RNP). The RNP shuttles back into the 
nucleus and creates a new L1 copy in a new site using target primed reverse transcription (TPRT). ORF1 and ORF2 
can also associate in trans with mRNA from Alu and SVA, facilitating their mobilisation too. (B) An overview of 
TPRT; ORF2 endonuclease activity creates a nick on the bottom strand at the AT-rich recognition sequence, 
exposing a 3’ hydroxyl residue. The poly A tail of the mRNA associates with the poly T at the recognition sequence. 
ORF2 reverse transcriptase activity then creates a cDNA extending from the poly T, which is used to prime the 
process. Finally, a second nick is created on the upper strand, resulting in a double strand break (DSB) and the 
newly synthesised molecule is integrated into the genome, however the mechanisms underlying this part of the 




1.2.3 A comparison of transposable elements in the mouse genome 
In 2002, Waterston et al. published the first draft of the mouse genome and compared it 
against the human genome8,27. From this analysis, it was observed that the mouse genome 
(2.5 Gb in size) is 14% smaller than the human genome (2.9 Gb in size). When comparing 
genomes at a structural level, it was found that 90% could be aligned into blocks of synteny, 
which highlighted conservation of gene order since humans and mice diverged from the last 
common ancestor (LCA) approximately 65 Mya – 75 Mya27.  When comparing genomes at 
the nucleotide level, only 40% of human DNA sequences could be aligned, highlighting 
sequence divergence between the two species827.  
Waterston et al. further compared the content of transposable elements in both 
human and mouse genomes. TEs constitute approximately 45% of the human genome, yet 
this analysis estimated that TEs constitute approximately 37.5% of the mouse genome27. It 
was predicted that ancestral TEs are more difficult to identify due to base substitutions in the 
DNA sequence. One hypothesis was that mice have a greater nucleotide substitution rate 
compared to humans, perhaps due to increased generation time, and is therefore a possible 
explanation regarding the current difference in identifiable TE content across human and 
mouse genomes. In contrast to this disparity in ancestral TE sequences, 32.4% (812 Mb) of 
the mouse genome and 24.4% (695 Mb) of the human genome were composed of lineage 
specific TE sequences (those that emerged following divergence from the LCA) 827. This 
suggests that transposition is more prolific in the mouse genome than in the human genome.  
TEs within the mouse genome follow the same classification (DNA transposons, LTRs, 
and non-LTR SINEs and LINEs) as shown in Figure 1.2., however different subfamilies do occur 
within each species. A comparison of TE content (based simplistically on classification) in 
human and mouse genomes is shown in Figure 1.6C. There are some similarities between TE 
content and activity between human and mice however there are also some differences. 




the mouse16, (Figure 1.6D). There are an estimated 3000 copies of L1 in the mouse genome 
that are transposition competent, compared to less than 100 “hot L1s” in human28. Humans 
have a greater proportion of the genome attributed to SINEs when compared to the mouse 
(Figure 1.6C) however there are actually more copies of SINEs in the mouse genome than in 
the human genome16 - due to the larger size of SINE elements in the human genome 
compared to SINEs in the mouse genome (based on sequence length in terms of base pairs). 
The only active SINE family in the human genome is the primate specific Alu, however mice 
have four including B1, B2, ID and B4. B1 is similar to Alu as it is derived from the same 7SL 
RNA gene27.  
Unlike non-LTR retrotransposons, LTR retrotransposons in human and mouse 
genomes have a highly dissimilar evolutionary history16,. LTR retrotransposons in the mouse 
genome including intracisternal-A particles (IAP), early transposons (ETn) and ERVs (e.g. 
murine leukemia virus, MuRRS, MuRVY and VL30) are still active and have contributed to a 
near two-fold increase in lineage specific repeats (Figure 1.6D), unlike HERVs in the human 
genome which are considered inactive16,. The overall contributions of each TE subfamily to 
the mouse and human genomes are of relatively equal proportions, highlighting similarities 
in genome TE composition between these two mammalian species.  
Non-LTR retrotransposon insertion sites across mammalian genomes follow a 
common trend27,29.  Analysis of placental mammalian genomes (including human and mouse) 
by Buckley et al. identified an insertion bias of lineage specific non-LTR retrotransposons in 
euchromatic regions and proposed a model that described different effects of purifying 
selection on different sized elements that was shared across species29. For example, LINEs 
are larger elements and therefore carry a larger mutational burden upon insertion, compared 




genome. This results in an accumulation of SINEs in GC rich, gene dense, euchromatic regions 
and accumulation of LINEs in GC poor, gene sparse, heterochromatic regions29.  
 
 
Figure 1.6. Comparison of TE content in human and mouse genomes. Overview of TE content in mouse genome 
and human genome. TEs classified based on Class I LTRs, SINEs and LINEs, or Class II DNA transposons. (A) TE 
content in human genome shown as percentage of DNA sequence. (B) TE content in mouse genome shown as 
percentage of DNA sequence. (C) Contribution of TEs relative to the entire genome sequence. (D) Contribution of 





1.2.4 Impact of retrotransposons on gene regulation 
Non-LTR retrotransposon insertions can result in changes to host gene regulation through a 
variety of mechanisms (Figure 1.7). One mechanism is the insertion of a TE that can introduce 
a novel transcriptional start site (TSS) from the internal promoter encoded within the TE 
(Figure 1.7A). An example of this is demonstrated in the context of the gene NAIP, in which 
a novel transcript is expressed from an upstream Alu, resulting in a novel protein being 
translated30.  
Another mechanism is via the introduction of novel transcription factor binding sites 
(TFBS), which are encoded within the TE sequence(Figure 1.7B). Therefore, TEs can function 
as cis-regulatory elements (CREs) and can up or downregulate gene expression dependent 
upon the proteins bound. This principle was first introduced as the “gene-battery” model by 
Britten and Davidson in 196931. This was revisited in a recent analysis of the human genome 
- in which Sundaram et al. identified >2 million TFBS overlapping with retrotransposons that 
resided within 5 kb of a gene promoter32. TFBS within TEs accounted for 17% of all TFBS 
identified within promoter neighbourhoods, highlighting that TEs provide a large source of 
TFBS in the genome32.  
Whilst insertion of TEs can be tolerated by the genomic neighbourhood and exapted 
as regulatory domains, they can also be deleterious if inserted into an intronic or exonic 
sequence, as they can introduce loss of function mutations, premature stop codons (Figure 
1.7C) and induce alternative splicing (Figure 1.7D). This is evident in the case of Rotor 
syndrome, an autosomal recessive disorder which is characterised by the accumulation of 
bilirubin in the blood33. It is a relatively benign yet rare disease, in which affected individuals 
carry a homozygous L1 insertion in intron 5 of SLCO1B3. This insertion causes aberrant mRNA 




The variable content of TEs in the genomes of different species drives species-specific 
gene expression patterns. One study that compared human and mouse genomes, identified 
using a panel of 26 orthologous transcription factors that 20% of their TFBS were in TEs yet 
less than 2% were conserved between species7. This indicated that TEs supply a large source 
of species specific TFBS7, which may contribute to the rewiring of gene regulatory networks. 
This principle was further validated by Chuong et al. who first showed that inducible gene 
expression changes in response to the proinflammatory cytokine interferon-γ (IFN-γ) differed 
between humans and mice34. This group then performed CRIPSR in HeLa cells, to delete ERVs 
in the human genome that were suspected of being co-opted as CREs for genes that were 
found to be differentially expressed between both species in response to IFN-γ. They found 
that inducible expression of target genes was severely affected in the ERV deleted HeLa cell 
lines, supporting the role of lineage specific TEs as CREs that influence species specific gene 
networks.  Utilising cancer cell lines in vitro, like HeLa, provides an inexpensive route to gain 
insight into certain biological mechanisms, but their use does carry some limitations35. Cancer 
cell lines possess unstable genomic and transcriptomic profiles compared to the original 
tissue from which they were derived, and also non-cancer tissues in vivo36. As a consequence, 
results obtained from in vitro studies utilising cancer cell lines may not necessarily reflect the 
biological processes that would occur in normal tissues. Thus, results obtained from cancer 
cell lines should be interpreted cautiously.  
Ultimately, any heritable mutation event will be subject to natural selection to 
determine its fate. TE insertions that confer an adaptive regulatory function will be selected 
for and more likely become fixed in the population34,37. Conversely, TE insertions that confer 
deleterious regulatory activity will likely be selected against and more likely be purged38. In a 
third scenario, it is also possible that a TE insertion may not confer an immediate adaptive or 
maladaptive effect, i.e. be a neutral insertion, however with time, they may be latently co-




such sequences can acquire mutations that may lead to deleterious activity, resulting in them 





Figure 1.7. Effects of transposable element insertions on cis-gene regulation.  (A) Insertion of a TE upstream of a gene can introduce a novel transcriptional start site (TSS) and generate new 
transcripts. (B) TEs can function as CREs by introducing novel transcription factor binding sites that may consequently upregulate or downregulate gene expression. (C) Insertion of TEs into genic 
sequences can introduce premature stop codons or introduce loss of function mutations. (D) TEs in genic sequences can also affect splicing or undergo exonisation, resulting in novel transcripts. 




1.2.5 Epigenetics modulation of retrotransposon activity and function  
For TEs to be maintained in the genome throughout evolution, equilibrium must be 
struck between expression (and consequent mobilisation) and repression (to protect genome 
integrity). Control of TEs is mediated through epigenetic modifications such as DNA 
methylation and histone modifications38 (Figure 1.7D). This balancing act has resulted in TEs 
(in mammalian genomes) being locked in an evolutionary arms race to evade epigenetic 
silencing mechanisms that suppress their activity.  
One such mechanism involves Kruppel-associated box (KRAB) zinc finger proteins 
(ZFPs) which bind to TEs and recruit KRAB-associated protein 1 (KAP1), also known as 
TRIM28. TRIM28 induces repressive histone modifications and further recruits DNA 
methyltransferases to methylate and silence the DNA39. Accumulation of sequence 
mutations within supressed TEs enable them to escape suppression and continue to mobilise. 
KRAB-ZFPs then rapidly evolve to suppress the new wave of TEs that escaped silencing38. This 
is referred to in evolutionary biology as the Red Queen Hypothesis, which describes the 
nature of antagonistic co-evolution. This hypothesis typically describes adaptation of an 
organism in response to a selective pressure (e.g. predator versus prey) however this theory 
can also be applied to TEs and silencing mechanisms which co-evolve within a genomic 
environment38. Other post transcriptional mechanisms such as Piwi-interacting RNA silencing 
also exist to suppress TEs40.  
 The epigenetic status of TEs can influence nearby gene expression (Figure 1.7D). This 
has been demonstrated in a mouse neural progenitor cell model, in which deletion of TRIM28 
resulted in loss of TE silencing (evident by an induction of ERV expression), and correlated 
with upregulation (average 3-fold) of genes with nearby ERVs (<50kb)41. In addition, 
epigenetic modulation of TEs plays a role in tissue specific gene regulatory networks. Tissues 
have distinct epigenetic signatures which can affect the ability of TEs to bind transcription 




not in others42. Hypomethylated TEs were also enriched with histone marks H3K4Me1, 
indicative of enhancer activity. This was then correlated with increased expression of 
proximal genes functionally relevant to the tissue type42 – highlighting TE function and 
downstream gene regulation may be modulated in a tissue specific manner.  
TE activity can also be modulated in response to stimulus. For example, loss of DNA 
methyltransferase (DNMT1) and enrichment of active chromatin histone marks (e.g. 
H3K4Me3/H3K9ac) at the L1 promoter has been demonstrated in response to 
Benzo(a)pyrene (a carcinogen found in tobacco smoke) in HeLa cells43. A recent study also 
demonstrated that a low level of maternal care received by mouse pups in the first few weeks 
of life, reduced the methylation status of the L1 promoter, increased L1 mRNA expression 
and increased L1 genomic copy number in the hippocampus44. One theory proposes that the 
increase in TE activity in response to stress introduces random genetic variation which can in 
turn undergo natural selection45. These examples highlight the influence of external physical 
and behavioural stimuli on epigenetic modulation of TEs across mammalian genomes, which 





1.2.6 Retrotransposons and genetic variation  
Retrotransposons are a large source of polymorphism within the human genome (Figure 
1.8C).  Retrotransposon insertion polymorphisms (RIPs) refer to specific elements that can 
be present or absent in individual genomes (i.e. not present in all human genomes). All non-
LTR retrotransposons have the capacity to mobilise therefore form the basis of RIPs within 
the human genome. These RIPs can occur in the germline, with an estimated de novo 
insertion rate of 1 in every 150 live human births for L1s, 1 in 20 for Alus and 1 in 1000 for 
SVAs46. It is currently estimated that each person carries 180 L1, 1283 Alu and 56 SVA RIPs8.  
Due to the impact of TEs on gene regulation, RIPs also contribute to the phenotypic 
variation observed between individuals.  For example, individuals carrying an SVA RIP in the 
second intron of the B4GALT1 gene, have reduced B4GALT1 mRNA expression in B-cells, 
highlighting the genetic variation supplied by TEs as important contributors of gene 
regulatory phenotypes47. In addition there are at least 142 documented examples of RIPs 
being responsible for disease, including haemophilia, X-linked dystonia parkinsonism (XDP) 
and neurofibromatosis type 1 – all classed as examples of insertional mutagenesis occurring 
in the germline48.  
RIPs can also occur in somatic cells during embryogenesis49. This generates somatic 
mosaicism within cell populations, or even entire tissues (dependent upon developmental 
stage), of an individual organism that is not heritable.  At present, insertion rates are 
contested, ranging between 0.04 – 80 insertions per neuron49,50.  In the last decade, there 
has been a focus on characterising L1 somatic insertion events in neurons, where they are 
hypothesised to contribute to neuronal plasticity by reshaping the genetic circuitry 
responsible for normal neuronal function49-51. One early study performed qPCR analysis on 
whole tissues and identified an increase in L1 genomic copy number in the adult human brain 
(compared to heart and liver)50. The greatest increase was observed in the hippocampus. 




insertions in the hippocampus and caudate nucleus of three individuals49. This method 
identified thousands of germline L1, SVA and Alu insertions (found in brain and blood, but 
not the reference genome) and identified thousands of putative somatic insertions (found in 
brain, but not blood or the reference genome). Whilst these studies indicated that de novo 
L1 insertions are a source of somatic mosaicism in the brain, they relied on using bulk tissue, 
therefore could not provide any insight into whether these events occurred during or post-
development.  
More recently, single cell sequencing has provided more insight into somatic 
insertions in individual neurones. A study by Evrony et al. sequenced 50 single neurons taken 
from cerebral cortex and caudate nucleus from 3 individuals (300 nuclei in total), versus ‘bulk 
DNA’ taken from whole tissues (cortex, caudate, cerebellum, heart, liver, lung)51. They found 
that 18% of single neurons taken from the brain contained a unique somatic insertion (i.e. 
insertion present in a single neuron and not in others), indicating that L1 mobilisation in the 
brain does occur post-development. The same research effort has not yet been carried out 
in non-neuronal cells, or in brain regions where highest levels of genomic L1 copy number 
have previously been reported (i.e. hippocampus).  
The majority of the literature focusing on TE polymorphism is dominated by RIPs but 
it is not the only manner in which TEs can be polymorphic. Retrotransposon sequence length 
polymorphisms also occur within TEs in the genome, due to their repetitive DNA content 
which is prone to replication slippage52. Several examples of sequence length polymorphisms 
have been documented in SVAs53,54. In addition to sequence variation supplied by TEs, they 
can also be subject to different epigenetic modifications, contributing epialleles to the 
genome which may affect regulated genes differently. An example of this is an LTR IAP 
retrotransposon insertional mutation upstream of the Agouti locus in the mouse55. This 




expression and determines variable coat colour in individuals that are genetically identical at 
the DNA sequence level. Genetic variation supplied by TEs is often overlooked due to 
difficulties mapping RIPs and inner sequence polymorphisms from short read sequencing, 
however improvements in long-read sequencing technologies and bioinformatic RIP 
detection tools such as the Mobile Element Locator Tool (MELT) are progressing this field 
forward56. At present, TE polymorphism (both RIPs and sequence length) represents a large 






Figure 1.8. Contribution of TEs to phenotype. (A) Species specific TE insertions contribute to the rewiring of gene 
regulatory networks. (B) TEs also provide transcription factor binding sites that function in response to different 
transcription factors and epigenetic landscapes present in different cell types, driving the expression of genes in 
a tissue specific manner. (C) TEs contribute to genetic variation by being polymorphic in sequence length and 
generating retrotransposon insertion polymorphisms, which in some instances may affect gene expression and 
potentially contribute to disease. Retrotransposon insertion polymorphisms can also occur during embryogenesis 





1.2.7 LINE-1 activity in ageing, disease and inflammation 
Cellular ageing can be characterised by an accumulation of genomic instability57. The role of 
TEs in the ageing process was first proposed by Driver & McKechnie in 1992, who 
demonstrated an association between somatic transposition of P elements in Drosophila and 
reduced lifespan58. TEs are enriched in heterochromatic domains, yet heterochromatin 
decondenses during ageing, which has been shown to lead to an increase in TE activity59. This 
leads to increased somatic mutagenic insertions and DNA damage, causing genomic 
instability associated with ageing59.  
TE activity also contributes to disease mechanisms that are not simply attributed to 
single TE mutagenic insertions. Increased levels of L1 ORF2p endonuclease causes DNA 
damage, which has been demonstrated in HeLa cells that showed increased numbers of γ-
H2AX foci (markers of DNA double strand breaks) in response to increased levels of 
ORF2p60,61. Therefore it is not surprising that there are numerous reports implicating the loss 
of L1 hypomethylation and increased L1 activity in conditions characterised by genomic 
instability like cancer62-71 and ataxia telangiectasia72.  
Loss of L1 methylation and increased L1 activity is also implicated in multiple 
neurological disorders including; Rett syndrome73, autism74, schizophrenia13,75, Alzheimer’s76 
and major depressive disorder77. The accumulation of DNA damage in the nervous system is 
a major problem with increasing age due to a lack of DNA-replication-dependent repair 
pathways (like homologous recombination) in post-mitotic neurons78, which will be discussed 
in more detail later.  
However, increased TE activity has also been characterised as normal part of chronological 
ageing. Several studies using model organisms like Drosophila melanogaster, Caenorhabditis 
elegans and Saccharomyces cerevisiae have demonstrated that the mechanisms which 




2013, De Cecco  et al. demonstrated in mouse skeletal muscle and liver, and in a mouse 
cellular model of senescence, that L1 mRNA expression increased with age59,84. Further study 
by this group in 2018 demonstrated that the increase in L1 mRNA results in cytoplasmic 
accumulation of L1 cDNA85,86. The cDNA is detected by cGAS, which stimulates STING 
signalling and the induction of type-I interferon (IFN), ultimately causing an inflammatory 
response85,86. This process is thought to resemble exogenous nucleic acids resulting from viral 
infection and has been shown to be at play in human autoimmune conditions like systemic 
lupus erythematosus87,88. L1 activity certainly plays a role in multiple disease contexts 
however the work by De Cecco et al. also highlighted the role of L1 activity in non-
pathological ageing –hypothesised to contribute to sterile inflammation associated with age 
related pathologies – which has been referred to as “inflammageing”.  
Neurological diseases involving neuroinflammation are increasingly being characterised by 
aberrant TE activity and induction of cytokines that mediate inflammatory pathways (Table 
1.1). Most of the research regarding TEs and inflammation in disease is focused on 
neurodegenerative conditions of the central nervous system, for which age is a primary risk 
factor. No efforts to address this mechanism have yet been published in the peripheral 
nervous system or relating to conditions like chronic pain.   
To summarise, from the evidence presented here, there are two models by which 
increased transcription of L1 contributes to age-associated cellular dysfunction (Figure 1.9): 
1. Genomic instability: Mobilisation of L1 resulting in ORF2p endonuclease mediated 
DNA damage and mutagenic insertion 
2. Sterile inflammation: Accumulation of cDNA in cytoplasm, triggering an 





Table 1.1. Diseases characterised by retrotransposon activity and inflammation. Adapted from Saleh et al.89 
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Figure 1.9. Model of L1 activation and consequences. Transcription of L1 and translation of the reverse transcriptase and endonuclease in the cytoplasm generates a ribonucleoprotein particle 
(RNP) containing the reverse transcribed L1 cDNA. This is then transported to the nucleus, where reintegration of the cDNA occurs through target-primed reverse transcription, potentially 
resulting in DNA damage. Accumulation of L1 cDNA in the cytoplasm following L1 activation is detected by cGAS, which initiates cGAS/STING signalling. This induces a type-I interferon response 




1.2.8 Associations between LINE-1 retrotransposons, TDP-43 and neurodegeneration 
TARDBP encodes transactive response DNA binding protein 43 kDa (TDP-43), a 
ubiquitously expressed protein with roles in DNA/RNA binding, gene regulation and mRNA 
regulation90. Several studies have highlighted associations between TDP-43 and regulation of 
TEs. Analysis of RNA-protein interactions and expression datasets in mouse, rat and human 
revealed TDP-43 binds TEs including L191. In addition, transgenic mouse models that 
overexpress TDP-43 and knockdown studies have both shown an increase in L1 transcripts91. 
This indicates that the proper regulation of TDP-43 is crucial for regulation of TEs, however 
the mechanism responsible for dysregulation in both contexts are not completely 
understood.  
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, 
characterised by death of motor neurons and cytoplasmic inclusions90. In ALS, lack of nuclear 
TDP-43 and cytoplasmic aggregates are present in over 97% of cases therefore a lot of current 
research explores the relationship between TDP-43 and L1 within this disease context90. 
Overexpression of hTDP-43 in a D. melanogaster model of ALS revealed impairment of small 
interfering RNA (siRNA) silencing mechanisms against TEs, resulting in an increase of L1 
transcripts92. Study of human brain cells with and without nuclear TDP-43 further revealed 
loss of nuclear TDP-43 was associated with chromatin decondensation across L1 loci, 
increased L1 mobilisation and overall transcriptome deregulation93. Multiple studies across 
several transgenic models (C. elegans, D. melanogaster and mouse) overexpressing human 
TDP-43 mRNA documented neurotoxic effects including reduced cell viability, neuron loss 
and mitochondrial dysfunction94-102.  Drosophila and mouse models of ageing (non-ALS) have 
both shown that TDP-43 protein and mRNA levels decrease with age103,104, which is 
interesting as the previous work discussed by De Cecco et al. described an increase of L1 
mRNA. It is not yet known if these two trends are biologically linked in ageing or in the 




1.3 Challenges in chronic pain research 
1.3.1 Chronic pain: a socio-economic burden 
Chronic pain is defined as persistent pain that occurs for a minimum of 12 weeks and can 
manifest from musculoskeletal pain, neuropathic pain, inflammatory pain and visceral pain5. 
Pain has evolved as a mechanism to protect an organism from noxious (harmful) stimuli in 
order to prevent injury and ensure survival (for e.g. individuals with congenital insensitivity 
to pain often have injuries that go unnoticed105), however this physiological response 
becomes problematic when it persists in the absence of harmful stimuli106.  
Pain is initiated when receptors that detect noxious stimuli are activated in sensory 
neurons (nociceptors). The cell bodies of sensory neurons are located in structures called the 
dorsal root ganglia (DRG) in the body and trigeminal ganglia (TG) in the head107. DRG and TG 
also contain glial cells, immune cells and blood vessels107. Nociceptors project into the skin 
and peripheral tissues to detect thermal, mechanical and inflammatory signals that indicate 
potential dangers and/or injury. When nociceptors are stimulated, they initiate an action 
potential along the neuron, which is then relayed to the central nervous system via the 
DRG107.  
 In the UK and USA, it is estimated that chronic pain affects between one-third and 
one-half of the population1,2. The occurrence of chronic pain causes the individual significant 
physiological and psychological distress, with depression often occurring as a comorbid 
condition108. The cost of healthcare expenses and loss of productivity attributed to pain is 
estimated to cost the US economy at least $560 billion each year3. The prevalence of chronic 
pain is associated with ageing therefore this burden is predicted to grow with an ever 
increasing ageing population1.  
Research conducted over the past few decades has revealed many of the 




by current therapeutics, which relies heavily on administration of opioids, and often leads to 
severe side effects and addiction. In 2018, it was estimated that 3% of the population in the 
US misused opioids4. As a result of this, the USA is currently in the midst of an opioid epidemic 
which has led to a drastic increase in the number of opioid based deaths from the use of 
illegal substances like heroin and heroin analogues like fentanyl4. This has resulted in the 
need for accelerated research, which will give further insight into mechanisms underlying 
pain and improve current management, with the National Institutes of Health launching the 





1.3.2 The genetics of chronic pain 
Systematic review of twin studies has estimated the heritability of chronic pain to be 16–
50%, indicating a strong genetic component109,110. Several monogenic pain disorders have 
been identified, a well-known example being a nonsynonymous mutation in the gene SCN9A, 
which encodes the Nav1.7 channel, and causes congenital insensitivity to pain (CIP)105. 
However, in general, chronic pain is a heterogeneous and complex disease, with variability 
between phenotypes including pain severity and response to therapeutics111.  
Extensive use of transgenic and knockout mouse models has identified 430 genes 
associated with pain (at the time of writing). These are published in the Pain Genes Database, 
curated by the Mogil lab101. Profiling genetic variants from hypothesis driven candidate gene 
studies in human cohorts has identified 846 common variant SNPs (found in >1% of the 
population) associated with pain (at the time of writing)112,113. These results are published in 
the Human Pain Genetics Database, curated by the Diatchenko lab. These databases 
demonstrate the large efforts made in pain biology and have been paramount in identifying 
the molecular components that constitute pain pathways. However, our understanding of 
pain is far from complete and the treatment of pain remains problematic.  
Genome wide association studies (GWAS) enable identification of common SNPs in 
association with phenotypes using an unbiased, non-hypothesis driven approach. Migraine 
is the most successful pain condition for which GWAS has been applied; four GWAS and four 
meta-analyses GWAS have been conducted to date114-120. Chronic pain GWAS has not been 
as successful, with only a few studies currently published that that focus on specific subsets 
of chronic pain phenotypes including; chronic widespread pain121, diabetic neuropathic 
pain122, multisite chronic pain123 and fibromyalgia124. Chronic pain is a difficult condition to 
apply the concept of GWAS to, due to its heterogeneity and difficulties in consistent pain 
reporting. An emerging trend is now beginning to view chronic pain as an umbrella term for 




system125. Going forwards, an alternative approach to chronic pain genetics may be needed, 
as the likelihood of obtaining a homogenous cohort to yield biologically relevant results from 





1.3.3 From bench to bedside: are current pain models appropriate?  
The use of rodent models in pain research has been essential in reaching our current level of 
understanding of pain mechanisms, however one limitation has been the failure of analgesic 
development in the last two decades. The latest review of therapeutics that have failed at 
clinical trial phase II revealed that 48% of failure was attributed to poor efficacy, followed by 
25% of trials failing due to safety issues126. This review included therapeutics across multiple 
disease areas (e.g. CNS, cancer, cardiovascular) and there is widespread debate regarding the 
translatability of preclinical research into effective therapeutics across human disease, 
including pain127. Several therapeutics for pain which have failed at phase II over the last two 
decades are listed in Table 1.2.  
A recurrent question in pain research is how representative are rodent models of 
human pain? In addition to genetic studies, other attempts to identify relevant clinical targets 
has been through the use of RNA-seq (Table 1.3Tab). This strategy aims to discover aberrantly 
expressed mRNA in association with disease or specific gene expression profiles in relevant 
pain tissues, however most studies have been conducted within a single species (i.e human 
or rodent), therefore species similarities and differences are frequently ignored.  
In an attempt to assess the appropriateness of mouse DRG as a model for human 
pain, Ray et al. compared the expression profiles of DRG in human and mice6. They described 
a subset of orthologous genes that were enriched in DRG, of which 63.8% of genes showed 
conserved expression patterns between the two species (R>0.68). This indicated that a large 
subset of genes specific to DRG function are conserved (many of them being core 
transcription factors), however there was also a large proportion of genes that showed 
species specific expression in DRG. Species specific expression patterns in DRG may therefore 
contribute to some of the difficulties facing chronic pain therapeutic development – which 




 Table 1.2. Pain therapeutics that failed at clinical trial phase II between 2001 - 2020.  
Therapeutic target Trial group Name Reason for failure Year Reference 
NMDA antagonist Post-surgical pain Amantadine Efficacy 2001 128 
Glycine antagonist Neuropathic pain GV196771 Efficacy and safety (adverse reactions) 2002 129 
Na
+
 channel blocker Neuropathic pain 4030W92 Efficacy 2002 130 
NMDA antagonist and morphine Chronic pain MorphiDex Efficacy 2005 131 
TRPV1 antagonist Post-surgical pain AMG 517 Safety (hyperthemia) 2008 132 
COX-2 inhibitor Neuropathic pain GW406381 Efficacy 2009 133 
Cannabinoid agonist Post-surgical pain GW842166 Efficacy 2011 134 
5-HT-3 antagonist Neuropathic pain Ondansetron Efficacy 2011 135 
Chemokine antagonist Posttraumatic neuralgia AZD2423 Efficacy 2013 136 






Table 1.3. RNA-seq studies conducted to identify novel pain targets.    
Tissue Disease Species Reference 
Knee synovial tissue Osteoarthritis Human 138 
Prefrontal cortex Peripheral nerve injury Mouse 139 
DRG Neuropathic pain Human 140 
DRG Diabetic neuropathy Rat 141 
DRG 
Peripheral nerve 



















n/a Human 144 
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1.3.4 Hot topic: targeting temperature receptors TRPV1 and TRPV3 
TRPV1 encodes transient receptor potential vanilloid 1, a voltage-gated ion channel that is 
activated by multiple physiological stimuli therefore considered to be polymodal signal 
mediator. TRPV1 is activated by noxious heat145 (>42°c), voltage146, ATP147, capsaicin148, 
endocannabinoids149 and other compounds. Interestingly, capsaicin is a compound found in 
chilli peppers, which is why it feels “hot” when we eat them. It is a key player in detection of 
nociceptive stimuli and pain signalling150-152. It is important to note that there are many 
receptors expressed in sensory neurons, that detect different types of noxious stimuli such 
as chemical153 and mechanical154, yet the work in this thesis focuses exclusively on thermal 
receptors TRPV1 and TRPV3.  
In the human genome, TRPV1 is encoded at a locus on chromosome 17 (chr17p13.2), 
adjacent to the gene TRPV3 which encodes transient receptor potential vanilloid 3. TRPV3 is 
activated by innocuous temperatures (>32°c)155, organic compounds including camphor156, 
2-ABP157 and calcium158. The genomic organisation of TRPV1 and TRPV3 in the human 
genome is conserved in the mouse genome in a syntenic block on chromosome 11 (Figure 
1.10).  
TRPV1 and TRPV3 are key nociceptive receptors159. However, they do not act in 
isolation and function as components of a complex molecular environment that contributes 
to pain signalling. Peripheral and central sensitisation that leads to chronic pain often results 
from inflammation-associated changes in the environment surrounding the nerve terminal, 
that typically occur due to tissue damage160. Following tissue damage, activated nociceptors, 
non-neuronal cells (keratinocytes, fibroblasts and endothelial cells) and immune cells 
(macrophages, neutrophils and mast cells) release a wide range of endogenous factors that 
accumulate around the peripheral nerve terminal161. These factors consist of a wide range of 
signalling molecules including cytokines, chemokines, proteases, protons, neutrophins, 




prostaglandins), peptides (substance P, CGRP, bradykinin) and neurotransmitters161. 
Nociceptor neurons express receptors like TRPV1 and TRPV3, that can be activated by these 
endogenous factors, which in turn heightens the excitability of the nerve fibre and increases 
sensitivity to temperature161,162.   
In the context of TRPV1, the channel itself can be modulated directly via protons and 
lipids, or conversely, other factors such as bradykinin, ATP and NGF bind to other receptors 
which results in downstream intracellular signalling pathways which in turn leads to 
modulation of TRPV1161,162. For example, NGF binds TrkA, which triggers downstream 
signalling pathways including PI3K-Src and ultimately phosphorylation of TRPV1, which 
lowers its activation threshold162. Activation of nociceptors results in the release of glutamate 
at the nociceptors central terminal which generates excitatory-post synaptic currents in the 
second order neurons in the dorsal horn161. In the case of injury, nociceptors also release 
increased levels of neurotransmitters, including substance P, which results in depolarisation 
of post-synaptic neurons and transmission of the pain signal to the brain161. 
Changes in expression of both TRPV1 and TRPV3 are associated with pain. TRPV1 
expression is increased in injured DRGs in mouse models163 and in several human pain related 
conditions including irritable bowel syndrome164, chronic pancreatitis165 and vulvodynia166. 
TRPV1 and TRPV3 mRNA and protein expression also increases in human peripheral nerves 
and DRG after injury167, and in keratinocytes of women with breast pain168. Activation of 
TRPV1 in keratinocytes has been demonstrated to activate nociception in mice169. It is 
hypothesised that keratinocytes release molecules upon activation of TRPV1 which 
subsequently activate sensory neuron terminals in a paracrine fashion, however the direct 
mechanism responsible for this is yet to be elucidated169. The role of a keratinocyte is not 
specifically to detect noxious stimuli however they are juxtaposed to sensory neurons in the 




pain signalling. TRPV1 mRNA expression is elevated in blood of patients with chronic pain170. 
TRPV3 expression is elevated in the skin of burn scars171. The mechanisms leading to 
increased TRPV1 and TRPV3 mRNA expression in these conditions are not currently well 
understood. Mice lacking TRPV3 also have impaired thermosensory function in response to 
noxious and innocuous heat (30–42°C)172. This was measured based on behavioural changes 
in TRPV3 knockout mice compared to wild type mice, in which wildtype mice showed a 
preference to occupy warmer surfaces (35°C) compared to knockout mice.  
TRPV3 has the highest expression level in human and mouse keratinocytes. TRPV3 
stimulation in keratinocytes (from environmental/inflammatory stimuli) induces ATP release 
which results in calcium influx in DRG neurons, thereby playing a role in nociceptive function 
in the skin of both species173. However, expression of TRPV3 between species is not 
conserved. TRPV3 has only been documented in mouse keratinocytes152,174 yet is expressed 
in a variety of tissues in human, including; brain, placenta, skin, small intestine, spinal cord, 
stomach, testes, trachea and DRG9,10. This was further validated in the RNA-seq study 
published by Ray et al., who identified TRPV1 mRNA expression as strongly conserved 
between human and mouse DRG but not TRPV36. These data indicated that the transcription 
of TRPV3 is differentially regulated between human and mice, suggesting potential species-
specific CREs at the TRPV1 and TRPV3 locus. 
Effective therapeutics targeting these channels are limited in the clinic. Capsaicin, 
applied topically, acts as an agonist of TRPV1 inducing desensitisation and is routinely used 
for treating neuropathic pain associated with arthritis175 and diabetes176. TRPV1 antagonists 
that have struggled to make it into the clinic are include AMG517, A-1165901 and AMG7905. 
AMG517 failed at clinical trial phase II due the side effect of hyperthermia in human 
subjects123. A-1165901 and AMG7905 failed in rodent models due to hypothermia132,177. 




TRPV3, named GRC15300 (originally developed by Glenmark), reached clinical trials for the 
treatment of pain in 2012, but this was discontinued by Sanofi following its phase II failure in 
2013 (the results of this trial have not been published). No other clinical trials targeting TRPV3 
have since been reported. Current research is failing to deliver safe effective therapeutics 
targeting these channels therefore it is important to better understand their transcriptional 






Figure 1.10. Synteny between human and mice TRPV1 and TRPV3 loci. A screenshot from UCSC browser (hg38) showing the organisation of genes in a syntenic block in the human genome on 
chromosome 17 (above) and mouse genome on chromosome 11 (below). The block runs from right to left in the human genome and left to right in the mouse genome. Gene transcripts are 




1.3.5 Epigenetics and neuroinflammation in the development of chronic pain 
An underlying cause of chronic pain is attributed to neuroinflammation resulting from tissue 
or nerve injury. There are multiple contributors to the activation of neuroinflammation in 
addition to trauma including age178, underlying autoimmune or inflammatory conditions like 
multiple sclerosis or osteoarthritis179,180, or even external triggers such as stress181, diet182,183 
and drug treatments184 (e.g. chemotherapy). Neuroinflammation drives the transition from 
acute to chronic pain by the process of peripheral and central sensitisation (increased 
sensitivity to stimuli)185. An example of peripheral sensitisation can be demonstrated with 
TRPV1 and response to the proinflammatory cytokine tumour necrosis factor-α (TNFα). In rat 
DRG neurons, p38 MAP kinase activates TRPV1 in response to TNFα186. This also increases 
TRPV1 mRNA levels, resulting in more TRPV1 channels in the peripheral terminal of 
nociceptors, which maintains thermal hypersensitivity187.  
Epigenetic modification in response to neuroinflammation is an underlying 
mechanism behind sensitisation188,189. This can occur in the DRG (peripheral sensitisation) or 
in pain-associated brain regions (central sensitisation) but as the work in this thesis is focused 
on the peripheral nervous system, we will present some examples from rodent models that 
occur in DRG. Rodent nerve injury models have demonstrated changes in histone 
modifications and DNA hypomethylation in DRG190-192. The increase of DNA (cytosine-5)-
methyltransferase 3A (DNMT3a) and methyl CpG binding protein 2 (MeCP2) has also been 
observed in rat DRG in response to nerve injury193,194. These examples demonstrate DNA 
methylation changes in response to neuroinflammation induced by peripheral nerve injury. 
In the case of pain gene TRPV1, chronic stress has been shown to induce histone 
acetylation at the TRPV1 promoter in mice DRG, resulting in increased mRNA expression195. 
Furthermore, knockout of HDAC4 (a histone deacetylase) in the mouse reduced TRPV1 




sensitivity, implicating the role of epigenetic modulation in transcriptional responses that 
initiate pain196.  
A large number of studies describing epigenetic changes in the DRG and their 
contribution to pain phenotypes have been reviewed extensively197 however many of the 
studies use rodent model of nerve injury. Expression of inflammatory genes also increases 
with ageing in the DRG however little is known the epigenetic mechanisms that contribute 
to this198. One study in humans estimated the epigenetic age of humans (from profiling the 
methylation status at genomic sites in blood, a technique termed Horvath’s epigenetic clock) 
and identified that an increased epigenetic age was more associated with chronic pain199, yet 
this area, specifically in the DRG, requires more attention.   
As discussed in the previous section “”L1 activity in disease, ageing and 
neuroinflammation” (section 1.2.7), epigenetic changes are well documented in other age-
related diseases like cancer and neurodegenerative conditions in the CNS. These diseases 
share a common biological theme – the activation of the TE family L1 and the occurrence of 
neuroinflammation. The recent work demonstrating the accumulation of cytoplasmic L1 
cDNA and induction of an inflammatory response in ageing tissues in the absence of cancer 
or neurodegenerative highlights their role as a driver of sterile inflammation, which is a 
hallmark of ageing and plays a role in many age-related pathologies. To the best of our 
knowledge, no study of retrotransposons in the peripheral nervous system (specifically the 
DRG) has yet been published, highlighting an unexplored area of research which could yield 













2.1.1 Cloning materials 
2.1.1.1 LB broth and agar 
LB broth and agar was required for use as growth medium and was prepared accordingly. LB 
broth was prepared using 25 g/L in distilled water. LB agar was prepared using 40 g/L in 
distilled water. All LB reagents from Fluka Analytical. Preparations autoclaved before use.  
2.1.1.2 Agar plates for bacterial growth 
Following transformation, bacteria were plated for growth on agar plates containing an 
antibiotic. This selected for bacteria that were transformed with a vector containing an 
antibiotic resistance gene. To make antibiotic containing agar plates, LB agar was heated in 
the microwave until melted. Once cooled, yet still liquid, 400 µl of ampicillin solution was 
added to the 400 ml LB agar. To prepare the ampicillin solution, Ampicillin sodium salt (Sigma, 
A0166) was dissolved in nuclease free water at a concentration of 1000 µg ml-1 and filter 
sterilised. 
2.1.1.3 Bacterial cell freezing media 
Bacterial cultures containing relevant plasmids were frozen down at -80 °C in LB broth 





2.1.2 Human cell lines and culture materials 
2.1.2.1 Culture media reagents 
Table 2.1. List of commonly used reagents in cell culture. 
Reagent Supplier (catalogue number) Cat. no. 
PBS pH 7.2 (1x) Gibco 20012-019 
Sodium pyruvate solution 100 mM Sigma S8636 
Fetal Bovine Serum, heat inactivated Gibco  10500-064 
Trypsin-EDTA solution Sigma  T3924 
Penicillin-Streptomycin solution Sigma  P0781 
L-glutamine 200 mM Gibco  25030081 
DMSO Sigma  PHR1309 
2.1.2.2 HAP1 cells and growth media 
HAP1 is a near haploid cell line, derived from male chronic myeloid leukemia cell line KBM-7 
by Horizon (catalogue no. C631). Further information is available at 
https://horizondiscovery.com/products/gene-editing/cell-line-models/PIFs/HAP1-parental-
cell-lines.  Culture medium was composed of Iscove’s Modified Dulbecco’s Medium (IMDM) 
(1X) (Gibco, 12440-053) supplemented with 10% FBS, 1% penicillin-streptomycin and 1% L-
glutamine. 
2.1.2.3 SH-SY5Y cells and growth media 
SH-SY5Y (ATCC® CRL-2266™) is a cell line derived from the neuroblastoma SK-N-AS, originally 
derived from a metastatic bone tumour. Culture media was a 1:1 ratio of Minimum Essential 
Medium Eagle (MEME) (Sigma, M2279) and Nutrient Mixture F-12 Ham (Sigma, N4888), 
supplemented with 10% FBS, 1% penicillin-streptomycin, 1% sodium pyruvate and 1% L-
glutamine.  
2.1.2.4 HEK293 cells and growth media 
HEK293 (ATCC® CRL-1573™) is a hypotriploid human cell line derived from human embryonic 
kidney cells. Culture media was made from Dulbecco’s Modified Eagle Medium (DMEM) 
containing 4.5 g/L D-Glucose and L-glutamine, supplemented with 10% FBS, 1% penicillin-




2.1.3 Murine DRG purification and primary cell culture materials 
2.1.3.1 Commonly used solutions and materials  
Table 2.2. Materials used for DRG dissociation and primary cell culture. 
Item Supplier  Cat. no. 
Hank’s Buffered Saline Solution Gibco 14175095 
HEPES (1M) Gibco 15630080 
Neurobasal™-A Medium Gibco 10888022 
Penicillin-Streptomycin (10,000 U/mL) Gibco 15140122 
L-Glutamine (200 mM) Gibco 25030081 
B-27™ Supplement (50X), serum free Gibco 17504044 
Fetal Bovine Serum, certified, heat inactivated Gibco 10082139 
Poly-L-lysine solution Sigma P4707 
Collagenase, Type 2 Worthington LS004176 
Glass Pasteur pipette Appleton Woods RC022 
BD Microlance™ Stainless Steel Needle 0.29mm Fisher Scientific 10442014 
Falcon™ Cell Strainer Fisher Scientific 10282631 
2.1.3.2 Fire polishing glass Pasteur pipettes 
In order to dissociate the DRG into single cells, they were passed through a glass Pasteur 
pipette with a modified pore diameter to achieve complete dissociation. An unmodified 
pipette was also required. These were autoclaved before use. The pore was modified as 
follows: 
1. Insert a 0.29mm needle into the Pasteur pipette pore. 
2. Hold this over a flame to shrink the Pasteur pipette pore around the needle. 
3. Allow to cool and remove the needle.  
2.1.3.3 Preparing DRG cell culture plates 
To aid the attachment of cells to culture plates, glass cover slips were placed at the bottom 
of each well and coated with poly-L-lysine. Once coated, plates were incubated overnight at 
37 °C and stored at 4 °C prior to use. Plates were washed with PBS and air dried before plating 





2.1.3.4 DRG dissociation solution 
DRG harvested from mice were placed in a dissociation solution and kept on ice prior to 
culture preparation. This was to preserve DRG during the lengthy harvesting protocol and 
during transport from the Biomedical Services Unit to the laboratory where culture 
preparation took place. Dissociation solution was prepared as follows: 
1. Remove 8.5 ml of Hank’s Buffered Saline Solution (HBSS) from 500 ml bottle. 
2. Add 3.5 ml HEPES to HBSS. 
3. Add 5ml Penicillin/Streptomycin. 
2.1.3.5 DRG collagenase solution 
Collagenase solution was used to break down the structure of the DRG and allow plating of 
single cells. This was prepared fresh during each dissociation, as follows: 
1. Aliquot 1 ml of dissociation solution into an Eppendorf tube. 
2. Dissolve 10 mg of collagenase powder in dissociation solution by incubating at 
37 °C for 10 mins. 
2.1.3.6 DRG primary cell culture growth medium 
DRG culture medium was used to maintain the primary cell culture for up to one month after 
plating. The media was prepared as follows: 
1. Add 38.6 ml of Neurobasal™-A Medium (supplemented with 10% FBS) to 50 ml falcon  
2. Add 200 µl L-glutamine 
3. Add 800 µl B-27 supplement  
4. Add 400 µl Penicillin/Streptomycin solution 





2.1.4 Mouse strains 
2.1.4.1 Thy1-YFP mice used for DRG samples 
Male and female Thy1-YFP mice200 (Jackson Laboratories) (JAX stock #003709) of various ages 
were housed at the Biomedical Services Unit at the University of Liverpool. Both male and 
female mice were included as increasing evidence supports sex-specific differences in dorsal 
root ganglia pain models201. These transgenic mice are bred from the C57BL/6 strain and 
express yellow fluorescent protein in sensory neurons. Mice were kept between 22-25 °C and 
subject to a 12-hour light/dark cycle. Mice were fed a standard laboratory diet (SDS, 801722). 
Food and water were ad libitum. No procedures were performed on these animals (therefore 
no Home Office license was required) however their use was in accordance with the UK 
Animals (Scientific Procedures) Act 1986 and were ethically approved by the University’s 
Animal Welfare Committee. Mice were culled using cervical dislocation.  
2.1.4.2 C57BL/6 mice used for brain samples 
Male and female C57BL/6 mice (Enivgo) were housed at the Central Research Facility at the 
University of Glasgow. Mice were kept at 22 °C and subject to a 12-hour light/dark cycle. 
Mice were fed a normal chow diet until 10 weeks of age, then either continued on a normal 
chow diet or switched to a high fat diet (Table 2.3). From 9 weeks of age, mice undergoing 
treatment trials were given either PBS or 1 µg of ES-62 via subcutaneous injection. ES-62 was 
purified from spent culture medium used for growth of the filarial nematode 
Acanthoceilonema viteae, as previously described in McInnes et al.202. Mice received 
Fenbendazole (150 ppm) used as an anthelminthic to control pinworm. Mice were fasted 
overnight prior to culling.  Mice were culled using cervical dislocation at 56 days (8 weeks) or 
500 days (71 weeks). All animal handling was conducted by Felicity Lumb and Jennifer Crowe 
at the Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. 
All procedures were undertaken under a UK Home Office Project Licence and in accordance 




Table 2.3. Dietary components for C57BL/6 mice. 
Component 
Chow High fat 
Proportion (%) Atwater fuel energy (%) Proportion (%) Atwater fuel energy (%) 
Fat 3.36 9.08 21.4 42 
Protein 18.35 22.03 17.5 15 
Fibre 4.23 n/a 3.5 n/a 






2.1.5 Human DNA samples 
2.1.5.1 Samples used for assay optimisation 
Genomic DNA from healthy members of the general population (all of German/European 
descent) were provided by Prof. Dan Rujescu at the Department of Psychiatry at the Martin 
Luther University Halle-Wittenberg, Germany. The average age of individuals was 46 years. 
Healthy controls were screened for psychiatric disorders and had medical records reviewed, 
including those of first-degree relatives, to rule out health issues. All individuals provided 
written informed consent and the study was approved by the ethics committee of Ludwig 
Maximilians University in Munich, Germany.  
2.1.5.2 Osteoporosis cohort used for genotyping study 
Genomic DNA from patients with osteoporosis and being treated for bone pain was provided 
by Daniel Carr at the Department of Molecular and Cellular Pharmacology, University of 
Liverpool, UK. Patients were recruited from the Royal Liverpool University Hospital, UK. DNA 
was purified from blood using the Chemagic™ Magnetic Separation Module I (Chemagen). 
This cohort contained both males and females, from ages ranging 44 – 91 years. Patients 
were split into 2 groups: (A) currently undergoing treatment with tramadol and (B) previously 
experienced adverse drug reactions (ADRs) to tramadol. Patients in group A were prescribed 
50 mg – 400 mg tramadol per day (in divided doses). Patients in group A were assessed for 
degree of pain intensity using the Visual Analogue Scale (VAS) ranging from 1 – 10, the McGill 
Pain Questionnaire (MPQ) and Medical Outcomes Study (MOS) SF-36. Pain scores from the 
visual analogue scale were taken prior to drug administration and three hours afterwards, 
upon which the difference was calculated. All patients were monitored for ADRs All patients 
gave written informed consent. This study was approved by the Liverpool Local Research 




2.1.5.3 Dyne-Steele cohort used for genotyping and methylation studies 
Genomic DNA from aged participants belonging to the Dyne-Steele cohort was provided by 
Prof. Antony Payton and Prof. Neil Pendleton at the Institute of Collaborative Research on 
Ageing at the University of Manchester, UK. This is a cohort of individuals that represent 
healthy cognitive ageing, all aged 50+ years, with a median age of 63 years at recruitment. 
The age at which the DNA samples were taken was not disclosed. DNA was purified from 
blood using DNAce MaxiBlood Purification System (Bioline) according to manufacturer’s 
instructions. DNA samples provided were from both sexes. Patients were given a 
questionnaire that included self-reported pain measures. Ethical approval was obtained from 





2.1.6 Other materials 
2.1.6.1 TBE buffer 
TBE buffer was used to make agarose gels. Reagents in Table 2.4 were used to make a 5X 
stock of TBE buffer in a final 2 L volume of distilled water. TBE buffer was diluted to a 0.5X 
working concentration prior to use using distilled water.   
Table 2.4. TBE buffer reagents. 
Reagent Supplier Cat. no. Weight (g) 
Tris base Sigma 10708976001 55 
Boric acid Sigma B6768 55 
EDTA Sigma EDS 5.84 
 
2.1.6.2 DNA markers 
Commonly used DNA markers are listed in the table below.  
Table 2.5. DNA size markers. 
DNA marker Included markers Supplier Cat. no.  
100 bp 100-1500 bp Promega G2101 
100 bp 50-1500 bp Cleaver CSL-MDNA-100BP 
1 Kb  250-10000 bp Promega G5711 








2.2.1 Bioinformatic tools  
2.2.1.1 UCSC genome browser 
UCSC genome browser was used to visualise genomic arrangements of transcripts (e.g. 
isoforms, non-coding RNAs), identify potential regulatory domains using ENCODE data (based 
on histone marks and conservation patterns), identify insertions of transposable elements, 
profile genetic variation (e.g. SNPs, CNVs) and to obtain DNA sequences for regions of 
interest in both human and mouse genomes for primer design 203. Genome assemblies used 
are specified throughout. All primer sequences are listed in appendix A, with reference 
numbers specified throughout.  
2.2.1.2 Primer design for amplification of gDNA and cDNA templates 
For amplification of gDNA using regular PCR, UCSC genome browser 
(http://genome.ucsc.edu/) was used to obtain the DNA sequence for the desired genomic 
target203. Sequences approximately 50-100 bp upstream and downstream of the target 
region were input into Primer3 (http://primer3.ut.ee/) to identify potential oligonucleotide 
sequences204. For amplification of cDNA using RT-PCR or qPCR, mRNA sequences were 
obtained and primers were designed within separate exons to enable detection of genomic 
DNA contamination (Figure 2.1). Alternatively, for qPCR, predesigned primers listed in the 
PrimerBank database (https://pga.mgh.harvard.edu/primerbank/) were used if validation 
data including agarose gels, dissociation curves and amplification plots were available 205. 
Potential primers were analysed separately using the OligoAnalyzer tool 
(https://www.idtdna.com/pages/tools/oligoanalyzer) to assess specific criteria206 (Table 2.6). 
Suitable primers were then input into BLAT available through UCSC 
(https://genome.ucsc.edu/cgi-bin/hgBlat) to check each sequence only complimented the 




increased likelihood of product specificity. A final check input primer sequences into the in 
silico PCR tool available through UCSC to predict amplicon size.  
Table 2.6. Criteria used for primer design. 
Parameter Definition Criteria 
Length Number of base pairs 18 bp – 22 bp 
GC content Percentage of G or C bases 40 % – 60 % 
Melting 
temperature 
Temperature at which 50% 
of primers dissociate from 
template 
55 °C – 65 °c 
Both primers in pair must have melting temperature 




producing structures such as 
hairpins 
Secondary structure must have a melting temperature 
greater than 10 °C below primer melting temperature to 
ensure it is broken before annealing during PCR 
Self-dimer 
tendency 
Likelihood of primer binding 
to itself 




Likelihood of forward primer 
binding to reverse primer 
No runs of >3 of same base (e.g. AAA in forward primer 
and TTT in reverse primer) 
 
 
Figure 2.1. Example of primer design for qPCR. (Above) Amplification from gDNA template results in large 
products containing introns that can be distinguished from smaller cDNA products. (Below) Amplification from 





2.2.2 Polymerase chain reaction techniques 
2.2.2.1 Standard PCR/RT-PCR 
All PCR reactions were performed using the GoTaq® Hot Start Polymerase enzyme (Promega) 
according to manufacturer’s instructions. An antibody is bound to this enzyme which blocks 
polymerase activity prior to denaturation at 95 °C for 2 minutes. This can reduce primer 
dimer and non-specific amplification. This enzyme was used for standard PCR amplification 
from genomic DNA and reverse transcription PCR (RT-PCR), using cDNA as a template. It was 
also used for the amplification of inserts used for cloning however sequencing validation was 
used to confirm the sequence was intact. Specific PCR protocols for each target are listed in 
appendix A. The details of all materials used for PCR are given in Table 2.7. Thermal cycles 
were performed using the SimpliAmp™ Thermal Cycler (Applied Biosystems). 
Table 2.7. Reagents used in PCR/RT-PCR reactions. 
Reagent Supplier Cat. no. Volume (µl) 
5X Green GoTaq® Reaction Buffer Promega M791B 4.0 
MgCl2 (25mM) Promega A351B 2.0 
Deoxynucleotide mix (10mM) Sigma DNTP100A 0.4 
Primers (20mM) Sigma n/a 0.1 
GoTaq® Hot Start Polymerase Promega M500A 0.1 
gDNA/cDNA template n/a n/a 1.0 









2.2.2.2 qPCR reaction setup 
For all qPCR reactions, GoTaq® qPCR Master Mix (Promega, A6001) was used according to 
manufacturer’s instructions. This contains all necessary components for amplification except 
primers, water and sample. This mix contains BRYT Green® Dye, which binds to double 
stranded DNA and exhibits a strong fluorescent signal upon excitation. CXR reference dye 
was also included in this mix to act as a reference dye between samples. The standard qPCR 
reaction components are given in Table 2.8. All reactions were set up in triplicate. Thermal 
cycles and fluorescent readings were measured using the Mx3005P® Real-Time PCR System 
(Stratagene). All primer sequences and thermal cycling conditions are specified in appendix 
A and are referred to throughout the text with entry numbers. 
Table 2.8. Reagents in qPCR reaction. 
Reagent Supplier Cat. no. Volume (µl) 
GoTaq® qPCR Master Mix (2X) Promega A6001 5.0 
Primers (10 µM) Promega n/a 0.1 
CXR Promega C5411 0.1 
cDNA n/a n/a 2.0 









2.2.2.3 Relative quantification using 2-∆∆Ct method 
Ct (cycle threshold) values represent the cycle number at which the fluorescence within the 
sample exceeds the background level. It is representative of the relative abundance in mRNA, 
therefore the threshold changes within each experiment. For example, a target gene with a 
Ct value of 30 would contain less cDNA templates than a sample with a Ct value of 20 because 
it takes more cycles for fluorescence to exceed the background. 2-∆∆Ct is a method to calculate 
the relative difference in expression of the target gene in experimental groups versus 
controls, when normalised against the reference gene of choice207. This value is 
representative of fold change of target gene expression in experimental samples versus 
biological controls. Three Ct values were available for each sample due to setting up triplicate 
reactions. Any sample with a standard deviation >0.3 between Ct values was visually 
inspected and the outlier removed. The 2-∆∆Ct was calculated in Microsoft Excel as follows: 
1. Calculate the mean Ct (reference) and mean Ct (target) for each sample. 
2. Mean Ct (reference) – mean Ct (target) = ∆Ct.  
3. Calculate the mean ∆Ct for all samples in the biological control group.  
4. Mean ∆Ct of each sample - mean ∆Ct (control group) = ∆∆Ct.  





2.2.2.4 qPCR primer validation and efficiency testing 
To ensure qPCR data was reliable, we calculated the efficiency of all primer sets used. This is 
a requirement of the 2-∆∆Ct method. A primer with 100% efficiency should double the number 
of PCR templates at each cycle, however this is very unlikely therefore it is recommended 
that primer efficiencies are between 90 – 100 %. To test each primer set, a qPCR test run was 
set up using a ten-fold serial dilution of cDNA template. The mean Ct values from each 
dilution were then plotted to generate a standard curve (Figure 2.2). The slope of the curve 




− 1) × 100 
Finally, melt curves were performed after qPCR thermal cycles.  A melt curve indicates at 
which temperature the double stranded DNA product denatures, resulting in loss of the 
intercalating BRYT Green® Dye. A single distinct peak indicates the presence of a single 
product and confirmed specificity within the reaction (Figure 2.2). The detection of two peaks 
indicated the presence of two products or complex secondary structure that did not 
immediately denature during the melting stage, resulting in some fluorescence being 
retained at a lower temperature. Any product indicating more than one peak were run on 
agarose gels to confirm the specificity of the primer set. If multiple products were detected, 
primers were redesigned.  
 
Figure 2.2. Primer validation. (Above) Example of standard curve used to calculate primer efficiency. (Below) 





2.2.2.5 Agarose gel electrophoresis 
Agarose gels were used to visualise and analyse nucleic acids. 1-2% agarose gels were used 
throughout, with higher percentage gels being used to generate higher resolution for smaller 
PCR products (< 500 bp) and lower percentage being used to separate larger PCR products 
(>1 kb). To make each gel, 0.5X TBE buffer was mixed with UltraPure™ Agarose (Invitrogen) 
and heated in a microwave until boiling and all agarose was dissolved. This solution was left 
to cool until no vapour could be seen, before being stained with ethidium bromide solution 
(Sigma) at a final concentration of 50 µg per 100 ml. Staining enabled visualisation of nucleic 
acids under UV light. Samples that did not contain any loading dye (e.g. restriction digest 
products or PCR products with a clear master mix) were mixed with an appropriate volume 
of 6X Gel Loading Dye Purple (NEB) to aid loading into wells. Sizing of nucleic acids was 
achieved by loading an adjacent 100 bp or 1 kb DNA marker (Cleaver). All gels were imaged 
under UV light using the BioDoc-It™ Imaging System (UVP). 
2.2.2.6 Capillary electrophoresis 
Capillary electrophoresis was performed to resolve PCR products that could not be resolved 
using agarose gel electrophoresis. We used the QIAxcel automated capillary electrophoresis 
system (QIAGEN). We used the DNA screening cartridge (QIAGEN, 929004) in conjunction 
with size markers ranging from 50 bp to 800 bp, and an alignment marker ranging from 15 
bp to 1 kb. Samples were screened using default parameters, the AM320 run method and 
injection time of 10 seconds. Products were verified on a 2.5% agarose gel ran for at least 3 





2.2.3 Nucleic acid preparation techniques 
2.2.3.1 Purification of DNA from agarose gels 
PCR and restriction enzyme digest products were purified using the Wizard® SV Gel and PCR 
Clean-Up System (Promega) according to manufacturer’s instructions. This is a column-based 
kit that binds double stranded DNA whilst other components are washed away and 
discarded. Following analysis of products using agarose gel electrophoresis, products were 
then excised from the gel with a scalpel under UV light. Exposure to UV light was kept to a 
minimum to prevent degradation to the sample. Gel pieces were dissolved in the supplied 
column binding solution at 60°c, before being passed through the DNA binding column. All 
samples were eluted in 30 µl of nuclease free water (Invitrogen) to produce the highest 
possible DNA concentration without compromising on efficiency of DNA recovery from the 
column. All samples were assessed for quantity and quality before being used for sequencing 
or cloning. PCR products, digested inserts/plasmids that were used for cloning were purified 





2.2.3.2 Miniprep DNA for subcloning applications   
To verify plasmids contained the correct inserts following cloning, plasmid DNA was required 
for use in diagnostic restriction enzyme digests, PCR and DNA sequencing. Bacteria colonies 
previously grown on agar plates were selected. A small amount of DNA was required for 
therefore colonies were transferred into a 5 ml suspension of LB growth media 
supplemented with 1% antibiotics, and grown overnight in a shaking incubator at 225 rpm at 
37°C. 2 ml of each culture was pelleted, providing enough cells for sufficient DNA yield whilst 
leaving enough culture for further growth stages and freezing of cells stocks. Cultures were 
stored for maximum of 1 week at 4°c. Plasmid DNA was then purified from the cell pellet 
using the Wizard® Plus SV Miniprep DNA Purification System (Promega) according to 
manufacturer’s instructions. All samples were eluted in 30 µl of nuclease free water 
(Invitrogen) to produce the highest possible DNA concentration without compromising on 
efficiency of DNA recovery from the column. All plasmid resources were stored at -20 °C 
unless stated otherwise. 
2.2.3.3 Maxiprep DNA for transfection in human cell lines 
To use plasmid DNA for transfection into human cell lines (for use in reporter gene assays) a 
large amount of DNA was required. A 50 µl aliquot of bacteria was transferred from 
remaining suspension cultures (previously validated) into an Erlenmeyer flask containing a 
100 ml suspension. The total 100 ml volume was pelleted. Plasmid DNA was purified from 
the cell pellet using the Plasmid Maxi Kit (QIAGEN) according to manufacturer’s instructions. 
Following ethanol precipitation, the DNA pellet was air dried for 10 minutes to allow 
evaporation of residual ethanol before being resuspended in 200 µl of nuclease free water 




2.2.3.4 Genomic DNA purification from human cell lines 
Genomic DNA from human cell lines was purified using the GenElute™ Mammalian Genomic 
DNA Miniprep Kit (Sigma) according to manufacturer’s instructions. Cells were first 
dissociated from plates using methods described in section 2.2.5.1. Cells were pelleted by 
centrifugation at 150 x rcf for 5 minutes at room temperature. Pellets were washed in room 
temperature PBS (Invitrogen) before being lysed using the supplied lysis buffer. DNA was 
eluted in 200 µl of nuclease free water (Invitrogen). All samples were assessed for quantity 





2.2.3.5 RNA extraction from human cell lines  
For RNA extraction from human cell lines, the Monarch® Total RNA Miniprep Kit (New 
England Biolabs) was used following manufacturer’s instructions. This column-based 
purification kit and was used instead of TRI Reagent™, as it removed the possibility of losing 
small RNA pellets during ethanol precipitation and ensured a sufficient yield of RNA from 
small cell numbers. All cell lines used were adherent, therefore cells were washed twice with 
PBS, prewarmed to 37 °c, to ensure complete removal of cell culture medium. Cells were 
then lysed directly in the plates in which they were grown using the supplied lysis buffer. This 
was to prevent any changes to RNA profiles or RNA degradation resulting from trypsinisation 
208. Lysed cell samples were first passed through a genomic DNA removal column before 
collecting the flow through containing the RNA. The flow through was then passed through 
an RNA binding column and treated for 15 minutes with the supplied DNase I (whilst bound 
to the column) to remove any residual genomic DNA that may have been carried over. RNA 
was eluted in 50 µl of nuclease free water (Invitrogen) to produce the highest possible RNA 
concentration without compromising on efficiency of RNA recovery from the column. All 
samples were assessed for quantity before being used for cDNA synthesis. 
2.2.3.6 Preserving RNA in harvested DRG  
All mouse DRG that were harvested for cDNA analysis were preserved to prevent degradation 
of RNA prior to extraction. DRG were first washed in PBS to remove any excess blood and 
then submerged in at least 500 µl of RNAlater (Sigma). This is a solution that penetrates 
tissues, stabilises RNA and inhibits the activity of RNase to preserve the RNA profile of the 
sample. All tissues were stored overnight at 4 °C to enable RNAlater to fully penetrate tissues 
before being frozen at -20  °C until RNA extraction (samples were not stored for longer than 




2.2.3.7 RNA purification from DRG  
DRG harvested from Thy1-YFP mice (section 2.1.4.1) had previously been stored in RNAlater® 
(Sigma) were washed twice in PBS (Invitrogen) to remove any traces from the sample and 
were placed into an RNase free Eppendorf tube. Tissues were submerged in the smallest 
volume of TRI Reagent® (Sigma) appropriate for the size of the tissue sample (1 ml per 50 – 
100 mg of tissue). TRI Reagent® is a solution that lyses cells/tissues, inhibits the activity of 
RNase and dissociates nucleoprotein complexes enabling the isolation of RNA, DNA and 
proteins from a biological sample. Tissues were then homogenised using a handheld 
electronic pellet mixer (VWR). Samples were then left at room temperature for 15 minutes 
to allow complete cell lysis and dissociation on nucleoprotein complexes. All centrifugation 
steps were at 12000 x g at 4°c. Samples were spun for 10 minutes to separate lipids (present 
in clear supernatant) resulting from accidental carryover of fatty tissue. Once the 
supernatant was removed, chloroform (Sigma) was added in a 10:1 ratio (chloroform: TRI 
Reagent®). Samples were shaken vigorously and spun for 15 minutes to separate the mixture 
into three phases (Figure 2.3). The aqueous phase was harvested for RNA precipitation and 
the remaining phases were stored at -20 °C for future isolation of gDNA and/or proteins. An 
equal volume of isopropanol (Sigma) was added to each sample and allowed to stand for 10 
minutes. Samples were spun for 10 minutes to precipitate the RNA. The RNA pellet was then 
washed in 1 ml of ethanol (Sigma) and spun again for 5 minutes. The RNA pellet was then 
allowed to air dry for 10 minutes before being resuspended in 50 µl of nuclease free water 
(Invitrogen). All samples were assessed for quantity and quality before being used for cDNA 
synthesis. Prior to cDNA synthesis, all samples were treated with DNaseI (Thermo Scientific) 
according to manufacturer’s instructions. This is an endonuclease that degrades any 




2.2.3.8 RNA purification from brain 
RNA was isolated from the right hemisphere of the brain of C57BL/6 mice (section 2.1.4.2) 
using the RNeasy Lipid Tissue Mini Kit (Cat. No. 74804, Qiagen). Genomic DNA (gDNA) was 
removed from the preparation using a gDNA eliminator column and DNaseI treatment as 
described in previous section. RNA quality was assessed using a Microplate 
Spectrophotometer with Take3 plates (Epoch). RNA was reverse transcribed into cDNA using 





Figure 2.3. Phase separation of biological samples using TRI reagent®. Centrifugation of biological samples 
following addition of TRI Reagent® and chloroform results in separation of cellular components into 3 phases. The 







2.2.3.9 cDNA synthesis 
To generate cDNA templates suitable for gene expression applications such as RT-PCR and 
qPCR, reverse transcription was performed on up to 1 µg of purified RNA to generate single-
stranded cDNA. All RNA samples within specific experiments were normalised to the same 
concentration (typically 100 ng/µl, however this did vary between experiments) prior to 
reverse transcription to ensure the same quantity of cDNA was produced for gene expression 
analyses, and efficiency of the reverse transcription reaction was not affected. RNA 
templates were reverse transcribed using the GoScript™ Reverse Transcriptase Kit (Promega) 
according to manufacturer’s instructions. Specific volumes of reagents are given in Table 2.9. 
The reaction was supplemented with both oligo(dT) and random primers to increase the 
likelihood that all PCR targets could be detected, regardless of being located at the 3’ or 5’ of 
the transcript (Figure 2.4). Following reverse transcription, all cDNA samples were diluted 
1:10 with nuclease free water and stored at -20°c. 
Table 2.9. Reagents used to synthesise cDNA in reverse transcription reaction. 
Reagents Supplier Cat. no. Volume (µl) 
GoScript™ 5X Reaction Buffer Promega A500B-C 4.0 
MgCl2 (25mM) Promega A3551 3.0 
Oligo(dT)15 primers (500 µg/ml) Promega C1101 1.0 
Random primers Promega C1181 1.0 
dNTPs (10mM) Promega U1205 3.0 
Recombinant RNasin® Ribonuclease Inhibitor (40 
u/µl) 
Promega N2111 0.5 
GoScript™ Reverse Transcriptase  Promega A5002 1.0 
RNA (100 ng/µl) n/a n/a 3.0 






Figure 2.4. Generation of cDNA templates based on different primer combinations. (Above) Use of only oligo(dT) primers begins reverse transcription at the 3’ end of the mRNA. Reverse 
transcriptase enzyme drops off the template after several thousand bases so for long transcripts, cDNA may not be generated that includes the 5’ end of the transcript. If the PCR target is at the 
3’ end of the mRNA, this is not an issue and products will be amplified (green box), however a target at the 5’ end may not be amplified and could falsely indicate no expression (red box). (Below) 
Use of a combination of oligo(dT) and random hexamer primers ensures that cDNA products are generated across the entire length of the mRNA transcripts and increases the likelihood that 




2.2.3.10 Quantification and quality controls  
Quantity and quality of nucleic acids were assessed using the NanoDrop 8000 
Spectrophotometer (Thermo Scientific) prior to downstream processing (e.g. cDNA 
synthesis) or use in assays (e.g. genotyping, cloning or sequencing). 260/280 ratios reflect the 
purity of a sample and are used to assess protein contamination. 260/230 ratios can be used 
to assess residual phenol from TRI reagent-based methods of nucleic acid purification or 
residual guanidine carryover from column-based purification methods. Ratios should be 
above 1.8 for DNA sample and 2.0 for RNA samples. Agarose gel electrophoresis was also 
used to visualise RNA integrity. 1 µg of total RNA was mixed with loading dye and ran on an 
agarose gel to visualise the presence of distinct 18S and 28S rRNA bands. Clear bands without 




2.2.4 Molecular cloning techniques 
2.2.4.1 Ligation of inserts into intermediate vector pCR®II 
The desired insert to be cloned was amplified using PCR. The quantity of PCR product 
required to perform a 1:1 ligation reaction was calculated using the equation below. Ligation 
reactions were always set up in a 3:1, 5:1 and 10:1 (insert:vector) ratio to cover a range of 
potential ligation efficiencies. Ligations were incubated overnight at 14 °C using the 
SimpliAmp™ Thermal Cycler (Applied Biosystems). All vector maps are given in appendix B.  
𝒙 (𝒏𝒈 𝒐𝒇 𝑷𝑪𝑹 𝒑𝒓𝒐𝒅𝒖𝒄𝒕) =
(𝒃𝒑 𝒐𝒇 𝒊𝒏𝒔𝒆𝒓𝒕) × (𝟓𝟎𝒏𝒈 𝒐𝒇 𝒗𝒆𝒄𝒕𝒐𝒓)
𝒔𝒊𝒛𝒆 𝒐𝒇 𝒗𝒆𝒄𝒕𝒐𝒓 (𝒃𝒑)
 
Inserts were initially ligated into the Dual promoter pCR®II vector using the TA Cloning® Kit 
(Invitrogen, K207020) according to manufacturer’s instructions. The reagents used are given 
in Table 2.10. Ligation reactions were incubated overnight at 14 °C prior to transformation. 
This method relies on the presence of 3’ A-overhangs in the PCR product to anneal to the 3’ 
T-overhangs in the vector (Figure 2.5). Taq enzymes add a 3’ A-overhangs to PCR products 
hence were always used for cloning purposes. 3’ A-overhangs are also prone to removal over 
time therefore PCR products were always purified and ligated immediately after 
amplification. The vector backbone contained the LacZα gene fragment, making it suitable 
for X-gal blue white screening of positive clones following transformation.  
 
Figure 2.5. Schematic of TA cloning. DNA insert previously amplified using PCR highlighted in green. Note the 
addition of A nucleotides at the 3’ end of the insert, generating A overhangs. The vector is lineated with 5’ T 
overhangs therefore complimentary base pairing between the A and T aids ligation of insert into the vector.  
Table 2.10. Reagents used for ligation of insert into intermediate vector pCR®II.  
Reagent Supplier Cat. no. Volume (µl) 
PCR product n/a n/a X 
5X Express Link™ T4 DNA Ligase Buffer Invitrogen 46300018 2.0 
pCR®II vector (25 ng/µL) Invitrogen K207040 2.0 
ExpressLink™ T4 DNA Ligase (5 u/µl) Invitrogen 15224041 1.0 




2.2.4.2 Ligation of inserts into expression vector pGL3-P 
Upon successful cloning of the desired inserts into the intermediate vector, inserts were 
digested out of the vector , purified and ligated into the reporter gene vector pGL3-Promoter 
(pGL3-P) (Promega, E1751 ) using T4 DNA ligase (NEB, M0202) according to manufacturer’s 
instructions. Ligation reactions were setup using reagents given in Table 2.11. and incubated 
overnight at 14°C. DNA mass to be used in ligation was calculated using equation in previous 
section.  
Table 2.11. Reagents used for ligation of insert into expression vector pGL3-P.   
Reagent Supplier Cat. no. Volume (µl) 
T4 DNA Ligase Buffer (10X) NEB B0202S 2.0 
Vector DNA (50ng) n/a n/a X 
Insert DNA n/a n/a Y 
T4 DNA ligase (40 u/µl) M0202S  1.0 
UltraPure™ DNase/RNase Free Distilled Water Thermo Fisher Scientific™ 10977035 final volume 20 µl 
 
2.2.4.3 Transformation of chemically competent cells 
To generate enough plasmid DNA for applications such as subcloning and in vitro use, they 
were propagated using bacterial host cultures. Transformation of bacteria was conducted 
using Subcloning efficiency™ DH5α competent cells (Invitrogen, 18265017) according to 
manufacturer’s instructions. 200 µl of cells were spread onto agar plates containing 
ampicillin. Plated were then inverted and incubated overnight at 37°C. Clones containing the 
intermediate vector were selected for using ampicillin and/or X-gal blue white screening. 
Clones were picked, grown and plasmid DNA was purified. If the DNA to be transformed was 
highly repetitive or had a high GC content, Endura™ Chemically Competent Cells (Lucigen, 
60240) were transformed following manufacturer’s instructions. Colonies were selected and 




2.2.4.4 Blue white screening 
Blue-white screening was utilised when the cloning site of the vector contained the gene 
encoding the enzyme β-galactosidase, which metabolises X-gal into 5-bromo-4-chloro-
indoxyl. This metabolite dimerises to produce a blue pigment called 5,5’-dibromo-4,4’-
dichloro-indigo, turning the colony containing the nonrecombinant vector blue. Colonies 
containing recombinant plasmids have an insert in the cloning site, therefore the β-
galactosidase gene is disrupted and consequently do not turn blue in the presence of X-gal. 
This enabled quick screening of colonies transformed with recombinant plasmids.  If blue 
white screening was required, plates were coated/spread with X-gal prior to plating of 
bacteria. 20 µl of X-gal solution at a concentration of 50 mg ml-1 (Promega, V3941) was mixed 
with 50 µl of LB broth and spread over prepared agar plates. Plates were then incubated at 
37  °C for 30 mins to allow the X-gal to soak into the plates before use.  
2.2.4.5 Plasmid DNA purification from bacteria cultures 
Colonies were picked using a sterile pipette tip, which was then placed into a 5 ml starter 
culture and grown overnight at 37 °C in a shaking incubator rotating at 225 rpm. Bacteria 
cultures were grown in a LB broth suspension supplemented with 100 μg/ml ampicillin. 
Sufficient growth was indicated by the culture turning turbid overnight. A 100 ml culture was 
then set up using a 50 µl aliquot from the starter culture if a large amount of high-quality 
DNA was required for transfection. The smaller 5 ml cultures were used to isolate small 
amounts of DNA used for diagnostic purposes or subcloning (Figure 2.6). This was carried out 
overnight at 37 °C in a shaking incubator rotating at 225 rpm. Bacteria were then pelleted in 
a centrifuge at 4 °C at 500 x rcf for 5 minutes. LB broth was removed from the pellet. Pellets 
were then used for plasmid DNA purification using either miniprep or maxiprep. All DNA 






Figure 2.6. Methods used to purify plasmid DNA constructs from bacterial cultures for use in different 
downstream applications. (A) Methods used to select colonies for growth in small volume cultures and 
purification of plasmid DNA using miniprep protocol; suitable for plasmid validation applications including 
restriction digest, PCR and sequencing. (B) Methods used to purify large amount of high-quality plasmid DNA 





2.2.4.6 Restriction enzyme digests 
Restriction enzyme digests were used as a diagnostic tool to confirm the presence and 
orientation of cloned inserts, and to enable subcloning of inserts from intermediate to 
expression vectors. Enzymes for diagnostic digests were chosen based on having one cut site 
near one end of the DNA insert and one cut site in the backbone of the SVA. Agarose gel 
electrophoresis can then be used to assess product size and determine which plasmids are 
correct. Enzymes for subcloning were chosen based on ability to generate compatible 
nucleotide overhangs. The basic set up of a restriction enzyme digest is given in Table 2.12. 
Each specific enzyme required a specific buffer; however all incubations were conducted at 
37  °C for at least 2 hours to allow complete digestion followed by a heat inactivation step at 
>65  °C for 15 minutes. Incubations were performed used the SimpliAmp™ Thermal Cycler 
(Applied Biosystems). Following digestion, samples were run on a 1% agarose gel for 1 hour 
at 100V to enable enough separation for diagnostic or subcloning use. If subcloning was 
required, digests were set up in triplicate and loaded into the same well to enable sufficient 
yield following gel purification. 
Table 2.12. Reagents used in restriction enzyme digests. 
Reagents Supplier Cat. no. Volume (µl) 
Multicore buffer (10X) Promega R9991 2.0 
BSA (10 mg/ml) Promega R3961 0.2 
Enzyme (10 U/µl) Promega n/a 0.5 
Template DNA (500 ng) n/a n/a X 





2.2.5 Human cells line techniques 
2.2.5.1 Maintenance and passaging of cell cultures 
All new cell lines introduced to the laboratory (from nitrogen stores or collaborators) were 
kept in isolation and screened for mycoplasma using the MycoAlert™ Mycoplasma Detection 
Kit. This was repeated every six months. All cell lines were grown at 37 °C in 5% CO2. All media 
used contained phenol red, which changes colour according to pH. Complete media was 
replaced when pH change induced a yellow colour in the culture, or more frequently. When 
cells reached 70 – 80% confluency, they were passaged to allow continuation of growth. All 
reagents were prewarmed to 37 °C prior to use. To passage, cells were washed twice with 
PBS before being dissociated using trypsin to detach cells from the growth surface. After 
addition of trypsin, cells were incubated for 5 minutes before trypsin was inactivated by 
adding 10X the volume of cell culture media. Cells were triturated gently to ensure complete 
dissociation. A proportion of the cell suspension was taken into a new flask. Cell were 
typically passaged using a 1:10 or 1:20 ratio, dependent upon application.   
2.2.5.2 Freezing and thawing cells in liquid nitrogen stores 
Cells to be used as future resource were stored in liquid nitrogen. Prior to freezing, cells were 
grown to 70-80% confluency in a T25 flask to ensure sufficient numbers could be frozen and 
recovered upon thawing. To freeze cells, cultures were dissociated using trypsin and pelleted 
to remove excess media. Cells were resuspended in 5 ml of freezing media. 1 ml of cell 
suspension was transferred to cryovials (at least 3 replicates) before being gradually frozen 
overnight at -80 °C using a Mr Frosty™ Freezing Container (ThermoFisher Scientific). 24 hours 
later, cells were transported on dry ice to the liquid nitrogen stores for long term storage. To 
thaw cells, vials were removed from liquid nitrogen and thawed in a water bath at 37 °C for 
at least one minute. Cells were resuspended in 10 ml of prewarmed media and pelleted to 
remove excess freezing media. Pellets were resuspended in an appropriate volume of fresh 




2.2.5.3 Transfection of reporter gene constructs into human cell lines for luciferase 
assays 
Transient transfection of plasmid DNA into human cell lines was carried out using TurboFect™ 
Transfection Reagent (Thermo Scientific™) according to manufacturer’s instructions. This is 
a solution of cationic polymers in water that form stable complexes with plasmid DNA, 
protecting it from degradation in culture, an ensuring efficient delivery into cells. High quality 
DNA is essential for effective transfection therefore only DNA purified using maxiprep 
protocols was used. 24 hours prior to transfection, cells were seeded into a 24-well plate at 
a density of 105 cells/well, containing 1 ml of media. Volumes of reagents used to generate 
the transfection mix are given in Table 2.13. pRL-TK is a Renilla luciferase control vector used 
for normalisation during luciferase assays and was included alongside constructs being 
tested. 100 µl of complete transfection reagent was added to each well in a dropwise 
manner. A minimum of 4 biological repeats were used for each construct being tested. A full 
media change was conducted 4 hours after transfection reagent was added to minimise 
toxicity and cell death. Cells were then incubated for 48 hours before luciferase assays were 
conducted.  
Table 2.13. Components used in complete transfection reagent.  
Reagent Volume (µl) 
Serum-free media 100 
TurboFect™ Transfection Reagent 2.0 
Plasmid DNA (500 ng) X 






2.2.6 Dorsal root ganglia techniques 
2.2.6.1 Dissection of DRG from mouse 
To obtain dorsal root ganglia for gene expression studies and in vitro assays, they were 
surgically dissected from mice. All mice were culled using cervical dislocation. Mice were 
culled individually as needed to prevent loss of RNA integrity209, as the DRG harvest protocol 
is very time consuming per animal (up to one hour). The dissection protocol has been 
adapted from one published online at bio-protocol.org (www.bio-protocol.org/e1785), to 
increase efficiency and further preserve RNA. It is essential that all surgical equipment is 
clean, sharp and mirror finished tweezers used to pull the DRG away from tissue are not 
blunt. Surgical equipment is listed in Table 2.14. Dissection procedure is given on next page. 
Table 2.14. Surgical equipment required for DRG harvest. 
Item Supplier Catalogue number 
Standard scissors Fine Science Tools 14002-12 
Spring scissors Fine Science Tools 91500-09 
Dumont #7b medical forceps Fine Science Tools 11270-20 






DRG dissection procedure is as follows: 
1. The animal is decapitated using standard scissors.  
2. The spinal column is immediately dissected using incisions on the ventral side of the 
animal. All tissue is trimmed away from the spinal column using spring scissors.  
3. Using spring scissors, horizontal incisions were made at the neck opening of the 
spinal column (Figure 2.7). This was performed in an alternating manner, whilst 
simultaneously lifting the ventral side of the column away using medical forceps to 
exposed the spinal cord. The spinal cord was then removed with tweezers.  
4. Using a dissection microscope, the DRG are apparent situated in between the 
vertebrate. Using mirror finish surgical tweezers, the DRG were gently pulled from 
their sockets and trimmed at the base to release the bulb (mirror finish tweezers 
must be used to limit tissue damage). If DRG were required for in vitro applications, 
all visible DRG along the length of the spinal column were harvested to maximise cell 
numbers. If DRG were required for RNA extraction, only larger lumber DRG were 
harvested as these are easier to isolate than the smaller cervical DRG whilst providing 
sufficient RNA yield.  
5. DRG were washed in PBS before being transferred to their storage or transport 
solutions.  DRG required for gene expression studies were placed immediately into 
RNA later prior to freezing or immediate RNA extraction. DRG required for in vitro 
assays were placed in Hank’s Buffered Saline Solution prior to dissociation into a 










2.2.6.2 Dissociation of DRG into single cell suspension 
To dissociate the DRG tissue into a single cell suspension that could be used for in vitro assays 
the following steps were taken: 
1. Prepare collagenase solution and preheat for 10 minutes at 37°c. 
2. Allow DRGs to settle to the bottom of the tube and gently remove the supernatant. 
3. Wash the DRGs using 5 ml of dissociation solution (repeat 3 times).  
4. Remove 3 ml of dissociation solution. Add 1 ml of collagenase solution. Incubate for 
1 hour at 37°c.  
5. Following the incubation, invert to resuspend the DRGs and centrifuge at 160 rcf with 
a ramp speed of 3.5. 
6. Remove the supernatant. Wash DRGs with 5 ml of dissociation solution (repeat 3 
times). 
7. Remove the supernatant and add 1.5 ml of dissociation solution to the DRGs. 
8. Triturate the DRGs using an unmodified Pasteur pipette approximately ten times 
until the suspension looks homogenous.  
9. Triturate the DRGs gently using the modified Pasteur pipette approximately ten 
times.  
10. If the mixture has large pieces of debris remaining, pass through a cell strainer.  
11. Centrifuge the suspension for 5 minutes at 160 rcf with a ramp speed of 3. This will 
prevent the cell pellet from being dispersed as the centrifuge accelerates and 
decelerates.  
12. Remove the supernatant and resuspend the cell pellet in 5 ml of DRG culture media. 
Centrifuge again. 
13. Remove supernatant and resuspend the cell pellet in 1 ml of DRG culture media and 




2.2.6.3 Transfection of DRG using nucleofection 
DRG were transfected using nucleofection. This method uses electroporation, which involves 
applying an electrical field to primary cells to increase the permeability of the cell membrane 
and allow the introduction of DNA. The Mouse Neuron Nucleofector™ Kit (Lonza, VPG-1001) 
was used according to manufacturer’s instructions. The DRG yielded from a single mouse 
following purification was approximately 60,000 cells. This protocol is most suited for cell 
numbers >100,000 therefore DRG were pooled from multiple animals (at least n=3). Prior to 
setup, cuvettes were prechilled to 4 °C to prevent the sample from overheating during 
nucleofection. Per sample, 100,000 cells were counted and suspended in 100 µl of 
Nucleofection® Solution and combined with 1 µg of the prepared vector. 2 µg of pmaxGFP® 
vector was used as a transfection control. The solution was then transferred to a cuvette 
(care taken to avoid bubbles, as this disrupts current) and placed into the nucleofection 
device. The Nucleofector™ 2b device was used to administer the voltage, using programme 
0-003. Cells from each transfection were then resuspended in 4 ml of fresh prewarmed media 
and 500 µl (approximately 25,000 cells) was plated into the wells of a 24-well plate. After 2-
4 hours (depending on cell adherence) media was replaced. Media was replaced again after 





2.2.7 Luciferase reporter gene assays 
Luciferase assays were conducted 48 hours after transfection using the Dual-Glo® Luciferase 
Assay System (Promega, E2920) according to manufacturer’s instructions. The transfected 
plasmid, either pGL3-P or pGL3-B, encode firefly luciferase, which is measured to assess for 
changes in transcriptional activity dependent on the insert. Cells were cotransfected with 
pRL-TK, a plasmid that encodes Renilla luciferase, which functions as an internal control to 
normalise data between reactions. All luciferase reactions were set up in quadruplicate. All 
luciferase readings were made using the GloMax® 96 Microplate Luminometer and the 
“DLRwithTwoInjections” protocol. This instructs the machine to automate the addition of 
luciferase assay reagents (described in the manufacturers protocol) to enable high 
throughput and take fast readings. To calculate differences in luciferase activity, a ratio of 
the RLU (relative light units) values from firefly luciferase and Renilla was calculated. The fold 






2.2.8.1 gRNA design 
UCSC genome browser (https://genome-euro.ucsc.edu) was used to retrieve DNA sequences 
250 bp flanking each side of the SVA. These sequences were input into a bioinformatic tool 
(http://crispr.mit.edu/) used to select ideal 20 bp nucleotide sequences upstream of PAM 
sites. This tool assessed sequences for potential off target effects and ranked them according 
to sequence specificity. Multiple guides were selected to test efficiency in vitro. To clone 
these sequences into the Cas9 vector and generate a functional gRNA molecule, a double 
stranded insert was needed which required several sequence modifications to generate the 
necessary overhangs. The PAM sequence was removed from each oligonucleotide before the 
complimentary sequence was generated. CACC was added to the 5’ end of the original oligo 
and an AAAC was added to the 5’ end of the complimentary oligo. This generated overhangs 
that were compatible with the Cas9 vector during the cloning stage. To generate double 
stranded inserts to encode a functional gRNA molecule, both complimentary 
oligonucleotides were annealed together. 6 µl of both oligonucleotides (100 µM each) were 
combined with 83 µl of nuclease free water and 5 µl of T4 DNA Ligase Reaction Buffer (NEB). 
This mix was heated at 95 °C for 5 minutes and allowed to cool back to room temperature 





2.2.8.2 Golden gate cloning of gRNA inserts into pSpCas9(BB)-2A-GFP  
The golden gate method was used to clone guides into the as described in Ran et al.210. This 
method relied on using BbsI to digest a small insert out of the plasmid and replacement with 
the guides. If the desired insert is ligated with the vector, the BbsI recognition site is lost and 
the enzyme will not cut, if the original insert is religated with the vector and BbsI can cut 
again. 50 ng of annealed guides were mixed with 150 ng of pSpCas9(BB)-2A-GFP, 2µl of 10X 
ligase buffer (NEB), 1µl of BbsI-HF (NEB), 1µl of T4 ligase (Promega) and nuclease free water 
to a final volume of 20ul. This was incubated for 10 cycles at 37 °C for 5 minutes and 16 °C 
for 10 minutes, then 37 °C for 30 minutes and 80 °C for 20 minutes to heat inactivate 
enzymes. 2 µl of the ligation mix was used to transform DH5α E. coli competent cells. Colonies 
were selected and DNA was miniprepped for screening. A restriction digest was performed 
using BbsI-HF (NEB), according to manufacturer’s instructions, to identify an insertion of 
annealed guides and therefore elimination of the BbsI restriction site. Clones containing the 
desired insert were grown overnight and DNA was maxiprepped. The presence of each guide 
within the plasmid was verified by Sanger sequencing from the U6 promoter and (primers 
are listed in appendix A; see entry 7 for gRNA sequences and entry 8 for U6 sequencing 





2.2.8.3 Transfection of CRISPR-Cas9 constructs into human cells 
Transfection was conducted using TurboFect™ (as described in section 2.2.5.3) however the 
transfection reagent was prepared as shown in Table 2.15 to enable the transfection of two 
constructs encoding different gRNAs. 
Table 2.15. Transfection reagent for dual transfection of CRISPR-Cas9 constructs. 
Reagent Supplier Volume (µl) 
TurboFect™ Transfection Reagent ThermoFisher Scientific (R0533) 2.0 
DMEM, high glucose Gibco™ 100 
CRISPR-Cas9 vector with 5’gRNA (250 ng/µl) n/a 2.0 
CRISPR-Cas9 vector with 3’ RNA (250 ng/µl) n/a 2.0 
2.2.8.4 Cell sorting using flow cytometry 
48 hours post transfection, GFP expressing cells were isolated using the BD FACSAria™ III (BD 
Biosciences). Prior to cell sorting, cell culture medium was removed, and cells were washed 
with PBS. Cells were then dissociated into a single cell suspension using trypsin. Cells were 
then pelleted at 150 rcf for 5 minutes (at room temperature) before being resuspended in 3 
ml PBS supplemented with 1% FBS in Falcon® Round-Bottom Polystyrene Tubes.  
2.2.8.5 Growth of clonal cell lines 
Transfected cells were seeded at a density of 1000 cells into 10 cm dishes. This enabled the 
growth of single cells into colonies without risking contamination from other colonies. When 
colonies were grown enough to be seen by eye (this could take up to 2 weeks), they were 
scraped using a p20 pipette tip and transferred into individual wells in a 96-well plate format. 
Clonal cell lines were grown until 70 – 80% confluent and split into two 96-well replicate 
plates at a 30:70 ratio. The less confluent plate was used for growth and the more confluent 





2.2.8.6 Identification of modified cell lines 
Initial genotyping was performed using direct cell lysis as a template for PCR. Cells were 
washed twice using PBS and lysed directly in wells using DirectPCR Lysis Reagent (Viagen, 
301-C) supplemented with Proteinase K solution (Sigma, P4850) according to manufacturer’s 
instructions. Plates were sealed with parafilm and placed in a rotating hybridisation over set 
at 55 °C overnight. Proteinase K was heat inactivated at 65 °C for 45 minutes prior to PCR. 
PCR primers and thermal cycles used to screen for deletions are listed in appendix A (entry 
9). PCR reactions were set up as described in Table 2.16. To generate enough cells for gDNA 
purification, RNA purification and creation of frozen stocks, cells were grown up in a T25 
flask. Validation of positive clones was repeated using purified gDNA from clones grown in 
T25 flasks, followed by DNA sequencing across predicted breakpoints using the same primers 
that were used for PCR. 
Table 2.16. PCR used to check for CRISPR modification. 
Component Volume (µl) 
5X Green GoTaq® Flexi Buffer 4.0 
MgCl2 (25mM) 2.5 
dNTPs (10mM) 0.4 
Forward primer (20µM) 0.1 
Reverse primer (20µM) 0.3 
GoTaq® Hot Start Polymerase 0.3 
Crude lysate/gDNA (10ng/µl) 1.0 






2.2.9 DNA sequencing 
DNA sequencing was conducted externally by Source Bioscience, UK 
(www.sourcebioscience.com). Sequencing primers are listed in appendix A and specific 
primers are referred to throughout results chapter with entry numbers. 5 µl of plasmid DNA 
(per read) normalised to 100 ng/µl with nuclease free water was used per read. 5 µl of PCR 
products (per read) normalised to 10 ng/µl with nuclease free water. All sequencing primers 
were prepared at a concentration of 3.2 µM in a volume of at least 5 µl per read. 
Electropherograms were visualised too assess quality using Chromas 
(https://technelysium.com.au/wp/chromas/) (Figure 2.8). FASTA files were exported to BLAT 
to check for the correct genomic region in UCSC genome browser.  
 
Figure 2.8. Examples of electropherograms used for quality control. (A) Good quality sequencing trace. (B) 





2.2.10 MBD pulldown 
2.2.10.1 Isolation of methylated and unmethylated DNA  
Methylated and unmethylated DNA was isolated from cells using the CpG MethylQuest kit 
(Millipore) according to manufacturer’s instructions. 500 ng of total genomic DNA was used. 
DNA was sonicated to <500 bp fragments using the S220 focused-ultrasonicator (Covaris). 
Sonicated DNA was then concentrated using Agencourt AMPure XP Beads (Beckman Coulter) 
using a 1:1.1 ratio and eluted in 25 µl water. DNA concentration was then measured using 
the Qubit dsDNA BR Assay Kit (Fischer Scientific). Capillary electrophoresis was used to 
validate the size of DNA fragments following sonication.  
2.2.10.2 Densitometry to estimate relative DNA methylation  
PCR products were loaded onto a 1% gel and ran for 1 hour at 100V. All products were loaded 
onto the same gel therefore all bands were imaged under the same conditions, reducing the 
effects of variability. The image was uploaded into ImageJ (https://imagej.nih.gov/ij/),  a 
freely available software commonly used to relatively quantify the intensity of PCR product 
bands using densitometry. Each band on the gel was converted into a peak. The area of both 
peaks, representing methylated and unmethylated DNA from each sample, were combined 
to generate a total value. The percentage of methylated DNA was calculated by dividing the 
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Mobilisation of transposable elements (TEs) leads to novel insertions which contributes to 
genome evolution and genetic variation between humans211,212. New insertions can be co-
opted for new functions which drives species-specific gene regulation213. Within individual 
genomes, TEs are mediators of epigenetic mechanisms that influence gene regulation in 
response to stimuli, for example in response to stress214. Analyses of non-LTR 
retrotransposons across the genome have revealed a positive correlation between SVA 
density (SVAs per Mb) and gene density (genes per Mb), indicating that SVAs preferentially 
insert into genic (gene dense) regions of the genome and thus may carry more capacity to 
exert greater effects on gene regulation15,215. L1 and Alu density do not positively correlate 
with gene density10. The reason behind this is currently unknown, however this potentially 
highlights a preference for SVAs to integrate into open chromatin204. More recently, 
bioinformatic analysis by Gianfrancesco et al. identified 30 loci that were enriched for SVA 
insertions (based on SVA copy number Mb), highlighting certain regions of the genome that 
were overrepresented for SVAs compared to other gene dense loci that were already 
expected to be enriched for SVA insertions216. The most enriched regions were KRAB-ZNF 
(zinc nuclease finger) gene clusters, however of interest to this project was a 1 Mb region on 
chromosome 17 (chr17:3000001-4000000), named chr17p13.2, which encodes pain 
associated genes TRPV1 and TRPV3148,150-152. All SVAs were SVA D and 5 out 6 were human 
specific, suggesting this region has undergone significant modification in recent human 
evolutionary history15,25.  
TRPV1 and TRPV3 mRNA and proteins are coexpressed in human DRG, yet TRPV3 
expression is not conserved. In mice, TRPV1 is well documented in DRG but TRPV3 is not 
expressed in DRG and current literature describes it being predominantly in keratinocytes 
(with no evidence to support expression in DRG) 9,10,152,174. TRPV3 expression has further been 




small intestine, spinal cord, stomach, testes and trachea, suggesting a wider role for TRPV3 
in human physiology compared to the mouse6,9,10,152,174. This suggests that the mechanisms 
which regulate tissue-specific expression of TRPV1 and TRPV3 are different in mice and 
human genomes - which may be important in the development of therapeutics targeting 
these channels by utilising preclinical mouse models.    
CREs are defined as non-coding DNA sequences that regulate transcription of 
neighbouring genes. Regulatory sequences and mechanisms controlling TRPV1 and TRPV3 
gene expression have not been well characterised in the human genome. A recent 
epigenomic study using primate genomes identified that SVAs are enriched in human specific 
CREs in the liver217. This highlights SVAs as ideal candidates to explore human specific gene 
regulation patterns in relation to differences observed between preclinical mouse models 
and humans. Closer inspection of the SVA enriched locus encoding TRPV1 and TRPV3 using 
UCSC genome browser (hg19) revealed an SVA insertion at the intergenic region between 
TRPV1 and TRPV3. The SVA was directly adjacent to an evolutionary conserved region (ECR) 
which we predicted to function as a CRE. The proximity of the SVA to the ECR could 
potentially disrupt conserved function via multiple mechanisms including transcription factor 
binding, DNA methylation and/or changes to secondary structure (e.g. G4-quadruplex), 
which may also potentially be modified in response to stimuli26. This highlighted the SVA as 
a candidate CRE and epigenetic modulator at this locus.    
In this chapter we provide an overview of the TRPV1 and TRPV3 locus which forms 
the basis of the research conducted in this chapter and chapter 4. We demonstrate using 
reporter gene assays that the SVA is functional as transcriptional regulator in the human cell 
line HEK293. We further demonstrate its capacity to function as a transcriptional regulator 
in a sensory neuron background, using murine DRG primary cell culture. Finally, we present 




modified HEK293 cell lines (carrying SVA deletions) direct changes in total TRPV3 mRNA 





3.2 Hypotheses and aims 
The hypotheses in this chapter are that the ECR identified at the intergenic region between 
TRPV1 and TRPV3 functions as a CRE, contributing to regulation of TRPV1 and TRPV3 mRNA 
expression. To further this, the human specific SVA insertion adjacent to the ECR is also 
functional as a CRE. We propose that the proximity of the human specific SVA to this ECR 
may exert species-specific regulatory properties which may contribute to human specific 
regulation of TRPV1 and TRPV3 mRNA expression.   
The aim of this chapter was to characterise if the ECR and SVA at TRPV1 and TRPV3 functions 
as a CRE and was achieved by completing the following: 
1. Generation of reporter gene constructs. 
a. Generate ECR reporter gene construct and assess function as transcriptional 
regulator in human cell line. 
b. Generate SVA reporter gene constructs and assess function as 
transcriptional regulator: 
i. Test in human cell line. 
ii. Test in mouse DRG primary cell culture. 
2. Generation of CRISPR modified cell lines to assess function of DNA sequence as CRE 
affecting TRPV1 and TRPV3 mRNA regulation.  
a. Optimise CRISPR protocol to delete entire regulatory domains 
b. Generate clonal cell lines containing ECR deletion 
c. Generate clonal cell lines containing SVA deletion 
d. Optimise RT-PCR/qPCR assays to measure TRPV1 and TRPV3 protein coding 





3.3.1 Assessing transcriptional regulatory domains using luciferase reporter gene assays 
3.3.1.1 Bioinformatic analysis of TRPV1 and TRPV3 locus using UCSC genome browser 
Tang et al. recently published an article describing the contribution of mobile DNA to the 
human genome15. Using the supplementary data, we identified the average number of 
human specific SVA insertions per Mb was 0.53 genome-wide, and 0.95 for chromosome 17. 
This highlighted chromosome 17 as enriched for SVAs compared to other chromosomes, 
however this was expected as it is the second most gene dense chromosome in the genome 
at 38 genes/Mb (behind chromosome 19 at 53 genes/Mb)15.  
Gianfrancesco et al. recently published an analysis of the distribution of SVAs in the 
human genome216. Analysis of this supplementary data identified that there were 6 SVAs at 
chr17p13.2 (Figure 3.1A); 5 were human specific. This highlighted a 10-fold enrichment in 
human specific SVA insertions compared to the genome average and a 5-fold increase 
compared to the chromosome 17 average. We further analysed the supplementary data 
from Gianfrancesco et al. and split the enriched loci based on SVA subclass. We identified 
that chr17p13.2 was the only enriched region in the genome that contained SVA D exclusively 
(Figure 3.1C).  
A recent comparison of repetitive elements in primate genomes identified that SVA 
D are the most active transposable element in the human genome218. This highlighted a 
region of the genome that had undergone a significant restructure in recent evolutionary 
history therefore was a target for further investigation. We conducted a full literature search 
of the genes encoded within this Mb to identify potential roles in pain pathways 
(Supplementary table 1). Several genes were reported to have roles in pathways relevant to 
pain however the literature was not as comprehensive as compared to TRPV1 and TRPV3.  




We used UCSC genome browser to explore the intergenic region in more detail. The 
intergenic region is 7452 bp in length and contains other repetitive DNA sequences that are 
conserved with other primate species (Figure 3.2A). 73% of the intergenic sequence was 
composed of TEs. The most common elements were hominid-specific Alus (36% of total 
sequence) followed by LINEs (12% of total sequence), none of which were full length. The 
SVA was the largest transposable element in this region and accounted for 19% of the 
intergenic sequence. The lack of conservation tracks corresponding to the SVA establish it as 
a human-specific repeat, therefore it emerged in the genome following divergence from the 
last common ancestor with chimpanzee.   
The SVA at the intergenic region between TRPV1 and TRPV3 is encoded on the 
antisense strand of DNA, like TRPV1 and TRPV3 (Figure 3.2A). The SVA is approximately 27 
kb downstream of the nearest TRPV1 TSS and 400 bp downstream of the TRPV1 3’UTR. The 
SVA is 5.7 kb upstream of the nearest TRPV3 TSS. The SVA is listed in RepeatMasker as 1385 
bp in length (chr17:3466973-3468357), however closer inspection of the SVA DNA sequence 
and flanking DNA sequences at the 5’ and 3’ end identified that the 5’ TCTCCC hexamer 
domain extends 17 bp upstream of the 5’ end, therefore the full SVA sequence is 1402 bp in 
length (chr17:3466973-3468374), containing an additional 3 TTTCCC hexamers than 
described in the RepeatMasker annotation. The manually annotated SVA sequence was used 
throughout this project.  
The SVA is adjacent to an evolutionary conserved region (chr17:3,466,258-3,466,820, 
hg19) which is conserved with the mouse (Figure 3.2A). This sequence is 600 bp in size and 
contains a MIR (Mammalian-wide Interspersed Repeat). MIRs are the most ancient family of 
TE in the human genome, enriched for TFBS and have been shown to act as conserved CREs 
in K562 and He-La cell lines219. ENCODE data overlaid across this ECR showed histone marks 




which was suggestive of transcriptional enhancer/repressor activity220. No histone data was 
available for the SVA as they are larger repetitive sequences which are difficult to map and 
often excluded from analyses. The data suggested this ECR may be functional as a CRE.  
However, we hypothesised that its modulation in humans may differ from the mouse due to 






Figure 3.1. SVA insertion identified at the intergenic region between TRPV1 and TRPV3. (A) SVA enriched 
megabase at chr17:3000001-4000000 encoding TRPV1 and TRPV3 (hg19). (B) Overview of TRPV1 and TRPV3 locus 






Figure 3.2. Overview of intergenic region between TRPV1 and TRPV3. (A) UCSC screenshot of chr17:3,461,289-
3,468,740 (hg19) highlighting all repetitive DNA elements listed in RepeatMasker. The SVA is annotated. The ECR 
is highlighted in green box which contains MIR element and is marked by Txn Fac ChIP v2 and histone marks from 
ENCODE data. The conservation track shows conserved regions in black and a break across the SVA highlighting 
specificity to the human genome. (B) Summary of transposable elements including count, combined size and 





3.3.1.2 Generation of reporter gene constructs  
To test the regulatory potential of the ECR and the SVA, we cloned them separately into the 
reporter gene construct pGL3-P (section 2.2.4).  Both targets were amplified from human 
genomic DNA using PCR (methods section 2.2.2.1). Primer sequences and PCR conditions are 
listed in appendix A (entry 1 for SVA primers and entry 2 for ECR primers). PCR products were 
initially ligated into the intermediate vector, pCRII, using the TA cloning strategy described in 
section 2.2.4.1.  
A restriction enzyme digest, using HindIII (Promega, R6041), was used to cut the DNA 
insert from the plasmid backbone to confirm the presence and orientation of inserts in 
selected clones (section 0) (Figure 3.3A). The empty pCRII vector was cut once therefore 
generated a linearised product 3971 bp in length (Figure 3.3B). Recombinant pCRII vectors 
containing the SVA insert were cut twice, generating product sizes of 4831 bp and 1101 bp if 
the SVA was in the forward orientation, and product sizes 5861 bp and 744 bp if in the reverse 
orientation. Similarly, for the ECR, if cloned in the forward orientation product sizes were 
5029 bp and 139 bp, and 3997 bp and 1171 bp in the reverse orientation (Figure 3.3C). We 
generated four constructs in total containing the SVA or ECR in forward and reverse 
orientations (Figure 3.3).  
Restriction enzyme digests were then performed on recombinant plasmids to cut out 
the insert, and also cut out a small sequence in the reporter gene vector to generate 
compatible ends that would enable subcloning (section 0). We digested the target insert from 
the intermediate pCRII vector using SacI (Promega, R6061) and XbaI (Promega, R6181). The 
reporter gene vector pGL3-P was digested using SacI (Promega, R6041) and NheI (Promega, 
R6501) to produce compatible ends (Figure 3.4). XbaI and NheI are isoschizomers, which 
recognise different (but similar) sequences yet generate compatible overhangs. This also 
prevented the orientation of the cloned inserts changing when subcloned from the 




Sequencing was used to verify the correct inserts and assess any mutations (e.g. 
indels), as this could affect transcription factor binding compared to the native form. 
Sequencing primers are listed in appendix A (entry 6).   
 
Figure 3.3. Diagnostic restriction enzyme digests showing target sequences cloned in both orientations into 
intermediate vector pCRII. (A) Schematic showing predicted digested product sizes following digest with HindIII. 
(B) Restriction enzyme digest showing cloned SVA insert in forward orientation (left) and reverse orientation 
(right). (C) Restriction enzyme digest showing cloned ECR insert in forward orientation (right) and reverse 





Figure 3.4. Subcloning strategy using restriction enzyme digests to generate compatible nucleotide overhangs. (Above) The intermediate vector pCRII was digested using SacI and XbaI to 
produce 5’ overhangs. The green insert represents the initial sequence ligated into pCRII using TA cloning. (Below) The expression vector pGL3-P was digested using SacI and NheI to generate 




3.3.1.3 SVA is functional as transcriptional repressor and ECR shows minimal activity in 
HEK293 cell model 
SVA and ECR constructs were transfected into HEK293 cells (section 2.2.5.3) and assessed 
using a reporter gene assay 48 hours later (Figure 3.6). Using the pmaxGFP plasmid (Lonza) 
to visualise fluorescence we estimated a transfection efficiency of 80% (Figure 3.5). Any 
changes in luciferase activity (comparing the recombinant pGL3-P containing the insert 
against the original empty vector) could be directly correlated with luciferase expression 
resulting from the presence of the insert, therefore determining regulatory activity in vitro.  
All assays consisted of 4 biological replicates, which were defined as independent cell 
cultures that were transfected separately (n=4). Luciferase activity was averaged from 
triplicate fluorescent readings. Cells were cotransfected with the pRL-TK vector which 
expresses Renilla luciferase and was used to normalise data between transfections. The basic 
vector, pGL3-B did not contain a promoter and did not express luciferase, acting as a negative 
control within the assay.  
pGL3-B showed relative luciferase activity approaching zero, indicating no luciferase 
activity and this assay was functioning correctly (0.03±0.00, n=4, P=0.03) (Figure 3.6). The 
SVA cloned into pGL3-P in the forward orientation showed a 2-fold decrease in luciferase 
activity (0.48±0.03, n=4, P=0.03). Similarly, the pGL3-P construct containing the SVA cloned 
in the reverse orientation showed a 1.6-fold decrease (0.62±0.03, n=4, P=0.03) (Figure 3.6). 
The reduction in luciferase activity directly correlates with luciferase expression, therefore 
the insertion of the SVA induced a repressive effect on gene expression in this HEK293 model. 
Thus, we concluded that this SVA can function as a transcriptional regulatory element. This 
could potentially be due to transcription factors directly binding the SVA sequence, or 
perhaps the SVA sequence induced a DNA structure which interfered with transcription 




The ECR cloned in the forward orientation showed a 1.3-fold increase in relative 
luciferase activity (1.3±0.02, n=4, P=0.03) (Figure 3.6). This was statistically significant 
however this was a very minimal increase therefore we could not consider this as biologically 
relevant in this case. The ECR cloned in the reverse orientation showed a 1.08-fold increase 
however this was not biologically or statistically significant (1.08±0.05, n=4, P=0.19) (Figure 
3.6). From this data we concluded the ECR was showed minimal activity as a transcriptional 
regulatory domain in this HEK293 model. As this was not tested in any other cell line, we 






Figure 3.5. Transfection of HEK293 with pmaxGFP. Images showing expression of GFP detected under fluorescent 
microscope 48 hours post transfection. (Left) Phase contrast images showing cell confluency. (Right) Fluorescent 
images showing GFP. Estimated transfection efficiency 50%. 
 
 
Figure 3.6. Results for luciferase reporter gene assay testing SVA and ECR reporter gene constructs in HEK293. 
Relative luciferase activity in empty (pGL3-P) vector was compared against baseline (pGL3-B) and reporter gene 
constructs (pGL3-P containing an SVA or ECR in forward and reverse orientations). Luciferase activity was 
normalised to the internal control vector (pRL-TK). Error bars represent standard error from the mean. Mann 




3.3.1.4 SVA is functional as transcriptional repressor in mouse DRG model 
Using the same constructs in DRG primary culture it was possible to assess if the SVA could 
co-opt transcription factors present within sensory neurons and function as a transcriptional 
regulator in this tissue. It was not possible to obtain human DRG during this project therefore 
mouse DRG were used as a model. A recent study of mouse and human DRG transcriptomes 
highlighted a conserved enrichment of transcription factors and supports the use of mouse 
DRG in this context6.  
Purified DRG cell suspensions were transfected using nucleofection, which is a harsh 
treatment and resulted in a lot of cell death and low transfection efficiency (estimated <10%) 
(Figure 3.7). An example of untransfected purified DRG taken from Thy1-YFP mice grown in 
culture is given in Supplementary figure 1 to highlight culturing conditions were optimal for 
DRG growth and the cell death observed in this experiment was due to transfection. 48 hours 
post-transfection, luciferase activity was assayed (Figure 3.8). Due to low cell numbers 
resulting from cell death, and to keep the number of mice culled to a minimum, it was 
decided to only test the SVA reporter gene construct in its forward orientation.  
pGL3-B showed a decrease in luciferase activity (0.50±0.01, n=4, P=0.03). The 
decrease in luciferase from pGL3-B was not as great as observed in HEK293 due to the low 
number of cells present in the assay, and the relatively high level of background fluorescence. 
A 1.6-fold decrease in luciferase activity from pGL3-P containing the SVA was observed 
(0.64±0.06, n=4, P=0.03), consistent with the results observed in HEK293. This indicates that 
the SVA is responsive to transcription factors within sensory neurons and can function as a 






Figure 3.7. Examples of DRG cultures 24 hours following transfection with pmaxGFP. (Left) Phase contrast 
images showing DRG neurons and cell debris resulting from cell death. (Right) Flourescent images showing 





Figure 3.8. SVA at TRPV1 and TRPV3 functions as transcription regulator. Relative luciferase activity in empty 
(pGL3-P) vector was compared against baseline (pGL3-B) and SVA vectors (pGL3-P containing an SVA in 
endogenous and reverse orientations). Luciferase activity was normalised to the internal control vector (pRL-TK). 
Error bars represent standard error from the mean (SEM). Mann Whitney tests were used to measure the 





3.3.2 CRISPR assay optimisation and generation of modified cell lines 
3.3.2.1 In silico design of CRISPR assay to delete SVA and ECR at TRPV1 and TRPV3 
We designed a CRISPR experiment to delete the SVA and the ECR at the intergenic region 
between TRPV1 and TRPV3 and assess the potential impact on TRPV1 and TRPV3 mRNA 
expression. The Cas9 enzyme utilised in this experiment was from Streptococcus pyogenes 
and encoded by the vector pSpCas9(BB)-2A-GFP (Figure 3.9). The Cas9 enzyme was guided 
to a target sequence in the genome by a sgRNA tag which contained a specific 20 nt sequence 
that binded to the complimentary strand of the target sequence in the genome (Figure 3.10). 
This sequence was directly upstream of a protospacer adjacent motif (PAM) site (5’-NGG-3’, 
where N can be any nucleotide) as this specific Cas9 nuclease creates a double strand break 
(DSB) 3 bp upstream of the PAM210 (Figure 3.10). A dual targeting approach was taken which 
involved co-transfecting cells with two pSpCas9(sgRNA) plasmids, to transcribe the required 
Cas9 machinery to generate two separate DSBs at the 5’ and 3’ end of the target sequence – 
which resulted in total excision of the target sequence and repair of each DSB via non-
homologous end joining (NHEJ)210.  
 Multiple sgRNAs were designed using in silico methods described in section 2.2.8.1. 
to enable excision of the ECR, SVA (separately) or both the ECR and SVA (together) based 
upon the combination used in different trials (Figure 3.11). Several guides were designed 
which differed by a few nucleotides as the predicted off target effects (capacity of the gRNA 
to bind elsewhere in the genome, resulting in additional DSBs) were dependent upon 
sequence. The option of having multiple sgRNAs also enabled us to test which combination 
of gRNAs created the most efficient deletion (discussed in section 3.3.2.3). All gRNA 






Figure 3.9. Overview of pSpCas9(BB)-2A-GFP. sgRNA oligonucleotides containing the 20 nt target sequence (black sequence) were modified via removal of the PAM sequence (red text) and 





Figure 3.10. Schematic of Cas9 cleavage guided by sgRNA. A 20 nt target sequence (green) directly upstream of a PAM site is cloned into the pSpCas9 vector. When expressed, the Cas9 enzyme 
has a sgRNA tag (red) which encodes the target sequence (green), which pairs with the complimentary strand of the target sequence. The guided Cas9 then makes a DSB (red triangle) 3 bp 





Figure 3.11. gRNA target sequences. Screenshot taken from UCSC genome browser (hg19) showing the SVA at 
the intergenic region between TRPV1 and TRPV3. gRNA target sequences were selected (shown inside black box). 
SVA is denoted. ECR is highlighted in green box. gRNA 1, 2 and 3 are upstream of the ECR. 4, 5, 6 and 8 are within 
the ECR. gRNA 7 is between the ECR and the SVA. gRNAs 9, 10 and 11 are between the SVA and the 3’UTR of 





3.3.2.2 Generation of CRISPR-Cas9 vectors containing gRNAs 
To clone the gRNA sequences into the Cas9 vector pSpCas9(BB)-2A-GFP, a double stranded 
oligonucleotide was required with specific sequence modifications to produce compatible 
ends for cloning (Figure 3.9). The target sequences were modified with the removal of the 
PAM sequence and the addition of 5’-CACC-3’ onto the 5’ end (Figure 3.9). The 
complimentary olidonucleotide to the target sequence was modified with 5’-AAAC-3’ onto 
the 5’ end (Figure 3.9). Complimentary oligonucleotides were then annealed and cloned into 
the BbsI site of the Cas9 vector using golden gate cloning (Figure 3.9). Successful cloning 
resulted in the disruption of the BbsI cut site and no restriction digest. All cloning was 
successful using BbsI digest (Figure 3.12). This was further confirmed using DNA sequencing. 
Plasmids containing gRNAs are referred to as pSpCas9(sgRNA) from this point onwards.  
 
 
Figure 3.12. BbsI restriction digest results showing successful cloning of gRNA inserts. Failure to digest using 
BbsI indicates recognition site was disrupted through cloning and therefore represents a recombinant plasmid. 
All plasmids were verified by sequencing. 2 results are present for each guide as 2 colonies were picked during 
cloning. Positive control is the linearised plasmid. Negative controls include the uncut plasmid (no enzyme present 




3.3.2.3 Optimisation of CRISPR-Cas9 strategy for efficient SVA deletion 
The CRISPR protocol was optimised by focussing efforts on deleting the SVA at TRPV1 and 
TRPV3. pSpCas9(sgRNA) plasmids were transfected in various combinations into different cell 
lines and screened using PCR to identify which gRNAs enabled the greatest modification 
efficiency and which cell line was most responsive to modification. PCR primers and thermal 
cycles are listed in appendix A, entry 9. Results from PCR would indicate if a modification had 
taken place. A large PCR product (2486 bp) indicates an unmodified region the SVA. A smaller 
PCR product (545 bp – 746 bp, dependent on sgRNAs used) indicates a modified region (not 
containing an SVA). All PCRs were performed on purified gDNA from pooled populations 48 
hours post transfection.  
3.3.2.3.1 HAP1 
We first trialled HAP1 cells, as they contained a haploid genome221. This would have enabled 
modification of a single allele and ability to measure gene expression in modified cells 
without effects being masked by a remaining allele.  
This cell line was problematic as the GFP from pSpCas9(sgRNA) vectors could not be 
detected after 24 or 48 hours under a fluorescent microscope, therefore potentially modified 
cells could not be isolated using FACS (no data to show). GFP from pmaxGFP (used as a 
positive control) could be detected however, indicating a low transfection efficiency <10% 
and an issue with the expression of pSpCas9(sgRNA) in HAP1 (Figure 3.13).  
The pSpCas9(sgRNA) vector was being expressed as some modifications were 
observed following genotyping, although this was likely at a low level as modified PCR 
products were evident on agarose gels at a very low intensity compared to the unmodified 
PCR product, indicating a poor modification efficiency (Figure 3.18).  
The poor modification efficiency may have been due to the poor transfection 




genetic aberrations in target sequences surrounding the SVA may have also contributed to 
inefficient modification. The lack of GFP from pSpCas9(sgRNA) was not resolved therefore 
were unsuitable for cell sorting using FACS. We concluded that HAP1 cells were not suitable 
for this assay as modification efficiency was poor and the lack of a Cas9-GFP tag would make 
it increasingly difficult to isolate modified clones.  
 
Figure 3.13. Transfection of HAP1 cells with pmaxGFP. (Left) Phase contrast of image showing cells at 
approximately 80-90% confluency, 48 hours post transfection. (Right) Flourescent microscopy image showing 







SH-SY5Y cells were trialled next, as  they are characterised by neuronal markers and are often 
used for in vitro assays within neurobiology222,223.  
PCR analysis revealed that all guide combinations generated  modifications (Figure 
3.18), therefore the assay was working more efficiently in this cell line compared to results 
in HAP1. pSpCas9(sgRNA7) and pSpCas9(sgRNA10) produced generated an SVA deletion with 
the smallest amount non target DNA also being excised, therefore these constructs were 
taken forward. GFP was expressed from pSpCas9(sgRNA) and fluorescing well at 48 hours 
post transfection therefore this cell line was suitable for cell sorting via FACS to isolate GFP 
positive cells and enrich for cells with potential modifications (no data to show).  
SH-SY5Y were then transfected with the selected constructs pSpCas9(sgRNA7) and 
pSpCas9(sgRNA10) and sorted based on GFP by FACS. The output from FACS with thresholds 
set to isolate live, single cells expressing GFP is shown (Figure 3.14). We set thresholds to 
detect cells that were identified as being live, single cells expressing GFP - suitable for single-
cell clonal expansions. No microscopy images were taken during this trial however the data 
from FACS showed more GFP- cells than GFP+ cells, indicating a transfection efficiency <50% 
(Figure 3.14). We set thresholds to sort the top 2% of GFP expressing cells, as we 
hypothesised those cells with the highest GFP expression would have the highest Cas9 
expression and thus more likely to carry the desired modification. A second sort was 
performed to remove any GFP negative cells that may have been included in the original sort 
(Figure 3.14).  
Following FACS, GFP positive and negative (controls) cells were plated at different 
densities across two 96-well plates (per well; 1, 5 and 10 cells) in anticipation of potential 
growth difficulties of clones in isolation (e.g. cell death resulting from few growth factors) 




improve after repeating with conditioned media (filtered SH-SY5Y cell media taken from 
overnight growth of unmodified SH-SY5Y). Untransfected cells did not show the same growth 
difficulties as transfected cells, highlighting that SH-SY5Y cells were particularly vulnerable to 
death if FACS was used to isolate GFP positive cells following transfection.  
The few GFP colonies were grown and genotyped using PCR however all results 
showed that they did not contain any modified DNA (Figure 3.15). The difficulties isolating 






Figure 3.14. Results from FACS cell sorting SH-SY5Y for isolation of CRISPR modified clonal cell lines. (Left) First 
sorting of cells based on live cell detection, single cell dissociation, GFP expression and final counts showing 200 
for every 10,000 cells sorted. (Right) Second sorting of cells based on the same parameters to remove any 
potential GFP negative (untransfected) cells from the population. 
 
Table 3.1. Results from low density seeding GFP of SH-SY5Y cells following FACS. Total cells plated = 196 wells.  
 GFP positive GFP negative (control) 
Seeding density (per well) Positive wells % Positive wells % 
1 0 0.0 4 2.1 
5 0 0.0 32 16.7 






Figure 3.15. No modifications identified in SH-SY5Y following isolation of clones. Clones identified from low 
density seeding were genotyped to detect SVA presence/absence following CRISPR. GFP+ cells previously isolated 
using FACS. GFP- cells were used as a negative control. Blank refers to no template control. Unmodified PCR 






HEK293 cells were the final cell line to be trialled for CRISPR as they are well characterised as 
being easy to transfect and produce high levels of exogenous proteins224-226. The ATCC 
website describes four copies of chromosome 17 (http://www.lgcstandards-
atcc.org/products/all/CRL-1573.aspx?geo_country=gb#characteristics), which is supported 
by Binz et al227. A review of publicly available SNP array data revealed no CNVs across 
chromosome 17 in HEK293, compared to HEK293T (a variant of cell line of HEK293), in which 
a large-scale deletion was identified (Figure 3.16A)225. An earlier study of the HEK293 
karyotype also found no aberrations on chromosome 17, supporting this data224. 
Visualisation of the SVA containing region using a HEK293 genome browser highlighted few 
SNPs, deletions and insertions providing evidence that this region would be readily 
susceptible to modification using CRISPR (Figure 3.16B). As previously described, HEK293 
populations were transfected with each combination of pSpCas9(sgRNA) vectors. PCR 
analysis (Figure3.18) showed the products corresponding to modified regions (range 545 bp 
– 746 bp) were much brighter on agarose gels than the unmodified regions (2486 bp). This 
suggested the modification efficiency in HEK293 was improved compared to HAP1 and SH-
SY5Y and was the chosen cell line to generate clonal cell lines. SpCas9(sgRNA7) and 






Figure 3.16. Bioinformatic assessment of intergenic region at TRPV1 and TRPV3 in HEK293. (A) SNP array data 
showing no copy number variation (CNV) in HEK293 and an example of CNV loss in HEK293T. Data taken from Lin 
et al225. (B) Detailed analysis of target region containing SVA shows few base pair changes to the target sequence 
in HEK293.  
 
 
Figure 3.17. Transfection of HEK293 with pSpCas9 GFP. (Left) Phase contrast image showing HEK293 cells at 
approximately 80-90% confluency, 48 hours post transfection. (Right) Fluorescent microscopy image showing 







Figure 3.18. Optimising pSpCas9(sgRNA) transfection combinations in human cell lines. Different combinations 
of pSpCas9(sgRNA) vectors were transfected into human cell lines. Modified genomic region containing deletion 
of SVA generated product size ranging between 545 and 776 bp. dependent upon combination of sgRNAs. Guide 
combinations are denoted at the bottom, with expected product sizes. Refer to Figure 3.11 for schematic of sgRNA 
locations. (A) HAP1 results showing minimal modified product from combination 6,11 and 7,9. (B) SH-SY5Y results 
showing modification in all combinations, with majority of product corresponding to unmodified product. (C) 





3.3.2.4 Isolation of HEK293 CRISPR modified clones with SVA deletions 
Previous results with SH-SY5Y highlighted difficulties in selecting clones from seeding cells 
in a 96-well format following FACS (section 0) therefore low-density seeding in 10 cm dishes 
was tested instead, as this enabled the release and uptake of growth factors between cells, 
increasing likelihood of survival. FACS was not used to cell sort HEK293 to avoid 
unnecessary strain on the cells, as the transfection efficiency (Figure 3.17) and modification 
efficiency (Figure 3.18)) were deemed sufficient to obtain enough modified cells.  
A total of 6 plates were seeded with 1000 cells each. Low density seeding allowed 
the growth of single cells into clonal populations, which were then picked (when visible by 
eye) and expanded in a 96-well format. Spreading the cells across 6 plates ensured that no 
single plate was out of the incubator for any length of time, which may have reduced cell 
viability. A total of 360 clones were picked across the six plates. 24 hours after picking, 215 
clones survived (71%) which were then grown in duplicate to provide enough cells for 
genotyping whilst enabling continuation of growth for further experimentation.  
Screening for modifications was performed using crude cell lysate as a PCR template 
to increase throughput, however this method failed to amplify larger PCR products (perhaps 
due to PCR inhibitors in crude lysate), therefore could only be used to identify if any SVA 
deletion had occurred but not identify if this was a partial or complete deletion (Figure 
3.19A).  
Using this screening method, 33 cell lines (12%) were identified that contained at 
least one SVA deletion. To determine the genotype of each cell line accurately, genomic DNA 
was purified from selected clones and the PCR was repeated (Figure 3.19B). Three results 
could be observed, a single product at 545 bp indicating a homozygous deletion (i.e. all copies 
of the SVA are deleted), a single product at 2486 bp indicating no SVA copies were deleted 




deleted and at least one copy of the SVA is present). A total of 23 cell lines were confirmed 
to contain a heterozygous SVA deletion and 3 cell lines that contained a homozygous SVA 
deletion. 6 false positives were identified in the crude lysis resulting from non-specific PCR 
products. This represents a 10% modification efficiency for heterozygous SVA deletions and 
1% modification efficiency for homozygous SVA deletions.  
Sequencing was then used to profile modification breakpoints and assess the 
accuracy of this CRISPR system (Figure 3.21). Sequencing primers are in appendix A, entry 8. 
For comparison, we selected all 3 cell lines containing a homozygous SVA deletion and 3 lines 
containing a heterozygous SVA deletion (Figure 3.20). Based on the PAM sequence chosen 
when designing the gRNAs, the Cas9 enzyme should cut the DNA exactly 3 bp upstream 
(referred to as DSB site) (Figure 3.21).  
One heterozygous cell line and all homozygous cell lines contained breakpoints that 
aligned perfectly with the predicted DSB sites at both the 5’ and 3’ end of the SVA (Figure 
3.21). The remaining two heterozygous cell lines contained different breakpoints. At the 5’ 
end the breakpoints were between 2 – 4 bp upstream of the DSB site, representing small 
deletions (Figure 3.21). At the 3’ end, both breakpoints were 18 bp upstream of the DSB site, 
representing a larger deletion although still relatively small (Figure 3.21). 4 out of the 6 cell 
lines had breakpoints confirmed at the predicted DSB sites, indicating a high level of editing 
accuracy and non-homologous end joining (NHEJ) DNA repair using this system. An overview 
of the entire CRISPR protocol optimised for the deletion of larger DNA sequences in HEK293 





Figure 3.19. Screening HEK293 clonal cell lines to identify SVA deletion. (A) PCR results from crude lysates 
identify products corresponding to modified region containing SVA deletion at 545 bp. No unmodified products 
at 2486 bp could be detected. (B) Same samples repeated PCR using purified genomic DNA as template confirmed 
genotype of clonal cell lines. Sample 1, 5 and 6 were false positives resulting from non-specific PCR products in 
crude lysate. Samples 2 and 3 were heterozygous containing at least one deleted SVA copy. Sample 4 was a 
homozygous deleted sample as all SVA copies were deleted.  
 
 
Figure 3.20. Clonal cell lines selected for gene expression analysis. PCR results showing clonal cell lines 
corresponding to unedited HEK293 (n=3), cell lines carrying a heterozygous SVA deletion (n=3) and cell lines 





Figure 3.21. Validation of clonal CRISPR modified cell lines. (A) PCR validation of clonal modified cell lines containing heterozygous and homozygous SVA deletions. B) Sequencing validation of 





Figure 3.22. Overview of final CRISPR protocol developed to generate cell lines containing large deletions. In silico design includes design of gRNAs and PCR primers to test for deletion.  Reagent 
construction includes preparation of oligonucleotides containing gRNAs and cloning into CRISPR-Cas9 vector pSpCas9(BB)-2A-GFP. Functional validation includes transfection of CRISPR-Cas9 
vectors containing gRNAs into cell lines, isolating genomic DNA and PCR to test for deletion – which informs which gRNAs are most efficient at generating required modification. Isolation of 
clonal cell lines includes transfection of selected gRNAs, isolation and growth of clonal cell lines (this can take up to 8 weeks), followed by genotyping to identify positive clones and expansion 




3.3.2.5 Isolation of HEK293 cell lines containing ECR deletions was unsuccessful 
We also attempted to delete the ECR independently and generate a double knockout cell line 
carrying a combined ECR/SVA deletion (Figure 3.11). Following the same protocol as 
described in the previous section (section 3.3.2.4). HEK293 was transfected using various 
combinations of pSpCas9(sgRNAs).  
To delete the ECR, pSpCas9(sgRNA4) was selected to create the 5’ DSB as this was 
the only guide that would enable deletion of the ECR conserved with the mouse, and not 
include a deletion of the adjacent Alu which was conserved with primates only, not mouse 
(Figure 3.11). To delete the ECR and SVA together, pSpCas9(sgRNA4) was paired with 
pSpCas9(sgRNA10) as this had already been used to generate the SVA clonal deletions, 
therefore would generate a more comparable deletion than using the other constructs.  
PCR products corresponding to modified regions were detected in both ECR deletion 
trial 1 (2733 bp) and ECR deletion trial 2 (2618 bp), indicating the constructs were working 
(Figure 3.23A). However, the intensity was very low compared to the product corresponding 
to the unmodified region (3264 bp), indicating the modification efficiency was also low.  
Constructs used in ECR trial 2 were taken forward as this appeared to work better. 
This was also the case for the double ECR/SVA knockout trial which showed a low intensity 
product corresponding to the region containing neither SVA or ECR (947 bp) (Figure 3.23B). 
This was repeated to however no ECR deletion could be detected. The double ECR/SVA 
deletion was replicated therefore was taken forward to isolate clonal cell lines.  
After low density seeding, and growth in 96-well format, 44% (n=42) of colonies grew 
to sufficient numbers for genotyping, the remainder did not survive. From these colonies, 





Figure 3.23. CRISPR modification of ECR deletion in HEK293 was unsuccessful. (A) Testing pSpCas9(sgRNA) 
combinations in ECR deletion trials (ECR1 and ECR2), and double knockout ECR/SVA shows modifications achieved 
in HEK293. (B) Repeat knockout of ECR and ECR/SVA with selected pSpCas9(sgRNA) show ECR modification was 
unsuccessful but ECR/SVA medication was achieved. (C) Genotyping of clones isolated from mixed population 





3.3.3 Measuring TRPV1 and TRPV3 expression in HEK293 lines carrying SVA deletions 
3.3.3.1 Optimisation of qPCR assay to measure total TRPV1 and TRPV3 mRNA and RNA 
quality controls 
To measure changes in TRPV1 and TRPV3 expression, we designed a qPCR assay to measure 
total mRNA. Primer sequences and thermal cycling conditions are given in appendix A (entry 
10). All data was normalised against β-actin (ACTB), a highly conserved cytoskeletal protein 
that is commonly used as a reference gene in RT-PCR228.  
Primer efficiencies were calculated using standard curves (Figure 3.25). ACTB primers 
were 100.8% efficient, TRPV1 primers were 109.57% efficient and TRPV3 primers were 
106.28% efficient. It is desirable to achieve a primer efficiency between 90 – 110%. Primer 
efficiencies of 100% indicates the polymerase is working at maximum capacity. Efficiencies 
>100% can indicate inhibitors in the reaction including excessive amounts of RNA template 
or contaminants such as ethanol or phenol, from RNA purification steps. The results were 
within the desired range therefore we proceeded with the experiment using these primer 
sequences. 
RNA quality control data did not indicate the presence of inhibitors, as all 260/280 
and 260/230 ratios were >2.0 and absorbance plots produced expected curves, therefore 
efficiencies >100% may have been due to pipetting error (Figure 3.24B). All RNA samples 
were intact and not degraded (Figure 3.24C). 
 All dissociation curves indicated the presence of a single product (Figure 3.25). 
TRPV1 and TRPV3 controls (including no reverse transcriptase and no template) did not 
amplify any product therefore we were confident that cDNA preparation and reaction setup 
had been conducted properly (Figure 3.25). We observed low level amplification in ACTB 
controls towards the end of the reaction (>35 cycles) but this was attributed to primer dimer 





Figure 3.24. Example of RNA quality controls. (A) Absorbance plots from Nanodrop showing peak absorbance at 
expected 260 nm. (B) Summary of 260/280, 260/230 ratios and RNA concentrations following purification – 
highlighting pure RNA samples. (C) RNA samples run on agarose gel indicating intact RNA form presence of 28S 





Figure 3.25. qPCR optimisation results and primer efficiencies. Amplification curves showing real time amplification of products from TRPV1, TRPV3 and ACTB primer sets. Dissociation curves 
show single peaks indicating amplification of single product. Standard curves were used to calculate slope of curve which was then used to calculate amplification factor and primer efficiency. 
No reverse transcriptase (No RT) and no template controls (NTC) show lack of amplification in TRPV1 and TRPV3 trials, indicating no contamination gDNA is present in preparation. The presence 




3.3.3.2 Total TRPV3 mRNA expression increases in cell lines carrying SVA deletion 
qPCR was used to measure total TRPV3 mRNA (normalised against ACTB) in HEK293 cells 
containing an SVA deletion compared against unedited HEK293. Cells transfected with Cas9 
vectors containing non-targeting RNAs (pSpCas9(ntgRNA)) were used as a control, and all 
data was normalised against this group.  
Untransfected cells showed no difference in TRPV3 expression compared to 
pSpCas9(ntgRNA) controls (0.97±0.05, n=3, P>0.05) (Figure 3.26). This indicated that 
transfection with the Cas9 enzyme alone (lacking a specific sgRNA) did not induce any 
observable change in total TRPV3 mRNA expression and supported that differences observed 
in edited cells were a result of the genetic modification.  
Cells with a heterozygous SVA deletion had a mean 4.6-fold increase in TRPV3 mRNA 
expression (4.56±2.9, range: 1.28-10.2, n=3, P>0.05). TRPV3 expression increased in all three 
cultures carrying a heterozygous SVA deletion.  
Cell lines carrying a homozygous modification had a mean 1.5-fold decrease in TRPV3 
expression (0.67±0.39, range: 0.01-1.35, n=3, P>0.05). Whilst statistical significance was not 
reached, changes in TRPV3 mRNA expression were only observed in cells carrying an SVA 
deletion, consistent with the results from the reporter gene assays showing the SVA 
functioned as a regulatory element in HEK293 (Figure 3.6). It was concluded that the SVA 





3.3.3.3 Total TRPV1 mRNA expression does not change in cells with SVA deletion 
qPCR was also used to measure total TRPV1 mRNA expression in modified cells 
compared against unedited cells transfected with pSpCas9(ntgRNA) as controls (Figure 3.27). 
Primers and thermal cycles are listed in appendix A, entry 10.  
Untransfected cells showed a mean 1.2-fold decrease in TRPV1 mRNA (0.80±0.03, 
range: 0.75-0.86) compared to cells transfected with pSpCas9(ntgRNA) (1.01±0.09, range: 
0.88-1.19, P>0.05). This indicated that transfection of cells with Cas9 was inducing some 
observable effect on TRPV1 mRNA expression. Cells with a heterozygous SVA deletion had a 
1.18-fold increase in TRPV1 mRNA expression (1.18±0.51, range: 0.58-2.19, n=3, P>0.05).  
Cells with a homozygous deletion had a 1.12-fold increase in TRPV1 mRNA expression 
(1.12±0.12, range: 0.95-1.34 n=3, P>0.05). The results between pSpCas9(ntgRNA) controls 
and modified cell lines were variable and within the same range, therefore changes to 
expression in cell lines containing an SVA deletion could not be specifically attributed to the 
genetic modification.  
TRPV1 mRNA expression differences in cell lines carrying a heterozygous 
modification were the most variable across the experiment, like the trend seen for TRPV3 
mRNA (Figure 3.26). This may have been a genuine reflection of SVA regulatory activity, but 
the possibility of off target effects could not be dismissed due to changes observed between 
untransfected and pSpCas9(ntgRNA) controls. For example, introduction of a double strand 
break in an exon of a protein coding gene could introduce a nonsense mutation and generate 
a gene knockout. If this gene is involved in the same pathway as TRPV1 (or a regulator of 
TRPV1), this could induce change in TRPV1 mRNA. This could hypothetically explain why we 
see no effect of pSpCas9(ntgRNA) controls on TRPV3 expression but observed them in TRPV1 
mRNA expression. Ultimately, it was concluded that the SVA does not contribute to the 





Figure 3.26. TRPV3 mRNA expression increases in CRISPR modified HEK293 cell lines carrying homozygous 
SVA deletion. All data normalised against ACTB. All results compared against unedited cells transfected with 
pSpCas9(ntgRNA). No statistical significance detected between edited and unedited cell lines (Mann-Whitney U 
test). Error bars indicate SEM.  
 
Figure 3.27. TRPV1 mRNA expression did not alter in CRISPR modified HEK293 cell lines with SVA deletion. All 
data normalised against ACTB. All results compared against unedited cells transfected with pSpCas9(ntgRNA). 
No statistical significance detected between unedited and edited cell lines (Mann-Whitney test). Error bars 





3.3.3.1 Development of a multiplex RT-PCR assay to detect isoform expression of 
TRPV1 and TRPV3 
Ensemble (hg38) was used to explore protein coding transcripts for TRPV1 and TRPV3. 
Transcripts predicted to trigger nonsense mediated decay and noncoding transcripts were 
not analysed in this experiment. There were 7 protein coding transcripts for TRPV1, however 
four of these transcripts encoded an 839aa protein. The other three encoded transcripts 
encode proteins sized 779aa, 829aa and 850aa. There were 4 protein coding transcripts for 
TRPV3. Each encoded a different sized protein; 765aa, 775aa, 790aa and 791aa. We designed 
primers to amplify a specific exon belonging to each protein coding transcript, to enable 
differential detection of isoforms using multiplex RT-PCR, in which each isoform generated a 
different sized product (Figure 3.28). The multiplex RT-PCR reactions developed for this assay 
followed the basic PCR protocol described in methods section 2.2.2.1, however nuclease free 
water was adjusted as multiple primers were included in each mastermix. The primers and 
thermal cycles are listed in appendix A, entry 11.  
Across all unedited, ntgRNA, and edited cell lines, we identified a single 240 bp 
product corresponding to TRPV1 transcript ENST0000572705.1 (Figure 3.29). According to 
GTEx, this transcript is expressed across all tissues with the highest levels in tibial nerve (read 
count 13.2), cerebellum (read count 12.4) and cerebral hemisphere (read count 11.8). We 
realised it was not possible to specifically detect TRPV1 transcript ENST00000576351.5 (197 
bp) in the presence of ENST0000572705.1 (240 bp) due to sharing the same exon content 
across the amplified region (Figure 3.28). We did not detect any band at 197 bp so we could 
ignore this error in this case, however it is important to note this for future studies. This data 
gives no evidence to suggest that the SVA influences protein coding transcript expression in 
HEK293.   
Three TRPV3 PCR products were identified across all unedited and edited cell lines. 




ENST00000576742.5 (159 bp) (Figure 3.29). All three isoforms were expressed in all unedited 
and edited cell lines, indicating no change in the expression of specific transcript variants in 
cells containing an SVA deletion. We realised that the primers designed to detect 
ENST00000301365.8 (243 bp) and ENST00000576742.5 (159 bp) were not specific to those 
transcripts in the presence of ENST00000616411.4 (927 bp), therefore we could not 
determine if these were specific isoforms or simply products amplified from 
ENST00000616411.4 (927 bp) (Figure 3.28). It was not possible to design specific primers for 
the smaller transcripts as the exon content other than at the 3’UTR is shared; therefore this 
should be taken into account in all future studies. This may explain why the intensity of 
different transcripts were relatively similar within each sample. From this data, we could only 
definitively confirm the presence of the larger transcript ENST00000616411.4 (927 bp). 
According to GTEx, this transcript is the second highest expressed transcript in human skin 
(read count 2.44). ENST00000381913.8 is the highest expressed TRPV3 transcript in human, 
across a broad range of tissues including testis, nerve and brain – however this transcript was 
not detected in HEK293. This data gives no evidence to suggest that deletion of the SVA 





Figure 3.28. Schematic of RT-PCR design to measure TRPV1 and TRPV3 isoforms.  Primers were designed within specific exons of each protein coding transcript for TRPV1 (above) and TRPV3 
(below).  cDNA and gDNA product sizes are given.  Protein size and transcript IDs are also provided. Grey boxes represent exons in each transcript. Arrows indicate exons in which primers were 
designed. Red arrows indicate lack of transcript specificity in the presence of other transcripts. In TRPV1, ENST00000576351.5 cannot be specifically identified in the presence of transcripts 
above it due to sharing the same exon content in the amplified region. Also, in TRPV3, ENST00000301365.8 and ENST00000576742.5 cannot be specifically identified in the presence of transcripts 





Figure 3.29. RT-PCR revealed no difference in TRPV1 or TRPV3 isoforms in CRISPR modified HEK293 cell lines. 






At present, genetic elements that contribute to human specific expression of TRPV3 have not 
been identified. We identified a human specific SVA insertion at the intergenic region 
between TRPV1 and TRPV3 and hypothesised that it exerted cis-regulatory effects, 
potentially contributing to the human specific expression of TRPV1 and TRPV3. Identification 
of human specific regulatory elements in genes implicated in pain will open an alternative 
avenue to explore the dysregulation of gene expression associated with chronic pain. This 
may help address the lack of translational research currently affecting the development of 
effective therapeutics.  
Using in vitro reporter gene assays, we first demonstrated the SVA was functional as 
a transcriptional regulator in HEK293 cells (Figure 3.6). This was consistent with previous 
publications utilising reporter gene assays to demonstrate SVAs function as transcriptional 
regulatory domains including; the SVA at Amyotrophic Lateral Sclerosis (ALS) associated gene 
FUS53 and the SVA at Parkinson’s Disease associated gene PARK7215. We did not obtain any 
strong evidence to suggest the ECR adjacent to the SVA was functional as a transcriptional 
regulatory domain in HEK293, however this may be a cell dependent effect and should be 
tested in additional cell lines. In this cell model, the reporter genes assay data demonstrated 
strong transcriptional effects of the SVA compared to the ECR (Figure 3.6). Testing the same 
SVA reporter construct in mouse DRG primary cell cultures also confirmed that the SVA had 
the potential to function as a transcriptional regulator in a neuronal context (Figure 3.8). 
These results indicated that the SVA has the capacity to bind transcription factors present in 
mouse DRG and function as a regulatory element or affect DNA structure affecting 
transcription factor binding at the SV40 promoter within the vector. Human DRG were not 
obtainable during this study, therefore mouse DRG were used as a model. A recent RNA-seq 
study conducted by Ray et al. identified that transcription factor expression profiles in human 




also exert regulatory function in human DRG6. Is important to note that whilst the expression 
of transcription factors in human and mouse DRG were largely conserved, other genes 
expressed in DRG did show species specificity (i.e. expressed in one species DRG, but not the 
other) – highlighting transcriptomic differences between the tissues of both species. Ray et 
al. only compared protein coding transcripts, thus the expression conservation of other 
factors, e.g. lncRNAs, which may also impact transcription in DRG is currently unknown6,229. 
Therefore, the results from the reporter gene assay conducted in mice DRG cannot be 
extrapolated to human DRG and further studies are required (discussed later).  
Whilst reporter gene assays are useful to assess potential regulatory activity, they do 
not prove that the sequence of interest will exert cis-regulatory effects on a gene of interest. 
Previous studies have also demonstrated that regulatory activity is variable in reporter gene 
assays dependent on the cell line used53,215. Therefore, we deleted the SVA from human cell 
lines using CRISPR to directly measure the relationship between SVA presence/absence and 
TRPV1 and TRPV3 expression and found that TRPV3 mRNA expression was mainly affected 
(Figure 3.26). We successfully developed a CRISPR protocol utilising a dual gRNA targeting 
approach to generate modified HEK293 cell lines containing SVA deletions (Figure 3.22). We 
also attempted to generate cell lines containing ECR deletions however we were unsuccessful 
(Figure 3.23). Sequencing of modified clones containing SVA deletions identified a high level 
of modification accuracy using this system. The repair of double strand breaks is mediated 
through non-homologous end joining (NHEJ), which is considered error prone in a mutagenic 
context. A study of NHEJ following CRISPR has reported at least 50% accuracy in repair of 
sites less than 150 bp apart230. The generation of large-scale deletions using CRISPR has been 
demonstrated by others (e.g. deletion of lncRNAs and even generating haploid cell lines) 
however the DNA repair efficiency following larger deletions is not well characterised221,231. 




A recent study used CRISPR to delete an intronic SVA insertion in the TAF1 gene 
(causative of X-linked Dystonia Parkinsonism), and also observed an increase in gene 
expression of TAF1 in modified cell lines (<2-fold). The trend was consistent with the data 
presented in this chapter however the fold change observed in TRPV3 mRNA expression is 
our study was much greater (up to 10-fold in one cell line) (Figure 3.26). The SVA in the TAF1 
study is a retrotransposon insertion polymorphism that affects a small population in the 
Phillipines54,232,233. The reported modification efficiency in that study was 30%, however it is 
important to note that this was performed in patient derived cell lines that contained a single 
copy SVA insertion232. The modification efficiency achieved in the work presented in this 
chapter was 10% for a heterozygous deletion and 1% for a homozygous deletion, highlighting 
the difficulty in using CRISPR to achieve the necessary modifications, especially deletion of 
more than a single copy. Low modification efficiencies have been discussed at local CRISPR 
workshops held within the Institute of Translational Medicine and are common to other 
researchers within the institute when using cell lines. There are currently no other published 
reports of SVA function being assessed using CRISPR (at the time of writing). 
Using qPCR, we identified that deletion of some SVA copies resulted in an increase 
in total TRPV3 mRNA expression and deletion of all SVA copies resulted in a decrease in total 
TRPV3 mRNA expression (Figure 3.26)- highlighting the SVA as a transcriptional regulator of 
TRPV3. The literature describes four copies of chromosome 17, therefore there are 
potentially four copies of the SVA, however to confirm if HEK293 were tetraploid at 
chr17p13.2, FISH would need to conducted227. There is conflicting evidence regarding the 
effect of long-term cultivation of HEK293 on karyotype changes therefore the results should 
be interpreted with caution as we did not karyotype our cell line during this study224,226. 
HEK293 cell lines carrying heterozygous modifications presented the largest variation in 
TRPV3 expression compared to unmodified and homozygous cell lines. It was not possible to 




heterozygous cell lines, however we propose the variability in expression in heterozygous cell 
lines may be due to different number of deleted SVA copies across the four copies of 
chromosome 17. Sequencing revealed that heterozygous cell lines had different repair 
breakpoints following NHEJ (Figure 3.21). NHEJ DNA repair can induce methylation changes, 
which could potentially have contributed to differences in mRNA expression between clones 
with different DNA repair breakpoints234.  We did not obtain any evidence from the CRISPR 
experiment to suggest the deletion of the SVA had any major effect on TRPV1 mRNA 
expression however these experiments were only conducted under basal conditions. We 
cannot discount it as a potential regulator in response to stimuli until further experiments 
have been completed. The SVA is located approximately 400 bp downstream of the TRPV1 3’ 
UTR, which could potentially affect mRNA stability. Therefore, TRPV1 protein levels should 
be assayed to assess if the SVA affects mRNA stability and consequently protein levels.  
The changes exerted to this genomic region via the deletion of the SVA may have 
resulted in epigenetic or structural changes that ultimately altered the expression of TRPV3. 
DNA methylation against transposable elements is a defence mechanism evolved by the host 
to silence retrotransposon activity38. Studies have reported that SVAs are typically 
methylated in the human genome due to their high GC content within the VNTR region235,236 
(typically thought of as mobile CpG islands). In chapter 4, we present data which highlights 
the SVA (specifically the Alu-like sequence) as a putative CpG island within the intergenic 
region (Figure 4.16). Thereby we propose that deletion of the SVA may alter the epigenetic 
status of the region, affecting the capacity of the ECR to bind transcription factors that could 
lead to changes in expression of TRPV3. Upon reflection, profiling the methylation status of 
the intact SVA in modified and unmodified cells would have strengthened this interpretation 
greatly. Follow up studies should repeat the reporter gene assays and measure TRPV1 and 
TRPV3 mRNA expression in CRISPR modified cell lines in response to a relevant stimulus, e.g. 




of gene expression. To summarise, the data from this CRISPR assay and subsequent qPCR 
gave evidence to support the role of the SVA as a cis-regulatory element at the TRPV1 and 
TRPV3 locus.  
Whilst trends were observed in TRPV3 expression, statistical significance was not 
reached. A limiting factor in this study is the low number of modified cell lines generated, 
reducing sample number available for qPCR assays. As gene expression can be variable 
between independently grown cell cultures, this study would be greatly improved by the 
generation of additional modified cell lines. A total of 23 heterozygous ∆SVA cell lines were 
identified, however only 3 were utilised in initial qPCR experiments. All available cell lines 
should be assayed to increase sample size and further explore the relationship between 
specific allelic deletions and effects of TRPV3 expression. PacBio long read sequencing has 
shown that aside from simple insertions and deletions, large complex rearrangements can 
result from repair of DSB introduced by CRISPR, which cannot be detected by short range 
PCR assays237. Profiling off-target effects was not conducted during this study however it is 
recommended that this is addressed in future studies via PCR amplification of predicted off 
target sites, followed by sequencing to verify any indels, as described by Hay et al238. Further 
recommendations include profiling the methylation status of the remaining alleles in cell 
lines carrying a heterozygous modification. This may address if some of the variability in gene 
expression is due to the epigenetic status of the remaining intact locus, which in turn may 
rule out the impact of off-targets effects on target gene expression.  
The simplistic hypothesis in this chapter focused on whether the SVA could function 
as a transcriptional regulator. The wider hypothesis was that the SVA insertion contributed 
to human specific expression of TRPV3 in the DRG, as documented in the literature. 
Reflecting on the current data presented in this chapter, we have given evidence to support 




genome does not contain SVAs, it could be hypothesised that presence of SVAs in the human 
genome could influence transcriptional changes in the human DRG that are not observed in 
the mouse – consistent with our original hypothesis that it functions as a human specific 
regulator at the TRPV1 and TRPV3 locus and could potentially contribute to the expression 
of TRPV3 in human DRG but not in the mouse. A recent study identified differential histone 
methylation and acetylation profiles across SVA subclasses in different tissues during 
embryonic gene activation and in adulthood, supporting the role of SVAs as tissue specific 
enhancers217,239,240. This could therefore potentially play a role in tissue specific regulation at 
this locus. To address the wider hypothesis properly, the CRISPR protocol described here 
should be repeated in a more appropriate in vitro model. This could be achieved by 
differentiating human iPSCs into peripheral sensory neurones241.  
Previous publications and the data presented in this chapter gives evidence that SVAs 
act as transcriptional regulators in the human genome. The work presented here is the first 
reported example of a reference SVA being deleted using CRISPR and is also the first report 
of an SVA affecting gene expression in a non-disease model. We demonstrated cis-regulatory 
effects on TRPV3 expression, which may contribute to the lack of translational research using 
preclinical mouse models. In addition, we suggest the epigenetic status of this regulatory 
element should be profiled to further explore mechanisms contributing to TRPV3 and TRPV1 







Genotyping the SVA at the 
TRPV1 & TRPV3 locus and 






Transposable elements offer a large source of genetic variation that is currently under-
characterised in the human genome, due to difficulties in mapping repetitive DNA sequences 
from short read sequencing. In addition to their functional role, SVAs can be polymorphic in 
the general population; either as a sequence length polymorphism and/or as a RIP53,242. 
Recent work identified a RIP SVA insertion in TAF1 intron 32 was causative of X-linked 
Dystonia Parkinsonism (XDP)232,233. Furthermore, this SVA RIP also displayed sequence length 
polymorphism within the TCTCCC hexamer repeat domain (copy number range 35 – 52), and 
that increasing hexamer copy numbers associated with reduced age of onset of XDP (range 
35 – 55 years), highlighting the relevance of SVA polymorphism in relation to phenotype54. 
This is a similar notion to the well-known CAG repeat expansion in the Huntingtin gene HTT, 
whose expanded alleles affect age of onset of Huntington disease243. The TAF1 SVA was later 
shown to affecting the expression of TAF1 mRNA however the effects of SVA sequence length 
polymorphism on TAF1 mRNA expression are unknown. Nevertheless, the effect of SVA 
polymorphism on gene expression have been proposed to contribute to individual 
differences and potentially disease risk244. The TAF1 SVA demonstrates an example of a RIP 
being a dominant cause of a monogenic disease.  
At present, genetic variation at the TRPV1 and TRPV3 locus has only been partially 
characterised by SNPs associated with sensory phenotypes. TRPV1 SNP rs222747 (coding 
missense, C=0.26/G=0.73, 1000 Genomes) is associated with cold hyperalgesia in 
neuropathic pain patients245. TRPV1 SNP rs222741 (intronic, G=0.25/A=0.75 1000 Genomes) 
with migraine246. TRPV1 SNP rs8065080 (coding missense, T=0.68/C=0.31, 1000 Genomes) is 
associated with increased sensitivity to capsaicin247,248. TRPV1 SNPs rs4790521 (3’ UTR, 
C=0.68/C=0.31, 1000 Genomes) and rs4790522 (3’ UTR, A=0.43/C=0.56, 1000 Genomes) 
have been associated with TRPV1 mRNA expression changes in a study of asthma, however 




the 3’UTR of TRPV1, and are both in close proximity to the SVA (Supplementary figure 2). 
SNPs associated with disease essentially function as a tagging SNP, indicating a causal variant 
that is in linkage disequilibrium (LD) with said SNP. LD is the non-random association of alleles 
at two or more loci in the general population, therefore tagging SNPs are a useful tool to 
indicate presence of a causal variant if LD can be established250. Therefore, despite numerous 
TRPV1 and TRPV3 SNPs identified in human cohorts to date, which associate with either 
changes in TRPV1/TRPV3 mRNA expression or pain phenotypes, the causal variants 
underlying these phenotypes (molecular or clinical) are yet to be identified in some examples. 
SVAs are hypothesised to function as CREs and can modulate gene x environment 
interactions via epigenetic modification251. Due to their high GC content, SVAs are described 
as mobile CpG islands and DNA methylation is one mechanism by which gene expression can 
be mediated via proximal SVA insertions26. Hypermethylation of the SVA insertion at the TAF1 
resulted in decreased TAF1 mRNA expression, causative of XDP252. Differential methylation 
of TRPV1 (intron chr17:3425000–3426000, hg19) and TRPV3 (intron chr17:3398500–
3399500, hg19) has been associated with heat pain-sensitivity in a study of monozygotic 
twins (median age 62 years)253. This implicates that methylation status at the TRPV1 and 
TRPV3 locus is a potential driver of pain in non-pathological ageing. No study has yet looked 
at the methylation status in association with genetic variants at this locus. Direct links 
between methylation status and TRPV1/TRPV3 mRNA expression have not been explored 
either.  
In chapter 3, we present data which suggests that the SVA insertion at the TRPV1 and 
TRPV3 locus functioned as a CRE in vitro. If shown to be polymorphic, this could lead to gain 
or loss of transcription factor binding sites or differential modulation by epigenetic 
mechanisms such as DNA methylation. Ultimately, this could carry functional implications for 




To address potential associations between SVA polymorphism and pain related 
phenotypes, we obtained access to two distinct groups. As pain is associated with ageing, the 
first group we genotyped was the Dyne-Steele cohort; a cohort of healthy aged individuals 
who were given a pain questionnaire. The second group we genotyped was a cohort of 
osteoporosis patients that were taking part in a trial that measured adverse drug responses 
to treatment with tramadol.  
Osteoporosis is an age-associated disease characterised by decreased bone mass, 
increased risk of bone fracture and chronic pain254. This cohort had corresponding pain data 
from a number of commonly used psychometric pain scales, including the visual analogue 
scale255 and the McGill pain questionnaire256, thereby providing an opportunity to associate 
genetic polymorphism with phenotypic pain data. Tramadol is a synthetic opioid used to treat 
moderate to severe pain across a wide range of conditions including bone pain in 
osteoporosis257. The primary mechanism of action of tramadol is via metabolism in the liver, 
by the enzyme CYP2D6, which produces the metabolite O-desmethyltramadol (M1), an 
agonist of the µ-opioid receptor that blocks ascending pain pathways257.  
In vitro studies in Chinese hamster ovary (CHO) cells, have shown that Tramadol also 
functions as an agonist of TRPV1258. This off-target effect has been proposed as a potential 
mechanism that may contribute to adverse drug reactions  (ADRs), often experienced when 
taking tramadol257,258. Several studies have investigated correlations between tramadol 
efficacy and genetic polymorphisms in its metabolising enzyme CYP2D6259, however no study 
has investigated polymorphisms associated between ADRs and the TRPV1 and TRPV3 locus. 
To further this point, TRPV1 is expressed in osteoclasts (bone cells) and has been shown to 
contribute directly to bone pain260. TRPV1 is also implicated in bone resorption in 
osteoporosis mouse models and immunoreactivity of TRPV1 is increased in the DRG in 




osteoporosis itself, alongside mediating pain. The osteoporosis cohort used in this chapter 
was therefore suitable to explore associations between genetic polymorphisms encoded 
within the SVA at the TRPV1 and TRPV3 locus, with pain phenotypes and adverse drugs 
reactions in response to tramadol. A recent study in the USA highlighted that people 
receiving tramadol are at a greater risk of developing long term opioid addiction compared 
to other opioids and more than 10% of people experience adverse drug responses 257. This 
demonstrates the need to explore genetic variants that may be able to predict the risk of 
ADRs in response to tramadol, in an attempt to address the poor management of opioid use.     
In this chapter, we screened the SVA at TRPV1 and TRPV3 for polymorphism and 
methylation status. Development of a simple PCR protocol enabled us to identify SVA 
sequence length polymorphism present within the CT-rich domain. DNA sequencing 
validated our findings and identified an unexpected repeat sequence contributing to length 
polymorphism, in addition to the previously published “hexameric” copy number. A specific 
heterozygous SVA genotype was shown to significantly associate with self-reported pain in 
non-pathological age-associated pain and similar trends were also observed with responses 
to tramadol in osteoporosis patients. Finally, we demonstrated differential methylation of 
the SVA between individuals and highlight further studies to explore the relationship 





4.2 Hypotheses and aims 
We hypothesised that the reference SVA present at the TRPV1 and TRPV3 locus may be 
polymorphic (based on sequence length) in the general population. We further hypothesised 
that any potential polymorphism could be utilised in genetic association studies and be 
tested for associations with complex disease phenotypes in a similar manner to SNPs.   
The aim of this work was to characterise genetic and epigenetic variation of the SVA encoded 
at the intergenic region between TRPV1 and TRPV3, and also identify potential associations 
with phenotypes relevant to pain, by completing the following: 
1. Characterise SVA genetic and epigenetic variation: 
a. Identify if the SVA is polymorphic in sequence length in the general population 
b. Characterise the polymorphism within composite sequences of the SVA  
c. Assess methylation of the SVA in blood and brain from the same individuals  
2. Identify potential associations between SVA polymorphisms and relevant pain 
phenotypes: 
a. Genotype the SVA in non-pathological ageing cohort  
i. Identify associations between SVA genotype and self-reported pain measures  
ii. Identify associations between SVA genotype and sex  
b. Genotype SVA in osteoporosis cohort (with bone pain) treated with tramadol 
i. Identify associations between SVA genotype and adverse drug responses to 
tramadol 
ii. Identify associations between SVA genotype and analgesic efficacy of tramadol  





4.3.1 Characterising genetic variation in the SVA at TRPV1 and TRPV3  
4.3.1.1 Annotation of composite sequences within SVA 
We defined the composite sequences that make up the full length SVA (Figure 4.1). 
The reference allele contains a 95 bp CT-rich domain at the 5’ end (position 1–95), which 
consists of 8 hexamer repeats and additional bases CATGG between the 5th and 6th hexamer 
repeats, and TCTCTTTCCACGG between the 7th and 8th hexamer repeat. Adjacent to the CT-
rich domain is a 362 bp Alu-like sequence (position 96–457). There is a central 424 bp Variable 
Number Tandem Repeat (VNTR) region (position 458–881). The VNTR sequences are variable 
in size 36-41 bp. There are 10 copies of the VNTR. Adjacent to the VNTR region towards the 
3’ end is a 497 bp SINE-R region (position 882–1377). At the 3’ end of the SVA there is a 25 






Figure 4.1. Annotation of composite sequences within SVA. (Above) Schematic representing the full length SVA 
and its composite sequences from 5’ to 3’ including a CT-rich domain, an Alu-like sequence, a central Variable 
number Tandem Repeat (VNTR), a SINE-R region and a poly A region. This was drawn to scale. (Below) Annotation 






4.3.1.2 SVA is polymorphic based on sequence length 
To screen for sequence length polymorphisms, we amplified the full length SVA (estimated 
product size 1511 bp) using PCR (methods section 2.2.2.1). Primer sequences and protocol 
are listed in the appendix A, entry 1. We used control samples (n=48) that were individuals 
from the general population and free from neurological disorders (refer to materials section 
2.1.5.1). During this analysis, we observed at least two different sized products at the 
expected 1.5 kb size marker, named long (L) and short (S), estimated to be approximately 30 
bp apart (Figure 4.2A). Due to the large sizes of the PCR products and the small difference 
observed, it was difficult to fully resolve them using agarose gel electrophoresis, and 
accurately identify the genotype. 19% (n=9) of samples could not be accurately identified, 
suggesting there were potentially more than two variants, however in those that were easily 
distinguished, we observed 23% (n=11) of individuals were homozygous short (SS), 33% 
(n=16) were homozygous long (LL) and 13% (n=6) were heterozygous short/long (S/L) (Figure 
4.2B and C). These frequencies indicated that this SVA polymorphism was a common genetic 
variant (>1% frequency).  
 We then designed a PCR strategy to amplify composite sequences including the 5’ 
CT-rich domain, the central VNTR and the 3’ poly A region (Figure 4.3). All primer sequences 
and thermal cycles are listed in appendix A, entries 3 – 5. We amplified each region using the 
same control samples (n=48) used for the full length SVA and screened them using capillary 
electrophoresis to achieve a higher resolution than standard agarose gel electrophoresis. We 
identified a minimum of 4 distinct PCR products for the 5’ CT-rich domain (expected product 
size 424 bp) at sizes 405 bp, 427 bp, 453 bp and 471 bp (Figure 4.4). We identified a single 
PCR product for the central VNTR (478 bp) and the 3’ poly A region (312 bp) therefore we 
obtained no evidence to suggest these regions were polymorphic in size (Figure 4.4). As we 




polymorphism in the VNTR or poly A in the same individuals, we focused on the CT-rich 
domain as the main source of polymorphism within this SVA.  
 
 
Figure 4.2. Common sequence length polymorphism identified in SVA at TRPV1 and TRPV3. (A) Agarose gel 
electrophoresis results showing examples of different sized products identified at expected product size for full 
length SVA. Lane 2 (denoted as n/a) indicates undetermined sample, due to poor resolution. LL indicates 
homozygous long genotype. SS indicates homozygous short genotype. S/L indicates heterozygous short/long 






Figure 4.3. PCR strategy developed to amplify composite sequences within SVA. Primers were designed flanking the SVA at the 5’ and 3’ end. Internal primers were then designed in the Alu-
like region to amplify the 5’ CT-rich domain and in the SINE-R region to amplify the 3’ poly A region. To amplify the central VNTR, the full length SVA was amplified first and then used as a 





Figure 4.4. Screening of composite sequences revealed size polymorphism in CT-rich domain. PCR products 
identified for CT-rich domain (expected size 424 bp), VNTR (expected size 472 bp), and poly A region (expected 
size 312 bp). (Above) Examples of agarose gels which show relatively poor resolution. (Central) Digital gels from 
capillary electrophoresis show different size PCR products for CT-rich domain and a single product for both VNTR 




4.3.1.3 Sequencing polymorphic variants revealed a novel 17mer repeat in the CT-rich 
domain 
To validate that the polymorphism observed using electrophoresis was due to the CT-rich 
sequence itself, and not due to variation within the flanking regions of the PCR product, we 
sequenced PCR products corresponding to different alleles. We named each PCR product 
based on increasing product size, a (404 bp), b (424 bp), c (453 bp) and d (478 bp). The 
sequence for allele b was taken from the reference genome as this was the expected size 
based on in silico PCR (hg38). The sequence for alleles a and c were generated by sanger 
sequencing (refer to methods section 0). Allele d could not be sequenced, perhaps due to 
complexity in secondary structure that could not be resolved. Sequences were aligned to 
visualise differences (Figure 4.5). We identified that the reference allele b was 95 bp in length 
and contained 12 TCTCCC hexamer repeats, alongside 2 interspersed C/GATGG repeats. The 
shorter allele a was 66 bp, contained only 8 TCTCCC hexamer repeats and contained a single 
C/GATGG repeat. The longer c allele was 111 bp, contained 13 TCTCCC hexamer repeats and 
4 interspersed C/GATGG repeats. The size differences from the shortest to largest allele were 
as follows; 20 bp, 29 bp and 25 bp). This was in line with the approximate 30 bp differences 
observed in the full length SVA which were difficult to resolve using agarose gels.  
After aligning the sequences, it was evident that much of the polymorphism was not 
due to differences in copy number of TCTCCC hexamers alone, but also due to a novel 17mer 
repeat composed of C/GATGG followed by 2 TCTCCC hexamers (Figure 4.5). The shortest 
allele a contained a single 17mer repeat and 8 hexamers. The reference allele b contained 2 
17mer repeats and 12 hexamers. The larger allele c contained 4 17mer repeats and 13 
hexamers. In the context of this SVA example, most of the polymorphism between alleles 
was supplied to the allele via differences in the copy number of 17mer repeats, not just 




 To assess if the 17mer repeat was a novel sequence in this particular SVA or if it 
occurred in others, we took a 34 bp sequence corresponding to 2 17mer repeats and used 
BLAT to identify other sequences in the genome (hg38). It was not possible to detect a single 
repeat using BLAT as it required a minimum input of 20 nt. We identified 55 SVAs in the 
human genome that contained at least 2 copies of this 17mer repeat (Figure 4.6). We 
observed that most 17mer repeats were present in SVA D. Relatively few copies were 
identified in the evolutionarily older subclasses SVA A, B and C. No SVA E were found to 
contain this 17mer repeat. To assess if this repeat was specific to human SVAs, we also 
screened the chimpanzee (panTro6) and gorilla (gorGor5) genomes (Figure 4.6). We 
identified 15 SVAs in the chimpanzee genome and 5 SVAs in the gorilla genome that 
contained this repeat, therefore it is not human specific. Across all SVA D in the human 
genome, 32.5% are conserved with the chimpanzee15, however out of all human SVA D 
containing the 17mer repeat (n=46), only 13% were conserved with the chimpanzee. This 
highlighted that the 17mer repeat was overrepresented in human specific SVA D.   
To summarise, sequencing data confirmed the polymorphism observed in the PCR 
product was present in the CT-rich domain and not the flanking sequences. As a further 
validation step, we resolved the characterised alleles using agarose gel electrophoresis, for 
visual comparison against capillary electrophoresis digital gel images (Figure 4.7A and B). An 
overview of the variation including PCR product sizes, CT-rich domain length, hexamer repeat 
content and 17mer repeat content is given in the table in Figure 4.7C. Here we demonstrated 
a minimum of 4 distinct alleles of this SVA at TRPV1 and TRPV3 that are present in the general 






Figure 4.5. Sequence variation within CT-rich repeats identified 17mer repeat contributing to polymorphism. The canonical repeat in the CT-rich domain has been extensively described as a 
hexamer CCCTCT repeat. Here we demonstrate that the polymorphism supplied to the SVA is a combination of hexamer repeat variation however have also identified a 17mer repeat that 





Figure 4.6. Number of SVAs containing 17mer repeat in CT-rich domain across primate genomes. Raw counts of 
SVAs containing at least two copies of the 17mer repeat in the human genome (hg38), chimpanzee genome 





Figure 4.7. Summary of polymorphic variants identified of the SVA at TRPV1 and TRPV3. (A) Summary of four 
alleles identified based on capillary electrophoresis. (B) Homozygous and heterozygous genotypes identified 
containing the four alleles.  (C) Summary table of PCR and sequencing data for each allele. (D) Schematic 




4.3.2 Genotyping studies 
4.3.2.1 SVA genotype associates with self-reported pain measures   
The CT-rich domain in individuals from the Dyne-Steele healthy ageing cohort (>50 years, 
mean = 66 years) was genotyped. Individuals (n=336) were subject to a pain questionnaire 
which assessed whether they were experiencing pain or free from pain. They were asked two 
questions: 1) if they had experienced pain in the last month, 2) had they experienced pain 
today. If participants answered “yes” to either question they were placed in the self-reported 
pain group. If participants answered “no” to both questions they were placed in the pain free 
group.  
We assessed if there were any associations between SVA genotype at the TRPV1 and 
TRPV3 locus and self-reported pain. A total of 184 participants (55%) reported they 
experienced pain, and 152 (45%) did not. No differences in allele frequencies were observed 
between either group (Figure 4.8B) however we identified a significant increase in the 
frequency of the heterozygous bd genotype in individuals that self-reported pain (18%, n=17) 
compared to the absence of self-reported pain (4%, n=3) (P=0.004) (Figure 4.8A). The sample 
size here is low, therefore the likelihood of a type II error (i.e. falsely rejecting the null 
hypothesis) resulting from low statistical power is increased. However, based on the available 
data, the combination of b and d alleles together is the variant of interest and not each 
distinct allele. The most frequent allele was d (46%), followed by c (28%), b (26%) and a (1%). 
This reflected allele frequencies observed in the initial genotyping study using healthy 
controls; d (43%), c (18%), b (35%) and a (4%).  
We stratified genotypic data based on sex as an independent variable and found no 
association between sex and any genotype or allele in this cohort (female n=282, male n=54, 
P>0.05) (Figure 4.9). These results suggested that in this cohort, the bd genotype is more 





Figure 4.8. Genotyping results showing association of SVA with self-reported pain measures. (A) Frequency of 
genotypes in Dyne-Steele cohort of aged individuals with self-reported pain measures; no pain (n=76) and pain 
(n=92). (B) Allele frequencies. (C) Summary tables showing exact counts and results from statistical analysis. 





Figure 4.9. Associations of SVA genotypes with sex in Dyne-Steele cohort. (A) Genotype frequencies in females 
(n=141) and males (n=27). (B) Allele frequencies. (C) Summary tables showing exact counts and results from 





4.3.2.2 SVA allele associates with males with osteoporosis  
We genotyped 74 individuals with osteoporosis that were experiencing bone pain (54 female 
and 20 male). At the time of recruitment, patients were placed into group A (currently 
treated with tramadol for bone pain, n=42) or group B (previous adverse drug reaction to 
tramadol and therefore not treated, n=32). Adverse drug responses (ADRs) were monitored 
in group A and previous ADRs were listed in group B (Figure 4.11). In total, 48 participants 
(65%) experienced ADRs and 26 (35%) were tolerant to tramadol.  
We first looked for associations between genotype and ADRs. We identified an 
increased frequency of the heterozygous bd genotype in individuals experiencing ADRs (25%) 
compared to tolerant individuals (8%) (P=0.118) (Figure 4.12). This was not significant, likely 
due to small sample size, but it is important to note that this genotype was significantly 
associated with the incidence of self-reported pain in the healthy ageing cohort detailed in 
the previous section 4.3.2.1 (P=0.004). There were no significant differences in allele 
frequencies between groups. Sample size was too small to address specific ADRs. 
We also addressed associations between SVA genotype at the TRPV1 and TRPV3 
locus and analgesic efficacy of tramadol (i.e. an improvement in pain scores following 
treatment). In group A (n=42), pain measures were assessed in response to tramadol using 
the visual analogue scale (VAS) (Figure 4.10). The difference in scores prior to and 3 hours 
post treatment were used as the criteria to test for associations between genotype and 
effective analgesia. 27 patients (64%) had a VAS difference ≥0 (increase in pain) after 3 hours, 
indicating that pain intensity had increased, or did not improve, following treatment, 
therefore tramadol did not produce the desired analgesic effect. 15 patients (36%) had a VAS 
difference <0 (decrease in pain), indicating that pain intensity had decreased following 
treatment, therefore tramadol had the desired analgesic effect. We observed an increase in 
the frequency of heterozygous bd genotype in individuals with a VAS difference <0 (good 




this was not significant. This means that the bd genotype was more frequent in individuals 
that had no improvement in pain score and therefore responded poorly to tramadol, as it did 
not exert the desired analgesic effect. On the contrary, we observed an increase in the 
frequency of homozygous dd genotype in individuals with a VAS difference <0 (good 
response, 47%) compared to those with a VAS difference ≥0 (poor response, 26%) but again 
this was not significant. To summarise, whilst not significant, we observed a trend of an 
increased frequency in this particular heterozygous genotype in individuals that had a 
reduced pain score (i.e. desired analgesic effect/good response) following treatment with 
tramadol. This observation is purely preliminary, as the small sample size is not sufficient to 
discern any true biological relevance.  
 Finally, we searched for associations based on sex as an independent variable. We 
identified no associations between genotype and sex (female n=108, male n=40, P>0.05). 
However, we did identify an increased frequency in allele c with males in the osteoporosis 
cohort (n=13, 33%, P=0.02) (Figure 4.14B). It must be reiterated that any results in this 
chapter which reached statistical significance should be replicated in a larger cohort. This is 
necessary to achieve sufficient power, in order to minimise the effects of a type II error (i.e. 






Figure 4.10. Example of Visual Analogue Scale used to calculate VAS difference. 
 
 
Figure 4.11. Adverse drug reactions (ADR) observed during tramadol study. Combined ADR frequencies from 
group A (actively taking tramadol) and group B (discontinued use due to prior ADRs). Frequency refers to 





 Figure 4.12. Genotyping results show no association in response to tramadol in osteoporosis patients. (A) 
Genotype frequencies in osteoporosis patients that are tolerant to tramadol (n=26) or reported adverse drug 
response (n=48). (B) Allele frequencies. (C) Summary tables showing exact counts and results from statistical 





Figure 4.13. Genotyping results show no association with pain scores in response to tramadol in osteoporosis 
patients. (A) Genotype frequencies in osteoporosis patients that showed an improvement in pain scores in 
response to tramadol (negative difference in pain score;  ∆VAS<0) (n=15) and those that did not show an 
improvement in pain score (no difference/positive difference in pain score; ∆VAS≥0) (n=27). (B) Allele frequencies. 
(C) Summary tables showing exact counts and results from statistical analysis. No statistical significance found 





Figure 4.14. Genotyping results show association between SVA allele in males with osteoporosis. (A) Genotype 
frequencies in females (n=54) and males (n=20) with osteoporosis. (B) Allele frequencies. (C) Summary tables 
showing exact counts and results from statistical analysis. Significant p-values indicated as <0.05*, <0.01**, 




4.3.1 Characterising epigenetic status of the SVA at TRPV1 and TRPV3 
4.3.1.1 G4 prediction is variable between SVA CT-rich alleles 
G-quadruplexes are alternate secondary DNA structures that form from multiple runs of G-
rich sequences264. Prediction tools have identified that they are enriched in the genome at 
cis-regulatory elements and they are predicted to play important roles in transcriptional and 
translational regulation at the DNA and RNA level265. In chapter 3, we gave evidence to 
support the role of the SVA at TRPV1 and TRPV3 as a cis-regulatory element, therefore we 
aimed to predict its potential to form G4 structures, and to further assess if the sequence 
length polymorphism identified in this chapter may potentially affect G4 formation.   
Bragg et al54 previously reported that sequence length polymorphism in the CT-rich 
domain results do not affect G4 formation. This analysis was conducted by DNA sequences 
generated in silico which contained variable numbers of hexamer repeats – however this data 
was inferred from PCR product size only and not DNA sequencing. They reported that an 
increasing number of TCTCCC hexamer repeats resulted in maintained G4 potential on the 
complimentary DNA strand containing AGAGGG hexamer repeats. We demonstrated in the 
previous section that a source of polymorphism within this composite sequence is from a 
17mer repeat, not simply hexamer repeats alone (Figure 4.5). Therefore, we aimed to assess 
if the increase in size of the CT alleles due to the 17mer, maintained predicted G4 formation 
in the same manner as simple hexamer repeat variation.  
We first assessed G4 prediction across the full length SVA (reference SVA listed in 
hg19, allele b). The programme we used, QGRS mapper (available at 
http://bioinformatics.ramapo.edu/QGRS/index.php), identifies Quadruplex forming G-Rich 
Sequences (QGRS) and assigns each QGRS a score from 0-100 indicating potential G4 
formation. We identified that the SVA sequence itself has few QGRS and relatively low G-
scores (Figure 4.15A). We then used the complimentary sequence to the SVA and identified 




of DNA (Figure 4.15B). The greatest potential for G4 corresponded was identified in the 
complimentary sequence corresponding to the CT-rich domain (AGAGGG repeats) (Figure 
4.15B).   
To assess difference between the alleles, we used the DNA sequences previously 
obtained for allele a, b and c. We did not include allele d as we could not simply infer the 
variation based on size of the PCR product alone, as variation is supplied by both hexamer 
and 17mer repeats. Based on findings from the full length SVA, we used the complimentary 
strand sequences only (AGAGGG) as no G-scores were identified for actual CT sequence 
(TCTCCC). The complimentary allele a sequence contained 2 QGRS, starting at position 4 
(length 21 nt, G-score: 72) and position 29 (length 38 nt, G-score: 59) (Figure 4.15C). The 
complimentary allele b sequence contained 3 QGRS, starting at position 10 (length 21 nt, G-
score: 72), position 34 (length 26 nt, G-score: 68) and position 68 (length 27 nt, G-score: 34) 
(Figure 4.15D). The complimentary allele c sequence contained 3 QGRS, starting at position 
4 (length 21 nt, G-score:72), 33 (length 26 nt, G-score:68) and 67 (length 26 nt, G-score: 67) 
(Figure 4.15E).  
All three alleles contain the same QGRS at the 5’ end, due to shared sequence 
similarity, supplied by the TCTCCC hexamer repeats (Figure 4.5). Towards the 3’ end of the 
CT-rich sequence, differences emerge between alleles, mainly from the 17mer repeat 
described in the previous section. Allele b is predicted to contain an additional QGRS towards 
the centre of the domain, compared to allele a. Allele c is predicted to contain the same 
number of QGRS as allele b however the score of the third QGRS in allele c is much greater 
than that in allele b, suggesting the likelihood of quadruplex formation is much greater.  
We concluded G4 potential is still present across the length of the CT-rich domain 




repeats. This indicates G4 potential is not maintained in the same manner across the 17mer 





Figure 4.15. Predicted G4 formation across full length SVA and in different CT-rich alleles. QGRS mapper predicted scores (0-100) indicate likelihood of G4 formation. (A) SVA sequence on 
antisense strand 5’-3’ shows weak G-scores <30 across entire length. (B) Complimentary sequence to SVA on sense strand shows increased G-scores and strongest signal generated from region 
corresponding to CT-rich region. Composite sequence boundaries are annotated. (C) Complimentary strand to CT-rich allele a. (D) Complementary strand to CT-rich allele b. (E) Complementary 




4.3.1.2 Analysis of CpG islands at intergenic region between TRPV1 and TRPV3 
We first identified putative CpG islands across the intergenic sequence between 
TRPV1 and TRPV3 (chr17:3461250-3468806, hg19) using Cpgplot software 
(https://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/). This software calculates the ratio 
of observed to expected CG dinucleotides within a sequence. Based on a 100 bp sliding 
window approach, the algorithm then searches for sequences at least 200 bp in length with 
a GC content of at least 50%. The algorithm identifies a CpG island if these criteria are met 
across a minimum of 10 windows. The antisense sequence was used as it encodes the SVA 
and both genes. We identified two putative CpG islands across the entire intergenic sequence 
(Figure 4.16C). The SVA was at position 433 – 1836 and the GC content was 59% overall (A, 
262; T, 308; G, 375; C, 457), supplying the greatest GC content to this intergenic region (Figure 
4.16B). The first CpG island was 208 nt in length and was located at position 582 – 789 and 
this corresponded to the Alu-like region of the SVA (position 150 – 375 in the SVA sequence) 
(Figure 4.16D). The second CpG island was 227 nt in length and was located at position 4109 





Figure 4.16. Identification of putative CpG islands across intergenic sequence between TRPV1 and TRPV3. (A) 
Observed vs expected CpG dinucleotides. (B) GC content presented as a percentage. (C) Putative CpG islands. (D) 
Schematic showing where putative CpG islands reside in the intergenic sequence. 1 corresponds to Alu repeats, 





4.3.1.3 Methylation status of SVA is variable between individuals 
To assess the methylation status of the SVA, we used an MBD pulldown to enrich for 
methylated DNA from whole genomic DNA taken from the temporal cortex and whole blood 
(refer to methods section 2.2.10). Methylated and unmethylated fractions of DNA were then 
used as templates for PCR to amplify the SVA and compare relative product intensity as an 
estimate for the amount of methylation present across the amplified region. These tissues 
were matched in the same individuals (n=12) (Figure 4.17). The genomic DNA samples were 
from the Dyne-Steele cohort and had previously been genotyped using the sequence length 
of the 5’ CT-rich domain (results section 4.3.2). We amplified the 5’ CT-rich domain (approx. 
400 – 460 bp) and the 3’ poly A region (312 bp) in the methylated and unmethylated DNA 
fractions using PCR. The VNTR (472 bp) was not included in this analysis as it required a 
nested PCR of the full length SVA (1151 bp) to be used as a template and ensure specific 
primer binding but and the DNA had been sonicated to <500 bp.  
Amplification of the 5’ CT-rich domain (400 – 460 bp) failed when using sonicated 
DNA as a template however amplification of the 3’ poly A region (312 bp) was successful and 
PCR products were subsequently confirmed for all unmethylated samples in both tissues. It 
was possible that the sonicated DNA fragments (<500 bp) were too short in this case to 
amplify the CT-rich target, therefore analysis of the poly A region was used to infer the 
methylation status of the SVA (Figure 4.18). It was not possible to identify the relative amount 
of methylated SVA copies using qPCR, as the product size for the poly A region was too large 
(>200 bp), therefore we used agarose gels and densitometry. The percentage of methylated 
SVA copies were calculated by comparison with the combined product intensities of 
methylated and unmethylated DNA fractions and was used for all statistical analysis (two-
sample t-test). Sex, genotype and self-reported pain measures were available for these 
samples, but we only stratified methylation status based on sex due to the low sample size 





Figure 4.17. Overview of unmethylated and methylated DNA fractions generated from genomic DNA. Temporal 
cortex and whole blood were taken from each individual. Genomic DNA was prepared and used in the MBD 
pulldown to isolate unmethylated and methylated fractions (methods section 2.2.10). These samples were used 
in PCR to assess methylation status of DNA. Some genomic DNA samples from whole blood were used in the 
genotyping study conducted in section 4.3.2. 
 
 
Figure 4.18. Amplification of SVA 3’ poly A region in unmethylated and methylated DNA from temporal cortex 
and blood. Matched DNA samples were taken from temporal cortex (t. cortex) and blood from the same 
individuals (n=12). Samples were from the Dyne-Steele cohort; ID numbers specified when possible. Males (M) 
(n=5) and females (F) (n=7) were used. SVA genotypes based on the length of CT-rich domain are specified. Self-





In temporal cortex, amplification of the SVA was significantly greater from the 
unmethylated fraction (90%) compared to the methylated fraction (10%) across all samples 
(n=12) (P<0.001) (Figure 4.19A). When stratified based on sex, this trend was still observed 
in males (unmethylated=76%, methylated=24%, n=5, P=0.001) (Figure 4.19A). No 
amplification was detected from the methylated fraction in female temporal cortex (n=7) 
(Figure 4.19A). As sample numbers were low, we were reluctant to infer any conclusions from 
this sex difference. Overall this data suggests that copies of this SVA are more frequently 
unmethylated than methylated in the temporal cortex, however it is undetermined if there 
are any sex-specific differences regarding the level of methylated copies.  
In whole blood, across all samples (n=12), amplification was significantly greater 
from the unmethylated fraction (76%) compared to the methylated fraction (24%) across all 
samples (P<0.001) (Figure 4.19B). When stratified based on sex, this trend was still observed 
in males (unmethylated=71%, methylated=29%, n=4, P=0.046) and females 
(unmethylated=80%, methylated=20%, n=4, P<0.001) (Figure 4.19B). Three females and two 
males did not amplify any product from the methylated fraction. Similarly, like temporal 
cortex, this data suggests this SVA is more frequently unmethylated in whole blood in both 
sexes.  
We then compared the levels of amplification from methylated fractions between 
temporal cortex and whole blood to assess for tissue specific differences. Across all samples 
(n=12), we observed a trend that showed an increase in methylation in the blood compared 
to the brain (temporal cortex=10%, whole blood=23%, P=0.10) (Figure 4.19C). However when 
we stratified this data based on sex, this trend disappeared in males, there was also no 
significant difference (temporal cortex=24%, whole blood=76%, P=0.726) (Figure 4.19C). As 
previously stated, in females, amplification was only detected in the methylated fraction 




methylated SVA copies in temporal cortex and blood are similar in males, but differences 
may occur in females, however this requires further investigation. Whilst trends were 
evident, this data also indicated that methylation status was variable between individuals, as 
most individuals lacked methylation in both tissues (n=6, 50%), some had methylation in both 
tissues (n=3, 25%), and others had methylation in one tissue but not in the other (n=3, 25%) 
(Figure 4.19D and E). Absence of methylation was more frequent overall in the temporal 






Figure 4.19. Methylation status of the SVA 3' poly A region. (Above) Percentage of amplification from methylated 
and unmethylated DNA fractions across all samples (n=12), males (n=5) and females (n=7) in temporal cortex (A) 
and whole blood (B). (Central) Percentage of amplification from methylated fraction compared between temporal 
cortex and whole blood across all samples, males and females (C). (Below) Percentage of amplification from 
methylated fraction of each individual; females (D) and males (E). Significant p-values indicated as <0.05*, 







In this chapter, we have identified sequence length polymorphism in the SVA encoded at the 
intergenic region between TRPV1 and TRPV3. The polymorphic nature of the SVA is variable 
in sequence length, which can at least in part be attributed to repeat copy number 
differences within the CT-rich domain. Previous studies have referred to this domain as 
hexameric53,54,215. We identified using sequencing that the CT-rich domain is polymorphic 
based on the copy number of 2 distinct repeats; the first a TCTCCC hexamer repeat, the 
second a 17mer repeat (C/GATGGTCTCCCTCTCCC) (Figure 4.5). This is the first description of 
the CT-rich domain within SVAs to contain a 17mer repeat. Our sequencing data also verified 
the PCR and capillary electrophoresis analyses used to genotype the CT-rich domain was 
robust and accurate at identifying the four distinct alleles (variable by sequence length) 
observed across the various cohorts. The frequency of all four alleles were >1% therefore can 
be classed as common genetic variants and this was the basis for focusing our study on this 
domain. We did not find any evidence to suggest the VNTR or poly A region were common 
genetic variants, however we cannot exclude the possibility that rare genetic variants 
(frequency <1%) may exist. This is also true for the CT-rich domain.  
 Further analysis identified the 17mer repeat as being enriched in human specific SVA 
subclass D, when compared to the other SVA subclasses. However this repeat was not found 
to be human specific as some SVAs containing this repeat were also identified in the 
chimpanzee and gorilla genome (Figure 4.6). Surprisingly we observed no 17mer repeats in 
subclass E. During this analysis, we used supplementary data from Tang et al15, who published 
an analysis of human specific mobile elements (hg38) based on conservation with other 
primates. SVA subclasses A, B, C and D are present in the human genome and in other primate 
genomes, however subclasses E and F emerged in the human lineage after divergence with 
the last common ancestor shared with the chimpanzee, therefore E and F are human 




SVA F were listed as human specific. Therefore, according to this dataset, 73.8% of SVA E and 
49.1% of SVA F were identified in other primate genomes. As SVA E and SVA F subclasses are 
human specific elements, this data was incorrect and highlighted a large error rate in the 
current genome build (hg38) for SVA annotation. This may explain why we observed no 
17mer repeats in subclass E, which had the greatest annotation error rate based on 
annotated conservation with other primates. Communication with the author informed us 
that full length SVA E and F are mapped correctly. However, SVA copies (from any subclass) 
can carry 5’ truncations or internal rearrangements, which are a hallmark of L1 mediated 
mobilisation, and can be incorrectly classified26,266. This results in some SVA sequences that 
are difficult to map being incorrectly classified as subclass E and F.  This then results in SVA 
copies that belong to subclass A, B, C or D incorrectly being identified as SVA E or F. This 
explains how a large proportion of SVA E and F currently listed in the human genome also 
appear in other primate genomes.  Another interesting observation in the data published by 
Tang et al. was that there are human specific occurrences of SVA A (1.9%), SVA B (1.6%) and 
SVA C (17%). It is typically thought that new SVA subclasses emerge via mutation to escape 
suppression by KRAB zinc finger nuclease proteins, therefore older subclasses are silenced 
and no longer transpose38. This data suggests that some have escaped silencing in the 
genome after divergence with the last common ancestor and created new insertions. Ancient 
Alu element subclasses AluJ and AluS have been reported to escape suppression in humans 
and generate polymorphism267,268, therefore it is plausible to hypothesise some ancient SVAs 
can generate human specific polymorphisms too. These findings highlight some of the 
current issues with SVA annotation in the current human genome build (hg38) and 
demonstrate that further work is needed to accurately classify SVAs.     
In chapter 3, we identified the SVA as a transcriptional regulatory domain. Here, we 
explored its role as a potential marker of relevant pain phenotypes. Previous work has 




age-of-onset of X-linked dystonia parkinsonism54. The most well characterised association of 
repeat polymorphisms and disease is the CAG-repeat copy number and age of onset in 
Huntington disease269. TRPV1 mRNA has been shown to increase 2.4-fold in human aged skin 
(mean 74 vs 26 years), highlighting age associated changes in gene regulation270,271. TRPV3 
has not been characterised in the context of ageing. Genotyping the SVA revealed a 
significant increase in the heterozygous bd genotype associated with an increase of self-
reported pain in healthy aged individuals (Figure 4.8).  
Next we genotyped the SVA at the TRPV1 and TRPV3 locus in a cohort of osteoporosis 
patients, some of which were being treated with the synthetic opioid tramadol, and many 
reported adverse drug responses (Figure 4.11). TRPV3 has not been implicated in 
osteoporosis or response to tramadol however TRPV1 has been implicated in both the 
pathogenicity and occurrence of bone pain in osteoporosis using animal models. Therapeutic 
action of tramadol is mediated by activation of µ-opioid receptors, however it has been 
identified as an agonist of TRPV1258, therefore this cohort offered the potential to explore 
associations between SVA polymorphisms at this locus, occurrence of osteoporosis and ADRs 
associated with tramadol.  The frequency of the heterozygous bd genotype was greater in  
osteoporosis patients who experienced an adverse drug response to tramadol (Figure 4.12) 
and reported a lack of analgesic efficacy after taking tramadol (Figure 4.13). We identified a 
minimum of 4 distinct alleles when screening the SVA for polymorphism, therefore upon 
reflection, the size of this cohort was very small (n=74) considering the aim was to identify 
associations between numerous genotypes and complex phenotypes. For example, when 
testing for associations between ADRs and genotypes, there were 10 possible genotypes, 
however each group contained less than 16 individuals. This resulted in statistical power that 




Sex differences are also well characterised in osteoporosis (extensively reviewed 
here272). Interestingly, we observed a significant increase in allele c in males with 
osteoporosis, but no associations between allelic frequencies and self-reported pain were 
found in healthy aged individuals from the Dyne-Steele cohort (Figure 4.14). These findings 
give some evidence to support SVA genotype in association with TRPV1-related phenotypes. 
Overall, the main limitation of the genotyping studies and methylation study was the low 
sample sizes available in each cohort. One study estimated  that in order to test a single SNP 
as a marker of a specific trait, the minimum number of cases required was 248 achieve 
enough statistical power, estimated using the Genetic Power Calculator under various 
assumptions about genetic models (e.g. allelic, dominant, recessive, co-dominant)273. This 
was only a single estimate and the actual number for each study will depend upon the 
biological question being asked (e.g. number of variants and genetic model). The SVA 
investigated in this chapter has a minimum of four distinct alleles, therefore requiring a much 
larger sample size. It was not possible to estimate the required sample size for this study as 
calculators such as the Genetic Power Calculator assume only two variants based on SNPs273. 
One strategy to overcome this problem could be to group alleles into risk and non-risk. 
However, in order to identify what may be classed as a risk allele, more samples would need 
to be genotyped to provide more evidence for a risk allele (preferably in a separate cohort). 
Another limitation is the use of self-reported pain measures, which are subjective between 
individuals. At this stage, it would be a more appropriate study to associate SVA genotype 
with gene expression as a molecular phenotype instead of complex trait phenotypes such as 
self-reported pain measures and/or ADRs. To overcome this, work is ongoing to develop 
tagging SNPs (SNPs in linkage with SVA genotype), which will enable large scale genotyping 
in larger datasets such as 1000 genomes, for which there is whole genome sequencing data 
available for over 4000 individuals. This would provide a better insight into genotype and 




We also investigated the epigenetic status of the SVA by predicting G4 structure in 
polymorphic CT-rich variants and assessed the methylation status of the SVA in whole blood 
and temporal cortex. We showed that G4 formation may vary dependent upon the 
polymorphism identified in the CT-rich domain. G4 DNA structure is hypothesised to act as 
an epigenetic regulator of gene expression. DNA methylation can stabilise G4 structures, 
demonstrated in the C9orf72 repeat expansion, which may also modulate epigenetic 
mechanisms274,275. We demonstrated that the SVA was more frequently unmethylated in 
both blood and temporal cortex, suggesting it may be active and unsilenced (Figure 4.19A 
and B). We identified a larger proportion of methylation in the blood however this was not 
significant (Figure 4.19C). Increased expression of TRPV1 mRNA and protein occurs in the 
temporal cortex of patients with epilepsy, implying a pathogenic role276. This disease model 
would be ideal to investigate SVA methylation and TRPV1 mRNA expression, to explore the 
role of the SVA as a tissue specific epigenetic modulator of gene expression. We then 
demonstrated that the SVA methylation status was variable between individuals. However, 
there were not enough participants to correlate this with the SVA genotype (Figure 4.19D 
and E). This methylation analysis had some limitations. The blood samples were taken when 
the participants were alive and temporal cortex were sampled at post-mortem. Therefore 
the difference in methylation status observed may be due to the difference in the age of the 
individual at the time of blood sampling versus the age of the individual at time of death and 
thus not necessarily reflect tissue-specific methylation patterns277.  Data relating to age of 
participants at time of blood sampling versus age at death was not available at the time of 
study. Post-mortem interval (PMI) can affect DNA integrity and methylation stability 
therefore results should be interpreted with caution278,279. Data relating to PMI was not 
available at time of study. Sample size was also very small (n=12) therefore we could not 
stratify genotype or phenotype data with methylation status. Comparison of alleles using 




provide some insight into whether methylation status is correlated with genotype and would 
overcome the lack of amplification following sonication of DNA, enabling full profiling of the 
SVAs methylation status. As we demonstrated in chapter 3, this SVA is functional as a 
transcriptional regulator (Figure 3.6) and evidence supports its role as a CRE (Figure 3.26). 
Considering these epigenetic factors, it presents a hypothetical mechanism in which DNA 
sequence variation of the SVA could affect the epigenetic mechanisms that influence gene 
regulation.  
To summarise, this is the first report of SVA polymorphism associated with a common 
trait (i.e. non-rare disease e.g. XDP). If validated in larger cohorts, this finding could 
potentially be used as a biomarker to predict efficacy and adverse drug responses of 
tramadol. More work is required in this area to reduce the administration of ineffective 
opioids in a personalised manner. Increasing the sample size via the application of tagging 
SNPs in the cohorts suggested will greatly improve the utility of this information and 
potentially delineate functional epigenetic mechanisms between genotype, methylation 









expression in neuronal 






Neuroinflammation is a key driver of central and peripheral sensitisation which  leads to the 
transition of acute to chronic pain, and can be caused by trauma (nerve injury), drugs 
treatments184 (e.g. chemotherapy), autoimmune conditions179,180,185. It is also considered to 
be one of the hallmarks of ageing - the primary risk factor for the development of 
neurodegenerative disease and associated with chronic pain in humans1,280. Studies in rodent 
models have provided insight into this mechanism and demonstrated age associated changes 
in DRG morphology and sensory thresholds which contribute to changes in pain 
phenotype198,281-284. Examples include increased DRG innervation following nerve injury and 
lower sensory thresholds in aged rats, leading to increased mechanical allodynia and thermal 
hyperalgesia281-283. Changes in inflammatory markers (e.g. CCL2, IL6, CD45, TGFβ1, CD68 and 
IL1β ) have been documented in rat DRG in ageing and in response to nerve injury198,284. 
Epigenetic mechanisms are also implicated in the transition of acute to chronic pain. Several 
studies have demonstrated global DNA methylation changes in response to nerve injury in 
rat and mouse models192-194. To our knowledge a longitudinal study of age-related DNA 
methylation changes in DRG has not yet been done.  
Recent work by De Cecco et al. demonstrated that L1 mRNA expression increased in 
non-pathological ageing, which resulted in L1 cDNA accumulation in the cytoplasm and 
induction of an inflammatory response via cGAS and IFN85,86. Age associated L1 activity 
associated with age is due to loss of silencing mechanisms (e.g. DNA methylation) and is 
implicated in many types of cancer62-71 and central nervous system neurological disorders89 
(discussed in introduction section 1.2.7). This data highlights TEs, and L1 activity, as a 
potential contributor in age associated neuroinflammation present in DRG, and thus may 
play a role in the development of chronic pain. However, there are no reports in the current 
literature (at time of writing) exploring L1 mRNA expression in the peripheral nervous system 




also been heavily implicated in regulating TE activity90,91 (discussed in detail in introduction 
section 1.2.7). A large body of evidence suggests that deregulation of TDP-43 expression 
results in defective mechanisms that suppress L1, yet the majority of research is conducted 
in regard to ALS (97% of ALS cases characterised by TDP-43 proteinopathy in the form of 
cytoplasmic inclusions). TDP-43 proteinopathy has been described in dorsal root ganglia from 
patients presenting with sensory neuropathy and that mutant TDP-43 has been shown to 
affect sensory function in DRG cultures285-287. This area of research is very limited and 
warrants further investigation, especially regarding the relationship with L1 in the peripheral 
nervous system.  
In addition to age related changes in neuroinflammation and its role in the 
development of chronic pain, inflammation can be modulated by diet. Studies in rodent 
models have demonstrated that consumption of a high fat diet causes an increase in 
cytokines and levels of brain inflammation182. A recent study showed that that obesity-
associated neuroinflammation is exacerbated in the hippocampus with ageing, 
demonstrating the synergistic effects between these two variables183. Obesity and pain are 
commonly comorbid conditions in humans, demonstrating the impact of diet on pain 
prevalence280,288,289.  Diet is therefore another factor to be considered in TE deregulation in 
the nervous system290. A group led by Prof. Margarett Harnett at the University of Strathclyde 
investigate effects of high fat diet (HFD) induced inflammation in mice. In addition, this HFD 
induced inflammation model was also being trialled for a novel anti-inflammatory treatment 
called ES-62. ES-62 is a secreted product from the filarial nematode Acanthocheilonema 
viteae. Previous work on ES-62 drug analogues 11a and 12b (referred to still as ES-62) has 
identified successful immunomodulatory properties in models of arthritis291, asthma292 and 
systemic lupus erythematosus293. ES-62 binds directly to the Toll/interleukin-1 receptor 
homology domain (TIR) of Myd88, a central signalling protein in the immune system, which 




of neuroinflammation and pain sensory neurons294. This presented a novel opportunity to 
assess the L1 and TDP-43 mRNA in an obesity-induced model of inflammation and in 
response to a novel treatment impacting inflammatory pathways relevant to pain.  
In this chapter we present a robust qPCR protocol developed to quantify L1 and TDP-
43 mRNA expression in the mouse. This was applied first to an ageing DRG model in which 
we present an increase in L1 mRNA with increasing age in both male and female mice. To 
further this, we also observed an increase in TDP-43 mRNA associated with increasing age. 
To our knowledge this is the first study of L1 in the mammalian peripheral nervous system. 
We also applied this methodology to a high-fat diet induced model of inflammation and 
measured L1 mRNA expression in response to a combination of variables including age, high 





5.2 Hypotheses and aims 
There were several hypotheses formed within this chapter and are presented as follows: 
1. L1 mRNA expression increases in the ageing mouse peripheral nervous system, 
specifically the dorsal root ganglia.  
2. L1 mRNA increases in the mouse ageing brain and can be modulated in response to 
diet.  
3. To further both points, we hypothesised that TDP-43 expression would play a role in 
L1 mRNA regulation in a broader neuroinflammatory context and therefore TDP-43 
mRNA expression could be correlated with L1 mRNA changes.  
We tested these hypotheses by completing the following aims: 
1. Develop a robust qPCR protocol to reliably measure L1 mRNA expression in mouse. 
2. Measure L1 and TDP-43 mRNA expression in DRG sampled from mice of increasing 
age.  
3. Measure L1 and TDP-43 mRNA expression in brains of mice from a model of HFD 
induced inflammation: 
a. Measure gene expression in young versus old mice. 
b. Measure gene expression in old mice fed HFD versus normal chow.  
c. Measure gene expression in old mice fed HFD and treated with anti-





5.3.1 Design and optimisation of L1 qPCR assay 
5.3.1.1 Identification of suitable reference genes for use in mouse models 
To assess gene expression reliably, it was necessary to identify two reference genes that were 
stably expressed in tissues across all biological groups within each distinct model, in 
accordance with MIQE guidelines295. A literature search was conducted to identify commonly 
used reference genes assayed in mouse models that included different sexes, ages and 
dietary conditions (Table 5.1). Primers were designed for ACTB, B2M, GAPDH, GUSB, HMBS, 
HPRT and PPIA. Primer sequences are given in appendix A, entry 12. RT-PCR reactions were 
set up for each primer sets and thermal cycles followed the touchdown PCR protocol 
described in section 2.2.2.1. Products were analysed using 2% agarose gels.  
First, RT-PCR was used to assess expression in the ageing brain C57BL/6 model using 
a sample from each biological group which differed based on sex (male/female), diet 
(chow/high fat), age (8 weeks/71 weeks) and treatment (ES-62/PBS). Agarose gel 
electrophoresis showed that in brain samples, B2M and PPIA had robust and consistent 
expression across all samples, therefore were selected for use as candidate genes in the brain 
(Figure 5.1).  
We then repeated the same RT-PCR assay in DRG samples taken from Thy1-YFP mice 
which differed based on sex (male/female) and age (ranging from 3 – 57 weeks). The previous 
results for GUSB, HMBS and HPRT showed evidence of non-specific products in brain samples 
which was attributed to poor primer design, therefore were not used in the screen for DRG 
samples. ACTB, B2M, GAPDH and PPIA were tested and showed that ACTB and PPIA were 
stably expressed across all ages in both sexes, therefore were used as reference genes in this 




Table 5.1. Candidate reference genes chosen for screen based on literature search.  
Variable Attribute Gene symbol Gene name Accession number Function Reference 




Succinate dehydrogenase complex, subunit 
A, flavoprotein (Fp) 
NM_023281.1 Citric acid cycle and the respiratory chain. 
297 
ACTB Beta-actin NM_007393.5 Formation of microfilaments in eukaryotic cells. 
Female 
SDHA 
Succinate dehydrogenase complex, subunit 
A, flavoprotein (Fp) 




NM_008084.3 Catalyses sixth step of glycolysis. 
Age 
2 months 
PPIA Peptidylprolyl isomerase A NM_008907.1 
Catalyzes cis-trans isomerization of proline imidic peptide 
bonds. Role in protein folding. 
298 
HPRT 
Hypoxanthine guanine phosphoribosyl 
transferase 
NM_013556.2 
Transferase that plays a role in the generation of purine 
nucleotide through the purine salvage pathway. 
22 months 
PPIA Peptidylprolyl isomerase A NM_008907.1 
Catalyzes cis-trans isomerization of proline imidic peptide 








B2M Beta-2 microglobulin NM_009735.3 Beta-chain of MHC class I molecules. 
299 PPIA Peptidylprolyl isomerase A NM_008907.1 
Catalyzes cis-trans isomerization of proline imidic peptide 
bonds. Role in protein folding. 






Figure 5.1. B2M and PPIA identified as suitable reference genes in brain samples from C57BL/6 mouse model. 
Agarose gels showing reference gene products across biological conditions. Lanes 1-8 contain a different 
biological sample, details of which are given in the corresponding table. Samples differed based on sex (male or 
female), age (8 weeks or 71 weeks), diet (chow or high fat) and treatment (ES-62 or PBS). B2M and PPIA are robust 
in both sexes across all ages, diets and treatments. ACTB and GAPDH showed variable expression. GUSB 
expression was very low therefore not suitable for use. HMBS and HPRT amplified non-specific products therefore 





Figure 5.2. ACTB and PPIA identified as suitable reference genes in DRG samples from Thy1-YFP mouse model. 
Agarose gels show reference gene products across biological conditions. Lanes 1-12 contain a different biological 
sample, details of which are given in the corresponding table. Samples differed based on age (ranging from 3 - 57 
weeks) and sex (male or female). ACTB and PPIA show robust expression across all ages in both males (lanes 1-6) 





5.3.1.2 qPCR primer specificity and amplification efficiencies 
Following RT-PCR, primers for reference genes ACTB, B2M, PPIA and target genes L1 and TDP-
43 were validated in an initial qPCR assay (Figure 5.3). Melt curves were used to identify at 
which temperature the PCR product separated into single stranded molecules, resulting in 
the dissociation of the fluorescent dye from the double stranded molecule. The decrease in 
fluorescence is measured and represented as a peak corresponding to that temperature, thus 
the presence of a single peak indicates dissociation at one specific temperature i.e. one 
specific product. The melt curves showed a clear distinct peak for each primer pair, indicating 
a single product was amplified. A smaller peak was also identified on the curve for ACTB, 
which suggested primer dimer or the presence of a secondary structure - which is more 
difficult to separate. Standard curves were plotted from the mean Ct values generated across 
a serially diluted cDNA template and were used to assess the efficiency of each primer pair. 
It is recommended that all primers within each experiment should have efficiencies between 
90 – 110% to generate data that is comparable across targets and suitable for gene 
quantification. ACTB, PPIA and LINE-1 showed good efficiencies; 93%, 101% and 98%, 
respectively (Figure 5.3). TDP-43 had an efficiency of 80%, this was just below the 





Figure 5.3. qPCR primer validation results. Melt curves are shown for all primer pairs showing single product 
amplification. Standard curves are shown with dilution factor on X axis and mean Ct value on Y axis. The gradient 






5.3.1.3 Specificity of L1 primers to subfamilies L1Md_A and L1Md_T 
There are many different subclasses of L1 transcripts in the mouse genome that have 
emerged throughout evolution. The structure of the L1 transcript is well conserved across 
ORF1 and ORF2 but the 5’ UTR can be highly variable. It is estimated that novel promoter 
sequences have been recruited to the 5’ UTR 11 times throughout evolution of the mouse 
genome, giving rise to multiple L1 subfamilies300,301. Most subfamilies of L1 do not mobilise 
in the genome but the two youngest subfamilies are still actively transcribed and able to 
mobilise; L1Md_A and L1Md_T300,301. Primers were designed to target the 5’ UTRs of active 
retrotransposon subfamilies L1Md_A and L1Md_T (Figure 5.4). These two subfamilies are 
considered to have non-homologous 5’ UTRs overall however homologous sequences were 
found between the two subfamilies that were suitable for primer design, which generates an 
amplicon of 124 bp in both subfamilies. Primers and thermal cycles are given in appendix A, 






Figure 5.4. Primers designed to target active L1 subfamilies. In-silico PCR screenshots taken from UCSC genome 
browser (mm10). Amplicon sequences provided underneath screenshot (primer is capitalised and bold, mismatch 
is red). (A) In-silico amplification of L1Md_A (e.g. chr2:108,553,343-108,553,466). (B) In-silico amplification of 





5.3.1.4 Validation of LINE-1 amplification from cDNA not gDNA 
Typical primer design for qPCR involves the primers complimentary to sequences in separate 
exons to exclude the amplification of larger products containing introns from potential 
contaminating gDNA (section 2.2.1.2). In the case of L1 mRNA amplification, it was crucial to 
determine that no gDNA was present in the cDNA sample. This is because L1 contains no 
introns, therefore any potential amplification from gDNA cannot be distinguished from that 
amplified from cDNA. The large number of L1 copies in gDNA would also provide a substantial 
amount of template even in a small amount of contamination, presenting a great potential 
source of error. To address this, all RNA samples were treated with DNaseI prior to cDNA 
synthesis. No reverse transcriptase controls and no template controls were included in each 
qPCR (Figure 5.5). The lack of amplification in the no reverse transcriptase control confirmed 
the absence of endogenous gDNA in the RNA samples used for cDNA synthesis. The no 
reverse transcription control was prepared using the RNA sample that yielded the greatest 
concentration and logically more likely to contain gDNA contamination. The lack of 
amplification in the no template control also confirmed the absence of exogenous gDNA 
contamination present in the prepared samples and reagents used. Therefore, we were 
confident that all amplification measured in this assay is a true reflection of mRNA levels and 






Figure 5.5. Amplification plots from cDNA templates and controls. Amplification from cDNA showing sigmoidal 
curves. Absence of amplification in no RT (reverse transcriptase) controls and no template controls show cDNA 





5.3.2 Profiling L1 and TDP-43 expression in DRG from mouse model of ageing 
We assessed L1 and TDP-43 mRNA expression in DRG taken from Thy1-YFP mice of increasing 
age; males ranging from 3 to 49 weeks and females ranging from 3 to 57 weeks. At least three 
mice of each sex were sampled at each age group. RNA was extracted from DRG samples 
from individual animals and cDNA was synthesised, keeping biological samples separate (RNA 
was not pooled). qPCR was performed to assay the expression of target genes L1 and TDP-
43. Relative quantification of target genes was normalised against ACTB and PPIA. Male and 
female data was analysed separately due to differences in age groups sampled. For instance, 
older female age groups were 31, 42 and 57 weeks and older male age groups were 20, 35 
and 49 weeks. This difference in age groups was due to the universities ethical policy 
regarding keeping animal usage to a minimum. At the time of study, the animals presented 
here offered a good range of age groups for both sexes (despite not being identical) and could 
provide useful biological samples, therefore they were utilised instead of buying and culling 
additional aged mice. The youngest mice aged 3 weeks were used as the biological control 
group in both sexes. To assist with data interpretation, the approximate age ranges of mice 
and their human life equivalencies is given in Table 5.2. 
Table 5.2. Life phase equivalencies of human and mice. Equivalencies are representative of C57BL/6 strain. 
Adapted from https://www.jax.org/news-and-insights/jax-blog/2017/november/when-are-mice-considered-old.  
Mouse age range (weeks) Mouse age range (months) Human age range (years) Life phase 
13-26 3-6 20-30 Mature adult 
43-60 10-14 38-47 Middle aged 






5.3.2.1 L1 expression increases in ageing DRG 
We measured L1 mRNA expression in ageing DRG (Figure 5.6). We observed a decrease in L1 
mRNA in females at 10 weeks that was approaching, but did not reach significance 
(0.54±0.44, n=3, P=0.08) (Figure 5.6A) . A decrease was also observed in the males at 10 
weeks (0.87±0.05, n=3, P=0.59) (Figure 5.6B). Whilst not significant, this decrease was 
observed in both analyses, perhaps reflecting a true biological effect. We observed no 
difference in L1 expression in females at 12 weeks (1.12±0.20, n=3, P=0.66) (Figure 5.6A) or 
in males (1.16±0.23, n=3, P=0.86) (Figure 5.6B) when compared to controls.  
However, in both sexes, as age increased, we begun to see a trend of increased 
expression that was first observed in ‘mature adulthood’ and was maintained throughout 
ageing. Older age groups differed between males and females however the same trend was 
observed. In females age 31 weeks we observed a 16-fold increase in L1 (16.34±4.80, n=3, 
P=0.08) (Figure 5.6A). A 12-fold increase was also observed in males at 20 weeks (12.52±1.80, 
n=3, P=0.05) (Figure 5.6B). This increase was maintained in both sexes. Females showed an 
8-fold increase at 42 weeks (8.44±1.90, n=3, P=0.08), and a 12-fold increase at 57 weeks 
(12.36±0.92, n=3, P=0.08) (Figure 5.6B). Males showed a 19-fold increase at 35 weeks 
(18.81±2.50, n=3, P=0.05) and a 15-fold increase at 49 weeks (15.92±0.05, n=3, P=0.05) 
(Figure 5.6B).  
The overall trend observed here was that L1 expression increased in DRG with age in 
males and females by several fold. Initially, we were surprised to observe fold changes of 
such magnitude and suspected it may be due to sample processing errors. Genomic DNA 
contamination would provide a large source of L1 template and likely result in a huge amount 
of amplification, and detection at earlier cycles in the qPCR reaction. We did not observe this 
and ran reverse transcriptase controls during each amplification to confirm absence of gDNA 
template (Figure 5.5), therefore we were confident that the large fold increases observed in 






Figure 5.6. L1 mRNA expression increases in ageing DRG. Relative expression of L1 normalised against ACTB and 
PPIA. Mice at 3 weeks used as biological control. Error bars indicate standard error of the mean. Significance 




5.3.2.2 TDP-43 expression increases in ageing DRG 
TDP-43 mRNA expression was then measured to identify potential correlations with L1 mRNA 
expression (Figure 5.7). In females, no difference in relative expression was observed at 10 
weeks (1.09±0.21, n=3, P=0.66) or at 12 weeks (0.97±0.14, n=3, P=1.00) (Figure 5.7A). This 
was also the same in males, with no difference at 10 weeks (0.99±0.05, n=3, P=1.00) or at 12 
weeks (1.04±0.07, n=3, P=0.86) (Figure 5.7B).  
Similarly to the data trends observed for L1, we began to see an increase in the older 
age groups. Females showed a 2-fold increase at 31 weeks (2.10±0.23, n=3, P=0.08) (Figure 
5.7A). This increase continued at 42 weeks, showing a 3.5-fold increase (3.47±0.72, n=3, 
P=0.08) and at 57 weeks, showing a 4-fold increase (3.96±1.30, n=3, P=0.08) (Figure 5.7A). 
The same overall trend was observed in males.  
Males at 20 weeks showed a 3-fold increase (2.98±0.77, n=3, P=0.05) (Figure 5.7B). 
Interestingly, the levels then began to decrease with age yet were still far greater than those 
at the younger age groups. Males showed a 2.6-fold increase at 35 weeks (2.62±0.11, n=3, 
P=0.05) and a 2-fold increase at 49 weeks (2.16±0.15, n=3, P=0.05) (Figure 5.7B).  
Overall, we consistently observed increased levels in TDP-43 expression in DRG from 
aged mice compared to young controls. Similarly to L1, this increase was observed during the 





Figure 5.7. TDP-43 expression increases in the ageing DRG. Relative expression of L1 normalised against ACTB 
and PPIA. Mice at 3 weeks used as biological control. Error bars indicate standard error of the mean. Significance 




5.3.3 L1 and TDP-43 expression in brain from mouse model of inflammation 
The previous section described L1 and TDP-43 mRNA expression in the DRGs sampled from 
Thy1-YFP mice of increasing age. This section describes gene expression changes in the 
C57BL/6 mouse model of the ageing brain, including conditions of dietary induced 
inflammation and in response to an anti-inflammatory treatment. No DRG were available 
during this study, which took place after the ageing DRG study in the previous section 
(therefore comparisons between these models are limited). Please refer to the overview of 
the biological groups and relevant comparisons made (Figure 5.8). RNA was extracted from 
the brains of individuals from each group, DNase treated, and cDNA was prepared. qPCR was 
conducted to measure L1 and TDP-43 mRNA, using the same methods developed for the 
ageing DRG Thy1-YFP model however relative quantification of target genes was normalised 
against B2M and PPIA. Male and female data was assessed independently as ES-62 increases 
median lifespan in males C5BL7/6 but not females302.  
 
Figure 5.8. Overview of biological groups available in ageing brain C57BL/6 mouse model. 4 groups were 
available in this model that differed in age, diet and treatment. Comparisons were made between relevant groups 
to assess if different variables (highlighted in bold) had any effect on L1 and/or TDP-43 mRNA expression. Group 
A and B were suitable compare for effects of ageing. Group B and C were suitable to compare for effect of dietary 




5.3.3.1 L1 expression does not increase in ageing brain 
To investigate L1 expression in the ageing brain in this model, brains were harvested from 
male and female mice at 8 weeks and 71 weeks. All mice were fed a normal chow diet in 
these groups therefore were assessed for the effect of age only. Unfortunately, female cDNA 
samples at 71 weeks did not amplify any product during qPCR (for either reference gene or 
target gene) therefore relative gene expression analysis could not be conducted in this 
instance. The reason for this failure could not be determined. The male samples were 
successful, and we observed a 1.1-fold increase in L1 expression in mice at 71 weeks 
(1.43±0.32, n=5, P=0.52) (Figure 5.9A). Previous studies show L1 expression increases with 
ageing84-86, which was also supported by our data from the ageing DRG model showing 
several fold increase after 12 weeks (Figure 5.6B), therefore we were surprised to not 
observe a significant increase in L1 mRNA in the brain at 71 weeks. Males at 71 weeks showed 
a significant 1.4-fold decrease in TDP-43, corresponding to a 30% decrease (0.72±0.09, n=5, 
P=0.04) (Figure 5.9B).  
 
 
Figure 5.9. L1 and TDP-43 expression in the ageing male brain. (A) L1 expression in brains sampled at 8 weeks 
and 71 weeks. (B) TDP-43 expression in brains sampled at 8 weeks and 71 weeks. Relative expression of L1 
normalised against B2M and PPIA. Error bars indicate standard error of the mean. Significance indicated by 




5.3.3.2 L1 and TDP-43 expression is unaffected in the ageing brain in response to high fat 
diet  
Previous studies have demonstrated that mice fed a high fat diet have a 5-fold increase in 
TDP-43 mRNA in the liver303. Calorie restriction reduces L1 mRNA expression approximately 
1.6-fold in aged mice skeletal muscle and liver84. In addition, L1 hypomethylation in 
peripheral blood is associated with obesity in humans304. Therefore, we were interested to 
see if the effect of a high fat diet had any impact on TDP-43 and L1 mRNA expression in the 
brain. No data from female mice in the chow fed group was available therefore data analysis 
could not be conducted. In males, we observed a 1.3-fold increase in L1 expression in 
response to a high fat diet (1.26±0.24, n=6, P=0.64) (Figure 5.10A). There was no difference 
in TDP-43 expression in response to a high fat diet (0.98±0.14, n=6, P=0.92) (Figure 5.10B). 
Our results show no evidence that high fat diet affects TDP-43 or L1 expression in this model.   
 
 
Figure 5.10. L1 and TDP-43 expression in the aged brain and in response to high fat diet. (A) L1 expression in 
brains of mice fed a chow or high fat diet. (B) TDP-43 expression in brains of mice fed a chow or high fat diet. 
Relative expression of L1 normalised against B2M and PPIA. Error bars indicate standard error of the mean. No 






5.3.3.3 L1 and TDP-43 expression increases in response to anti-inflammatory drug ES-62 
We assessed if ES-62 treatment had any impact on L1 and/or TDP-43 mRNA expression. As 
the results show in previous section 5.3.3.2, the effect of a high fat diet did not affect TDP-
43 or L1 expression. However, we proceeded and measured L1 and TDP-43 in the aged brains 
of mice that were fed a high fat diet and then treated with anti-inflammatory drug ES-62 or 
PBS (refer back to Figure 5.8). Mice injected with PBS were used as the control group.  
We observed a 3-fold increase in L1 expression in male mice treated with ES-62 
(2.97±1.6, n=5, P=0.31) (Figure 5.11A) and a 3.5-fold increase in female mice treated with ES-
62 (3.55±1.1, n=6, P=0.23) (Figure 5.11B) compared to controls. We observed a similar trend 
when measuring TDP-43 mRNA. In males we observed a 3-fold increase in TDP-43 (3.05±1.8, 
n=5, P=0.52) (Figure 5.11C) and a 2-fold increase in females (1.84±0.35, n=5, P=0.13) (Figure 
5.11D) compared to controls.  
None of the results were statistically significant, likely due to the levels of variability 
in relative expression values. It should be noted that these higher levels of variation were 
only observed for the ES-62 treated group and not the PBS treated group, nor any of the 
other biological groups assayed in this model, suggesting variable but biologically significant 





Figure 5.11. L1 and TDP-43 expression in the ageing brain and in response to ES-62 treatment. (A) L1 expression 
in male brains in response to PBS (control) or ES-62 treatment. (B) TDP-43 expression in brains in male brains in 
response to PBS (control) or ES-62 treatment. (C) L1 expression in female brains in response to PBS (control) or 
ES-62 treatment. (D) TDP-43 expression in brains in female brains in response to PBS (control) or ES-62 treatment. 
Relative expression of L1 normalised against B2M and PPIA. Error bars indicate standard error of the mean. No 







Neuroinflammation in the central and peripheral nervous system is a key driver of 
neurological disorders and chronic pain185. Recent work has identified age-associated 
accumulation of cytoplasmic L1 cDNA and induction of inflammation85,86. However, the 
majority of the literature regarding L1 in neuroscience has focused on the mechanism of 
mobilisation and its contribution to neurodegeneration in the central nervous system. Here 
we aimed to expand on this by developing a qPCR assay to measure L1 mRNA expression in 
several contexts.  
First, we hypothesised that age associated derepression of L1 would occur in the 
peripheral nervous system. Therefore, we addressed L1 expression in DRG in an ageing 
mouse model. Secondly, we hypothesised that L1 expression would be affected in response 
to dietary induced inflammation in the brain, potentially carrying lifestyle implications for the 
ageing population, therefore we addressed L1 expression in HFD induced inflammation in the 
brains of mice. Thirdly, we hypothesised that TDP-43 mRNA expression would change with 
age, and potentially be modulated in response to diet - implicating TDP-43 in a broader 
context of neuronal dysfunction. Therefore, we also measured TDP-43 mRNA alongside L1 in 
both DRG and brains of mice.  
Here we have successfully developed a robust methodology to measure L1 mRNA 
expression in the mouse using qPCR. An RNA-seq based approach such as TEtranscripts would 
offer a complete overview of TE expression however this is not always feasible305. We 
recommended the use of specific reference genes for use in ageing mouse models, based on 
RT-PCR (Figure 5.1 and Figure 5.2). The primers for this qPCR assay specifically targeted the 
active murine L1 subfamilies L1Md_T and L1Md_A. The current consensus from human cell 
line models and human tumours have identified that L1 expression and resulting mobilisation 
events occur from a few select loci encoding active L1 sequences – referred to as “hot 




(to date there is one defined example at chr4:21650298–21,656,544 (GRCm38/mm10))308, 
yet this assay captures expression of such “hot” L1 elements that encode the machinery 
required to cause DNA damage and retrotranspose. This assay could therefore be useful in 
future experiments to correlate expression with other data e.g. methylation status of hot L1s 
and/or interferon levels, to further understand L1 mRNA expression in neuronal models of 
ageing.  
The onset of human chronic pain is associated with increasing age1,309. Degeneration 
of DRG has also been documented to occur in ageing mice, specifically first observed during 
middle age (11 to 13 months)283. L1 activation has previously been documented to occur in 
ageing mouse liver and skeletal muscle and is a proposed mechanism of neuronal 
dysfunction. However, to date, no investigation of L1 in the peripheral nervous system has 
been reported in either mouse or human.  We identified a decrease in L1 mRNA expression 
in DRG in both males and females aged 10 weeks (Figure 5.6). Female mice typically reach 
sexual maturity by 8 weeks and males by 5 weeks (however can vary between mouse strain) 
thus the effects seen here may be some reflection of puberty. Hormone levels can affect the 
levels of L1 expression310,311. L1 and Alu methylation status has also been linked to hormone 
levels and age of puberty onset/sexual maturation312. There is currently no literature 
specifically addressing retrotransposon expression and sexual maturation/puberty however 
defective piRNA pathways and aberrant L1 expression have been been implicated in 
Cryptorchidism, a disorder caused by a hormone imbalance during mini-puberty313. This 
highlights an interesting avenue to further explore the expression of L1 not just in 
development and ageing, but also in other life phases that may be subject to large hormonal 
influences.  
One of the main findings in this chapter was that L1 mRNA expression was detected 




increases showed at least a 12-fold increase after 20 weeks, with the largest increase of 19-
fold occurring in males at 35 weeks (Figure 5.6B). De Cecco et al. previously described a 6-
fold increase in muscle of mice aged 36 months (156 weeks) compared to young controls 
aged 5 months (21 weeks)84. In a follow up study, aged mice at 24 months (104 weeks) and 
young controls at 4 months (17 weeks) were used and showed the same trend86. L1 mRNA 
increases varied greatly across tissue with age, for example; 3-fold (intestine), 10-fold (liver) 
and 60-fold (skin)86. This also placed into context that the large fold changes observed in our 
ageing model were not unreasonable. To further this, Bedrosian et al. recently reported that 
L1 mRNA is detected in mouse hippocampus at the early post-natal stage (P0-P7)44. However, 
from these studies it is not clear at which life phase L1 mRNA expression may increase. We 
used mice that represented several stages of life and profiled a significant increase in L1 
mRNA at a similar age to the controls previously used, highlighting changes in L1 likely occur 
much earlier than previously documented.  
To summarise, previous studies placed emphasis on the increase in L1 in aged tissues 
and imply this is a biological effect of old age, yet our results here highlight that in the dorsal 
root ganglia there is an increase during ‘mature adulthood’ that is maintained throughout 
age.  The age ranges addressed in our DRG model demonstrated an increase in L1 mRNA 
expression in the mouse life phase that equates to ‘mature adulthood’, which holds 
relevance for the study of age-associated disorders like cancer and neurodegeneration. 
Mature adulthood is also the age at which we observed an increase in chronic pain 
prevalence in humans, therefore it is tempting to hypothesise that this may be a mechanism 
associated with the onset of chronic pain1,309.  
It has been reported that the increase of L1 expression is associated with an increase 
in INF-α and INF-β expression86. Some evidence supports INF-α as an endogenous pain 




neuroinflammation, which also occurs in DRG following nerve injury314-316. This highlights that 
more work is needed regarding the role of type I interferon response in ageing DRG, and to 
assess its potential contribution to age associated pathology. IFN expression should be 
measured in a follow up study. 
The increase in L1 expression was also correlated with an increase in TDP-43 
expression occurring at the same time points (Figure 5.7), supported by the current literature 
reporting overexpression of TDP-43 and derepression of TEs92. TDP-43 mRNA levels have 
been shown to decrease with ageing however the previous studies only measured mRNA in 
brains of mice up to 50 days old (7 weeks)103,104. Our data extends much further beyond this 
time point and is more appropriate and reflective of age-associated neuronal changes. TDP-
43 has been minimally described in the DRG but no study has yet been done to address mRNA 
levels in ageing DRG285-287,317, our data is the first report of age-associated changes in TDP-43 
mRNA in the DRG.  
Krug et al. demonstrated that overexpression of hTDP-43 in Drosophila impaired 
siRNA silencing and resulted in an increase in TE expression, which is consistent with our data 
showing an increase in TDP-43 and an increase in L1 expression92. Neuronal expression of 
TDP-43 has been shown to affect age-dependent efficacy of siRNA silencing92. The 
mechanism for this effect is yet to be elucidated however it is predicted that TDP-43 directly 
interacts with siRNA machinery318. There is overwhelming evidence that overexpression of 
TDP-43 results in neurotoxic effects which contributes to neurodegeneration94-102. Several 
case studies have also implicated TDP-43 in sensory neuropathy yet so far it has been 
generally ignored as a potential contributor to sensory neuron degeneration285-287. This study 
highlights changes in age-dependent TDP-43 mRNA levels in DRG, and thus L1 derepression 
as a potential mechanism contributing to age associated degeneration in the peripheral 




It must be highlighted that the Thy1-YFP mice used for this part of the study are 
transgenic, originating from (C57BL/6J x CBA)F1. The transgene contains the gene for yellow 
fluorescent protein (YFP), cloned from jellyfish, under the thymus cell antigen 1 promoter200. 
This promoter is a 6.5 kb fragment cloned from the 5’ upstream region of the gene Thy1, that 
drives neuron specific expression, therefore YFP is expressed in DRG200. There are several 
strains of this transgenic mouse. The insertion site in the strain used in this study (B6.Cg-Tg 
(Thy1-YFP)16Jrs/0) has not yet been mapped (for further information, refer to the MGI 
website http://www.informatics.jax.org/allele/MGI:3505585). Potential confounding effects 
of this transgene on global gene expression, and in particular, the effects on L1 expression 
are currently unknown. Several abnormal neuronal phenotypes have been reported in the 
YFP strain, including abnormal; cerebral cortex pyramidal cell morphology319, neuromuscular 
synapse morphology and synaptic transmission320, therefore the results from this study 
should not be extrapolated to non-transgenic models until the appropriate studies have been 
completed. The Thy1-YFP strain was utilised in this study due to difficulties obtaining 
wildtype mice of appropriate ages, therefore this study should be repeated in a wildtype 
mouse strain such as C5BL7/6 to rule out potential confounding effects on gene expression 
resulting from the YFP transgene. 
In contrast to the result observed in DRG, in the brain we observed a decrease in 
TDP-43 with age (Figure 5.9B), consistent with in vivo Drosophila and mouse models that 
show TDP-43 mRNA expression decreases with age103,104. In vitro studies have also previously 
identified a 32% decrease in aged mouse primary cortical and motor cells321. The data from 
this model supports the literature describing a decrease of TDP-43 mRNA in the ageing male 
brain. The literature also describes an increase in TE expression in response to loss of nuclear 
TDP-4393, attributed to loss of Dicer-2 mediated siRNA silencing322 and heterochromatin 
maintenance323, however we only observed a small increase in L1 mRNA expression which 




seen in controls. Differential L1 copy numbers have been identified in certain regions of the 
brain (e.g. hippocampus has elevated levels)324 therefore it could be possible that as we 
processed the entire left hemisphere of the brain, any increases in mRNA levels in specific 
brain regions were diluted during processing. In contrast, TDP-43 is ubiquitously expressed 
therefore age associated changes would be easier to detect.  
Diseases associated with obesity such as type II diabetes, cardiovascular disease and 
cancer are the fastest rising in terms of prevalence in the western developed world325. 
Excessive consumption of high fat diets contributes to these health problems and 
mechanistically induces chronic low-grade inflammation in the central nervous system326. 
Dietary changes can affect the methylation status and expression of L1 and TDP-43, however 
this has previously only been addressed in muscle and adipose tissue84,303,304. Therefore, we 
were interested to assess if a high fat diet had any effect on expression of L1 and TDP-43 
mRNA specifically in the brain. We found no evidence that high fat diet induced changes in 
L1 or TDP-43 expression using the HFD induced inflammation model.  
The HFD induced inflammation model was fairly limited in assessing changes in 
expression as it was based on comparison of mice at a single age point in response to diet. 
No young controls that were fed different diets were available. The effect of dietary induced 
inflammation affects certain regions of the brain more than others (e.g. cerebellum but not 
cortex), therefore processing the whole brain may have dampened any observable changes, 
as discussed previously326. Upon reflection, a better study would be to profile L1 expression 
in response to a high fat diet with age using several time points specifically in the cerebellum 
(adopting a similar approach to the DRG model). As we previously documented age-
associated increase in L1 in DRG, it would be relatively easy to extend the relevance of this 
study to pain, by sampling DRG taken from the HFD induced inflammation mouse model. 




the time of study (due to difficulties obtaining tissues from collaborators), however it is highly 
recommended that these expanded studies should be completed in the future to offer more 
insight into the interplay between ageing, diet and retrotransposon expression and how this 
may affect the peripheral nervous system.  
The anti-inflammatory secretory product of A. viteae, ES-62, has successfully been 
used to treat some inflammatory conditions (e.g. arthritis291, asthma292 and systemic lupus 
erythematosus293) however in some murine autoimmune models it has failed, including type 
I diabetes, multiple sclerosis and inflammatory bowel disease327. It has been postulated that 
the MyD88-dependent signalling that is targeted by ES-62, may be compensated for by some 
other inflammatory pathway, resulting in the intended anti-inflammatory effects to fail. In 
this model, we observed an increase in both L1 and TDP-43 expression in response to ES-62 
treatment. This was not observed in response to high fat diet in aged mice, therefore the 
effects here either are because of ES-62 alone or a combinatorial effect between ageing, high 
fat diet and treatment. The relevant controls were not available in this model to decipher 
which variables contributed to this effect.  
ES-62 disrupts MyD88 dimerisation and impairs the induction of inflammatory 
cascades involving NF-κB and MAPK328. Inhibition of MyD88 leads to defective ERCC1-DNA 
repair (via NER) and accumulation of DNA damage61,329. Ercc1 deficient mice contain 
increased numbers of γ-H2AX foci in cells (indicative of DSBs) and in vitro studies have shown 
that ERRC1 deficiency results in increased levels of L1 mobilisation330,331. ERRC1 has also been 
suggested to play a role in the orientation bias observed in L1 insertions in transcribed 
genes332. This highlights a direct role between ERCC1 and L1 activity. MyD88 is involved in 
immune activation in response to pathogenic nucleic-acids (detection via TLR7 and TLR9) and 
has been shown to play a role in systemic lupus erythematosus (SLE)333. However since 




mediated through cGAS/STING signalling85,86. Deficiency of MyD88 has no effect on the 
induction of cGAS, suggesting that these two inflammatory pathways are independent334. 
Therefore, we propose a hypothetical mechanism by which ES-62 could potentially disrupt 
ERCC1-mediated DNA repair and result in an accumulation of DNA damage, loss of 
suppression of L1 and ultimately result in an increase of L1 mRNA (Figure 5.12). It must be 
emphasised that this is a theoretical explanation for the increases observed in L1 expression 
and more studies would need to be conducted to test this hypothesis.  There is no relevant 
information available in the literature regarding the relationship between TDP-43 and 
MyD88, however in the same Ercc1-deficient mouse model as previously described, a follow 
up study found that TDP-43 pathology (namely cytoplasmic inclusions/aggregates) were not 
affected335. Inhibition of MyD88 (via ES-62) supresses activation of NF-κB, which has been 
shown in a separate study to decrease TDP-43 expression336. This was not the effect seen in 
our study, suggesting that another unknown mechanism may be responsible. It has not yet 
been confirmed whether the ES-62 SMAs can cross the blood-brain barrier and target MyD88 
as described. The blood-brain barrier is compromised in the case of inflammation, resulting 
in increased permeability337. Even if ES-62 cannot cross the barrier and directly affect MyD88 
in the brain, some response in the brain is evident, therefore further research should still try 
to dissect what mechanism is responsible.  
The sample sizes used in this study were relatively small, as this study was intended 
to act as an initial proof of principle. Despite trends being observed, relative expression 
values were variable which when combined with a small sample size, led to statistical 
significance not being reached. This study would benefit from increasing the sample sizes, 
which could also be ethically justified now that the initial results have given cause for further 
investigation. It must also be emphasised that differences in L1 and TDP-43 trends observed 
in DRG and brain should be interpreted with caution. The differences observed may simply 




background) and housing conditions between Liverpool and Strathclyde. All C5BL7/6 mice 
used in the high fat diet model in Strathclyde were treated with fenbendazole to control 
pinworm, whereas the Th1-YFP mice used in the ageing model in Liverpool were not. 
Fenbendazole has been reported to affect mRNA expression of transcription factor E2A and 
also impact the activation of B lymphocytes in aged mice (22 months compared against 2 
months)338. As the work conducted in this chapter focused on both neuroinflammation and 
ageing, this treatment may have contributed to differences observed between animal 
models used in these studies. The potential impact on the targets studied in this project are 
unknown. This is a potential effect that may have and is therefore an important consideration 
for future experimental design. Many of these mice sampled (e.g. males and females used in 
ageing DRG study) were litter mates. Bedrosian et al. demonstrated that murine L1 mRNA 
expression can be influenced in the first week of life by the level of maternal care received 
by the animal, e.g. less maternal care resulted higher L1 mRNA levels compared to those that 
received high maternal care44. Less maternal care was also associated with greater L1 mRNA 
variability between individuals. Maternal care was not controlled for in this study therefore 
is an important factor to consider, especially with small sample numbers. Future experiments 
should be conducted using a single mouse model to enable direct comparison of data across 
tissues.  
Our collaborators recently published a preprint documenting a >10% increase in 
lifespan in males treated with ES-62302. The ideas that both L1 mRNA and lifespan increased 
in the same model are not in agreement if we assume that increased L1 expression is 
detrimental to cellular function, which seems to be the dominating trend in the literature at 
present. Earlier work has demonstrated that increases in L1 retrotransposition is most 
common in the dentate gyrus, which is associated with memory and learning and adult 
neurogenesis339. Therefore increased L1 expression in the brain in non-pathological ageing 




necessarily be detrimental to the survival of an organism340. Further work is needed to 
quantify L1 mRNA expression levels with specific markers of cellular degeneration, which 
would rely on more advanced techniques than relative quantification in order to establish 
‘healthy’ basal levels and those considered ‘toxic’. To summarise, we have demonstrated L1 
and TDP-43 changes in various neuronal models of ageing and inflammation, highlighting that 
these targets may have relevance in non-pathological age-related neuroinflammation (i.e. 
not just in neurodegenerative disorders of the CNS), in both the peripheral nervous system, 
and in response to anti-inflammatory treatment ES-62 in the brain.   
In ageing DRG, we observed an increase in L1 in association with TDP-43 increase, 
however this may be a normal observation in ‘healthy’ animals and not necessarily reflective 
of any age-associated neurodegeneration in these animals. This study should be expanded 
to assess for markers of degeneration in DRG such as TrkC expression as described by 
Vaughan et al.283. To further this, IFN-α and IFN-β should be assayed to correlate with 
changes in L1 expression and assess the presence of L1 mediated neuroinflammation. TDP-
43 pathology research highlights the loss of nuclear TDP-43 and accumulation of cytoplasmic 
TDP-43 as a pathological mechanism, therefore this should also be assayed to assess if the 
age-associated changes are causative of any cytoplasmic inclusions, which may be of 
relevance to peripheral neuropathy and chronic pain pathology.  
Expression of L1 has two downstream consequences that we currently understand, 
the first is mobilisation which can cause genomic instability/novel insertions which ultimately 
rewires the genetic circuitry that dictates neurobiological processes. The second is induction 
of an interferon response via accumulation of L1 cDNA in the cytoplasm. We have provided 
the first evidence that L1 is expressed in the peripheral system, specifically DRG. If further 
studies can attribute L1 expression with neuroinflammation in the peripheral nervous 




transcriptase inhibitors (originally developed for HIV), which are currently being trialled in 
Aicardi–Goutières Syndrome, and showing effective reduction of interferon response341. We 
also documented an age-dependent increase in L1 mRNA associated with an increase in TDP-
43 expression, highlighting a target for further analysis regarding age associated neuronal 
dysfunction in the peripheral nervous system. Importantly we identified that changes in L1 
and TDP-43 expression occur in mature adulthood, not old age. Some recent studies have 
failed to identify any association between TDP-43 and L1 expression342,343. However, these 
methods were based on RNA-seq data which is subject to multiple errors (e.g. false positives 
resulting from exonisation). The literature places a large focus on L1 accumulation with 
ageing, but the relevant longitudinal studies in mammals have not yet been done. In addition, 
we have also documented an increase in L1 in association with ES-62 treatment, which 
highlights a potential alternative inflammatory pathway that may explain its failure in several 







Figure 5.12. Hypothetical model of ES-62 induction of L1 expression. (Left) Activation of inflammatory response 
via MyD88 in response to high fat diet. Activation of NF-κB and MAPK mediates inflammatory response. MyD88 
also enables ERCC1-DNA repair via Ras pathway. (Right) Inhibition of MyD88 via ES-62, and inhibition of 
inflammation through NF-κB and MAPK. Loss of ERCC1-mediated DNA repair could hypothetically lead to 
accumulation of DNA damage, genome instability and loss of L1 suppression. This in theory could induce 









6.1 Thesis summary  
The ultimate goal of this thesis was to conduct the first investigation into the potential role 
of retrotransposons in the context of chronic pain. To date, the field of pain genetics has 
made great use of genetic studies and animal models to identify the key molecular 
components of pain mechanisms, however the development of effective analgesics has not 
reflected this effort, partly due to a lack of translational research from rodent models to 
human. The work conducted in the first part of this thesis addressed the role of a human 
specific SVA insertion as a candidate regulatory domain for species specific differences 
observed in the expression patterns of pain genes TRPV1 and TRPV3. We provided evidence 
to support the SVA is functional as a human specific regulatory domain at this locus. 
Furthermore, we identified this SVA as polymorphic and demonstrated potential for its 
application as a biomarker for pain related phenotypes.  
The work conducted in the second part of this thesis explored neuronal L1 expression 
in different mouse models. L1 expression is associated with neuroinflammation in CNS 
neurodegenerative disorders and has been shown to increase in normal ageing in non-
neuronal tissues however no study has investigated the potential contribution of L1 activity 
to the neuroinflammation that is a driving force in the development of chronic pain. We 
identified age-associated changes in L1 mRNA expression in DRG, presenting the first insight 
into L1 activity in the peripheral nervous system. Our data also highlighted a role for L1 
activity in the brains of mice in response to the anti-inflammatory treatment ES-62, which is 
typically associated with increased longevity. This raised further questions regarding the 
pathogenicity of L1 in the ageing brain in the context of anti-inflammatory intervention. To 
summarise, the work undertaken in this thesis has highlighted the relevance of 
retrotransposons in several aspects of chronic pain research including species specific gene 






6.2.1.1 The SVA at the TRPV1 and TRPV3 locus is a human specific transcriptional 
regulator 
Translating findings from preclinical rodent models into effective therapeutics often fails – 
due to a lack of efficacy or unsafe side effects when therapeutics are tested in humans during 
clinical trials126,127. This in part due to genomic and transcriptomic differences between mice 
and humans. The mouse and human genome are highly similar in terms synteny, however 
many differences are apparent including the content of transposable element specifically in 
terms of lineage specific repeats (Figure 1.6), which has contributed to the evolution of each 
species (Figure 1.8).  
In the context of pain, RNA-seq studies comparing human and mouse DRG have 
identified a moderate level of conservation between the transcriptomes of humans and mice 
(63.8% genes shared similar tissue specific gene expression patterns) however have also 
highlighted a large degree of divergence between transcriptomes6, which is highly relevant 
in the context of understanding human pain pathways and therapeutic discovery. An 
example of this is demonstrated in the case of TRPV1 and TRPV3, two pain genes that are 
adjacent to one another on the same syntenic block between humans and mice (Figure 1.10), 
TRPV1 is expressed in DRG in both human and mice, yet TRPV3 is only expressed in human 
DRG (and not in mouse DRG) - highlighting species specific gene regulation6,9,10,152,174.  TRPV1 
and TRPV3 are symptomatic of the lack of translational research resulting from rodent 
models as several pharmaceuticals targeting these channels have failed to reach the clinic. 
Transposable elements influence species specific gene regulation, however have not been 
previously investigated in regards to species specific differences that may influence pain 
genes7,34.  
Chapter 3 focused on the transcriptional regulation of TRPV1 and TRPV3. 




region between TRPV1 and TRPV3, that was adjacent to a conserved ECR containing a MIR 
element which was predicted to function as a CRE (Figure 3.1). We hypothesised the SVA was 
functional as a novel CRE in the human genome, affecting human specific gene regulation 
and responsible for the species-specific differences described in the literature. Using reporter 
gene assays, the SVA was shown to function as a transcriptional regulator in the cell line 
HEK293 (Figure 3.6) and in murine DRG (Figure 3.8). This demonstrated the SVA sequence 
was functional in a neuronal cell type, which holds relevance for future studies investigating 
this element further in the context of pain. We did not obtain any evidence to support the 
role of the ECR as a transcriptional regulator in HEK293 cells, but reporter gene assays can 
vary greatly based on the cell line used215, therefore it should be tested in others.  
The SVA was then deleted in the cell line HEK293 using CRISPR (Figure 3.20). Cell lines 
containing a heterozygous deletion showed increased yet variable TRPV3 expression 
compared to unedited cell lines (Figure 3.26). We also observed variable TRPV1 expression 
in cells containing a heterozygous deletion (Figure 3.27). Homozygous deleted cell lines did 
not show the same variability as heterozygous deleted cell lines for either TRPV1 or TRPV3. 
HEK293 cells are reported to carry four copies of chromosome 17 therefore we estimated 
there were four copies of the SVA227. A different number of deleted SVA copies may explain 
this variability due to differential transcriptional influences. For example, in the context of 
TRPV3, a deletion of a single SVA copy may result in a slight increase in expression but the 
deletion of 2 copies may result in a greater increase.  
In chapter 4, it was demonstrated that the SVA was polymorphic in sequence length 
at the CT-rich domain (Figure 4.5). We concluded the variable results obtained in the 
heterozygous deletions may have been affected by different combinations of remaining 
alleles. We did not genotype the cell lines for polymorphism at the time of study however 




shown to function in response to stimuli, therefore TRPV1 and TRPV3 mRNA changes this 
should be addressed in future experiments should assess potential changes in response to 
inflammatory stimuli, which may give insight into the potential role of the SVA in the process 
of sensitisation. We were unable to generate any ECR deletions using CRISPR (Figure 3.23). 
The efficiency of the protocol may have been dampened by genomic structure or poor guide 
design.  
Taken together, the data presented in chapter 3 gives evidence to support the role 
of the SVA at the TRPV1 and TRPV3 locus as a human specific CRE which may in part explain 
the species-specific differences observed in the literature. To the best of our knowledge, at 
the time of writing this is the first report of a CRISPR mediated SVA deletion that is present 
in the reference genome (i.e. not an insertional mutation as previously demonstrated by the 
SVA in TAF1). The insertion of the SVA into this locus means it could potentially affect gene 
expression by the introduction of novel TFBS, affect DNA structure (e.g. G4 quadruplex 
formation as shown in chapter 4), or confer differential epigenetic modifications to the 
region.  
Ultimately, the SVA may be an important regulatory factor relevant to consider in 
human conditions characterised by increased levels of TRPV1 and TRPV3 expression. This 
work was focused on TRPV1 and TRPV3 as they are well known pain genes, however this 
study was not conducted in a pain model, therefore the findings presented here can also be 
expanded to other conditions in which aberrant regulation of these genes is relevant, e.g. 
increased TRPV3 expression is also implicated in psoriasis344. Going forwards, studies like this 
offer insight into the regulatory differences between rodents and humans, and highlight the 
functionality of TEs in species differences, which is crucial to understand in order to develop 
effective therapeutics. The future work to be completed regarding the functional activity of 




6.2.1.2 The SVA at the TRPV1 and TRPV locus shows potential as a biomarker for pain 
phenotypes 
Increased TRPV1 and TRPV3 mRNA expression is evident in tissues associated with pain163-
168,170,171. Multiple SNPs have been identified across the TRPV1 and TRPV3 locus in association 
with pain phenotypes245-249. Some SNPs have also been identified in association with TRPV1 
and TRPV3 mRNA changes in asthma (Supplementary figure 2), however the causal 
mechanism has not yet been identified. TEs represent a large source of polymorphism in the 
genome however are largely unexplored, due to their repetitive nature, which means they 
are often excluded from genomic data analyses and are therefore overlooked.   
In chapter 4, we investigated the SVA at the intergenic region between TRPV1 and 
TRPV3 for sequence length polymorphism. Using PCR, we identified at least 4 distinct SVA 
alleles which were conferred at least in part due to 4 different sized CT-rich domains (Figure 
4.3), which were all identified as common genetic variants in the general population. We 
identified using DNA sequencing the CT-rich domain was composed of different TCTCCC 
hexamer repeat copy numbers but also different copy numbers of a novel 17mer repeat 
(Figure 4.5). We showed this novel 17mer was present across multiple SVA subclasses 
throughout the genome, with a specific enrichment in subclass D (Figure 4.6). Subsequently, 
from this analysis we identified SVA subclass E and F are burdened with annotation errors in 
the current genome build hg38. This carries implications for evolutionary and genome wide 
studies of SVAs and further improvement to SVA annotation are required.  
Based on the CT variants identified, we genotyped two cohorts that were relevant to 
pain to look for associations between genotype/allele frequency and pain phenotypes and 
assess its potential use as a biomarker. The prevalence of pain is associated with ageing1 
therefore we first genotyped a healthy aged cohort (Dyne-Steele) with self-reported pain 
measures and identified significant associations between a heterozygous SVA genotype and 




with age, this would have to be genotyped in a far larger cohort with more robust pain 
measures. This however is unlikely as chronic pain is such a complex and heterogenous 
disease. As demonstrated by GWAS, identifying genetic variants in association with broad 
chronic pain phenotypes is difficult and likely not very informative in a biological context. If 
biomarkers can be developed to identify those at risk of pain with ageing, measures could be 
taken earlier in life to reduce risk (e.g. changes to diet to reduce neuroinflammation). Perhaps 
as our understanding of chronic pain develops in the era of personalised medicine, we will 
be able to more appropriately stratify chronic pain subgroups and manage this condition 
better.  
Tramadol, a strong opioid used to treat pain has been shown to function as an agonist 
of TRPV1258. Many patients treated with tramadol experience ADRs and poor analgesic 
efficacy257, hypothesised to be mediated in part by the activation of TRPV1. No genetic 
variants at TRPV1 have been studied with regards to tramadol response therefore we 
investigated SVA genotypes with these response outcomes in an osteoporosis cohort being 
treated with tramadol for bone pain. We also observed the same heterozygous SVA genotype 
(associated with self-reported pain in healthy aged individuals) trending in association with 
ADRs (Figure 4.12) and poor analgesic efficacy (Figure 4.10) in osteoporosis patients treated 
with tramadol for bone pain. ADRs and poor analgesic efficacy resulting from tramadol are a 
large problem not only for osteoporosis patients but for a patients suffering from pain in 
general257. Tramadol has also been shown to be a prime contributor to opioid misuse in the 
US4. As a result, if patients that are predicted to respond poorly to tramadol can be identified, 
this would prevent unnecessary administration of the drug. The SVA should therefore be 
genotyped in much larger cohorts to assess its utility as a biomarker for ADRs and efficacy in 
response to tramadol. In addition, we also identified an increased frequency of a specific SVA 
allele in males with osteoporosis (Figure 4.14B), but not in healthy aged individuals (Figure 




males however due to the small sample size this would have to be investigated in a much 
larger cohort. In summary, regarding the polymorphism of the SVA we found interesting 
associations that warrant further investigation. These studies are discussed in the “future 
work” section.  
In chapter 4, we also conducted a preliminary investigation into the methylation 
status of the SVA and identified there is an increased frequency of unmethylated copies in 
both temporal cortex and whole blood (Figure 4.19A and B), which could indicate the SVA is 
active. This would support the results observed in chapter 3, which indicated the SVA was 
functional as a transcriptional regulator at the TRPV1 and TRPV3 locus (Figure 3.6, Figure 
3.27). Interestingly, we also found variable methylation patterns across tissues between 
individuals (Figure 4.19D). No association could be made regarding links between the 
methylation status of the SVA and its genotype however it could be hypothesised that 
different SVA variants could be subject to different epigenetic modifications and thus confer 
different regulatory properties, i.e. function as an epiallele.  
We can apply the findings from chapter 4 to the variable gene expression results 
observed in the CRISPR modified cell lines generated in chapter 3 (Figure 3.20). Cell lines that 
carried a heterozygous SVA deletion displayed the most variable TRPV1 and TRPV3 
expression when compared to both wild-type controls and modified cell lines carrying a 
homozygous deletion (Figure 3.27). We discussed in the previous section (6.2.1.1) this could 
have been the result of a different number of SVA copies being deleted across the four copies 
of chromosome 17, however this could also be influenced by the different alleles remaining 
(if shown to be heterozygous). Furthermore, as we demonstrated the SVA is functional, the 
original hypothesis can be expanded beyond a simple genetic association of SVA variants and 
phenotypes. Due to the mechanisms in which TEs can affect gene regulation (Figure 1.7D), 




locus, and thus act as a functional genetic variant affecting TRPV1 and TRPV3 expression, 





6.2.1.3 L1 expression increases in mouse DRG with ageing  
Neuroinflammation is classed a hallmark of ageing and is an underlying driver of chronic 
pain1,280. L1 expression has also been shown to increase in ageing mouse non-neuronal 
tissues, which leads to an accumulation of L1 cDNA in the cytoplasm – which ultimately 
induces an inflammatory response85,86. In the CNS, a large body of research has emerged 
describing the loss of TE silencing and the induction of inflammatory markers as a contributor 
to neurodegenerative disorders like ALS89. Despite the increasing evidence that L1 is a 
contributor to neuroinflammation in the CNS, it has not yet been explored in the peripheral 
nervous system.  
In chapter 5, we developed a robust protocol to profile L1 mRNA expression in mouse 
tissues (as it was not possible for us to obtain human tissues) and produced an ageing DRG 
RNA resource representing mice from early life phases (e.g. pre-puberty) to middle aged. This 
functioned as a model to study age related changes in the peripheral nervous system, which 
is a key driver of pain. We found L1 was expressed in DRG across the lifespan of both male 
and female mice and observed a significant increase in L1 mRNA expression during the 
transition between early and mature adulthood (Figure 5.6). We were surprised to observe 
relatively large fold L1 increases as early as mature adulthood as previous studies had 
indicated this was symptomatic of old age. This observation is very interesting in regards to 
chronic pain, as this is the same age/life phase at which we observe an increase in chronic 
pain prevalence in humans1,309. However, before any conclusions regarding the biological 
impact in ageing DRG and links to pain can be made, several inflammatory markers must be 
profiled in this model. This is discussed in the “future work” section (6.3.3).  
TDP-43 is an RNA binding protein which has been heavily associated with L1 regulation. 
We observed a positive correlation between increasing L1 and TDP-43 mRNA with ageing in 
this mouse model (Figure 5.7). This could point to a response of TDP-43 in an attempt to 




increase in L1 – an observation documented throughout the literature. Whilst the 
relationship between L1 and TDP-43 is not clear until further studies have been completed, 
an overwhelming theme in the literature is that overexpression of TDP-43 is neurotoxic94-102. 
The bottom line is that we observed age-associated increase in both TDP-43 and L1 mRNA 
expression in DRG and increased expression of both has been heavily implicated in age 
associated neuronal dysfunction.  
A key study missing from the literature is DNA methylation profiling in the DRG with 
increasing age. This would offer insight into a potential cause of L1 expression in the ageing 
DRG, which has been discussed in multiple studies79-83. If the role of L1 in the ageing DRG can 
be demonstrated in the future to be a mechanism underlying sterile inflammation that 
contributes to the development of chronic pain, it would offer a novel therapeutic strategy. 
For example, reverse transcriptase inhibitors have been shown to limit interferon response 
in Aicardi-Goutieres syndrome341 (which is characterised by L1 activity) –  thus highlighting a 
way to dampen L1 induced inflammation in the peripheral nervous system. 
Whilst limited, there is evidence to support the role of L1 activation and 
retrotransposition in learning and memory, particularly in the dentate gyrus, and that L1 can 
be induced in response to stress to generate neuronal diversity339,340. Therefore, it must be 
considered that not all L1 activity is detrimental to an organism’s fitness. Based on the 
method of relative quantification, we cannot be certain if the increase level of L1 mRNA is 
problematic for the cell without the follow up studies to profile inflammatory or 
neurodegenerative markers. We can however conclude that L1 plays a role in the peripheral 





6.2.1.4 L1 expression is modulated in the ageing brain in response to treatment with 
anti-inflammatory drug ES-62  
Age-associated neuroinflammation can further be exacerbated in obesity, which is often a 
comorbidity that occurs with pain280,288,289. Therefore, the role of diet in L1 modulation was 
of interest to this project. In chapter 5, we expanded on the theme of L1 and age-associated 
neuroinflammation by measuring L1 and TDP-43 mRNA in the brains taken from a mouse 
model of HFD induced inflammation. We observed a decrease in TDP-43 mRNA in the brain 
of aged male fed normal chow (Figure 5.9B). No female samples were available for 
comparison however this did reflect reports in the literature that TDP-43 protein expression 
decreases with age103,104. We did not identify an increase in L1 mRNA expression in the brain 
(Figure 5.9A) however we postulated this may have been due to methodological issues – i.e. 
purifying RNA from the entire left hemisphere when L1 activity may depend upon brain 
region (e.g. increased activity in the hippocampus)324. We did not find any increase in L1 
mRNA or TDP-43 in response to high fat diet (Figure 5.10)– which did not support our 
hypothesis, however this study and the interpretation of the data could have been improved 
with the addition of young control mice fed normal chow or HFD.  
The most interesting finding from the HFD induced inflammation mouse model was 
an increase in L1 mRNA expression in HFD induced mice that were also subject to treatment 
with anti-inflammatory drug ES-62 (Figure 5.11). An increase in TDP-43 was also observed in 
this condition (Figure 5.11), again demonstrating a link between L1 and TDP-43 in a non-
neurodegenerative context. Previous studies using this drug had success when tested in 
various mouse models of inflammatory disease291-293 (e.g. asthma) but failure in autoimmune 
models (e.g. multiple sclerosis)345. It had been proposed that the MyD88 inflammatory 
pathway that is inhibit by ES-62 was compensated for by some other inflammatory pathway, 
as a possible explanation for the drugs failure327. From the data and a literature search of the 




proposed a model involving the DNA repair protein ERRC1 – which already has well 
established links with L1 activity330-332. In mice fed a high fat diet, a central inflammatory 
signalling protein named MyD88 triggers inflammation via NF-κβ and MAPK pathways328. It 
also induces the Ras pathway, which promotes DNA repair via ERCC161,329. In the presence of 
ES-62, these inflammatory and DNA repair pathways are inhibited61,329. The absence of ERCC1 
has been shown to result in an increase in both DNA damage and L1 mobilisation330,331. 
Previous work has further shown that L1 activity (and cDNA accumulation in the cytoplasm) 
induces inflammation through activation interferon response via cGAS/STING signalling85,86. 
Therefore in this model we hypothesised that ERCC1 is potentially inhibited by ES-62  via 
indirect inhibition of MyD88, resulting in DNA damage, loss of L1 suppression and induction 
of the interferon response (Figure 5.12). This alternate route to inflammation could explain 
the lack of efficacy in certain inflammatory models.  
Interestingly, ES-62 treatment in this HFD induced inflammation model results in a 
>10% increase in the lifespan of males302. One current theory is that somatic L1 activity 
associated with ageing negatively impacts longevity however this model suggests 
otherwise45. Our results did not identify any major sex specific differences in L1 at the time 
at which these animals were culled (500 days) (Figure 5.11), however it would be interesting 
to profile the L1 mRNA and markers of DNA damage in mice which are long-lived 
(approximately 700 days) after natural death to assess if increased levels of L1 can be 
tolerated and if differences occur between sexes. This may be an important indicator of 
healthspan, which is important to maintain with increased lifespan in any case. These findings 
demonstrate the interplay between DNA repair mechanisms and inflammatory responses 
and the importance of both mechanisms of cell maintenance and defence in terms of 
longevity. As a result of these findings, and of those in the ageing DRG model, further studies 
are now underway to explore age associated L1 induced inflammation in broader neuronal 




6.3 Future work 
6.3.1 Future experiments using CRISPR and cell lines containing SVA deletion 
To expand of the work conducted in chapter 3, we can explore the effects of the SVA deletion 
beyond the TRPV1 and TRPV3 locus and look more broadly across chr17p13.2 (Figure 3.1). 
This region was identified by Gianfrancesco et al. as one of 30 loci in the genome that were 
enriched for SVA insertions216. All SVAs at chr17p13.2 were enriched for SVA D, and the 
majority were human specific – indicating that this region of the genome had undergone 
significant change in recent evolutionary history. In addition, other genes at this 1 Mb region 
were described in pathways that are relevant to pain (Supplementary table 1).  
The CRISPR and qPCR protocol developed in this thesis provides a good framework 
to assess the impact of the SVAs on the regulation of other genes at this region. For example, 
does the deletion of the SVA at TRPV1 and TRPV3 affect the expression of other genes across 
the region? Or, how might deletion of all the SVAs at this region influence gene expression? 
This CRISPR protocol should also be applied to induced pluripotent stem cells (iPSCs), which 
can be differentiated into sensory neurons241, to further test the effects of the SVA in a model 
more appropriate to pain biology. This assay could also be applied to a HaCaT (immortalized 
human keratinocyte cell line) M5-stimulated model of inflammation to assess the SVA 





6.3.2 Linking SVA genotype to function 
To expand on the work conducted in chapter 4, the development of a tagging SNP is currently 
in the pipeline with our collaborators Neil Pendleton and Antony Payton at the University of 
Manchester. This involves a bioinformatic approach imputing SNPs using a software called 
PLINK (http://zzz.bwh.harvard.edu/plink/download.shtml). This will identify SNPs that are in 
linkage disequilibrium with specific SVA alleles and enable us to use the SNP as a tag. If 
successful, this will enable us to computationally genotype larger cohorts must faster than 
the PCR based approach and will enable us to explore associations with more phenotypes 
and/or correlate with other datasets to give insight into the function of the SVA.  
Our group also has access to data from the NABEC: North American Brain Expression 
Consortium. This dataset has SNP array, gene expression and methylation data from the 
brains of 382 neurologically healthy individuals. This would enable investigations into SVA 
genotype, methylation status and effects on TRPV1 and TRPV3 expression (which are both 
expressed in brain in human). The sample size of the preliminary study conducted in chapter 
4, in which we looked at the methylation status of the SVA, was too small to identify any 
associations between genotype and methylation status. The development of tagging SNPs 
would enable us to overcome this limitation. For example, we could explore questions such 
as: does SVA genotype associate with methylation status, and does this affect TRPV1 and/or 
TRPV3 expression?  
This methodology can also be applied to data generated by the 1000 genomes 
project which contains whole genome sequencing and RNA-seq for over 4000 individuals. 
This would enable us to discern links between SVA genotype and molecular phenotype. In 
chapter 4, we showed data to suggest that SVA genotype was potentially associated with 
complex phenotypes such as pain and response to tramadol. The development of a tagging 
SNP would enable other researchers to explore this variant in much larger cohorts and 




6.3.3 Further studies addressing L1 mRNA expression 
We are extending our collaboration with the University of Strathclyde to further assess the 
role of L1 and TDP-43 expression in the brain. Initial studies will profile inflammatory markers 
such as INFα and INFβ using qPCR, indicating an inducible interferon response from the 
presence of L1 cDNA86. This will also be conducted in the ageing DRG resource to address 
neuroinflammation associated with L1 in the peripheral nervous system. In addition, the 
roles of previously characterised genes that are associated with L1 activity in 
neurodegenerative disorders, such as SIRT6 and TREX1, will be profiled using qPCR to identify 
potential roles in the L1 mRNA changes observed in these models. To further assay the 
impact of L1 mRNA increases in neuronal models, genomic L1 copy number will also be 
measured using a PCR assay.  
We have also proposed a collaboration with the Pain Neurobiology Research Group at 
the School of Behavioural and Brain Science at the University of Texas Dallas (UTD), USA. This 
group perform RNA-seq in human DRG from healthy controls and individuals with well 
characterised pain. Utilising resources generated by collaborators and protocols developed 
throughout this project, we can address if L1 mRNA is expressed in human DRG, as was 
documented in mice, and profile the methylation status of “hot L1s” in relation to L1 mRNA 
expression. There is also scope within this project to measure genomic L1 copy number or 
even somatic insertions in the DRG (compared against whole blood) to give insight into the 
level of somatic variation that may exist in the peripheral nervous system. We can further 
correlate these findings with gene expression to address the functional relevance.  
In addition to work on L1, we can also address questions regarding the genotype of 
the SVA at TRPV1 and TRPV3 in relation to specific DRG molecular phenotypes using RNA-seq 
data. This will enable us to further address the relevance of this SVA insertion in pain 
pathways. Using a valuable resource like this will undoubtedly raise the profile of 




opportunity for therapeutic intervention and hopefully offer better understanding of age-
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Supplementary table 1. Associations between genes at chr17p13.2 with pain and inflammation. 
Gene Name Comment Reference 
ASPA Aspartocyclase 
Deregulation causes accumulation of N-acetyl 
aspartate and nitric oxide synthase resulting in 
neurodegeneration. Cause of Canavan disease.  
346 
SHPK Sedoheptulokinase 
Newly identified protein in the PPP pathway, 
which is implicated in neurodegeneration. 
347 
TAX1BP3 Tax-1 binding protein 
Overexpressed in osteoarthritis and plays a role 
in Wnt/B-catenin signalling which is deregulated 
in pain states 
348  
EMC6 
ER membrane protein 
complex subunit 6 
A novel regulator of autophagy, which is altered 
in experimental models of neuropathic pain  
349,350 
P2RX5 
Purinergic receptor P2X 
ligand gated ion channel 5 
Purinergic receptors are associated with 
neuropathic and inflammatory pain. This 
receptor is associated with ischemic pain 
resulting from exercise.  
351 
ITGAE Integrin subunit alpha E 
Role of integrins implicated in the maintenance 




dependent protein kinase 
kinase 1 
Role in regulating apoptosis, a process which is 
disrupted in DRG in association with 
neuropathic pain. Also plays a role in endosome 






reticulum Ca2+ transporting 
3 
Role in intracellular calcium homeostasis. 
Numerous links between calcium 
dyshomeostasis and neurological disease like 
Alzheimer’s, Huntington’s and Parkinson’s 
disease have been established therefore the 
role of ATP2A3 and calcium homeostasis may 
also be relevant in chronic pain pathways.  
356,357 
ZZEF1 
Zinc finger ZZ-type and EF-
hand domain vontaining 1 
Its function is unknown however the family of 
EF-hand Ca2+-binding proteins are one of the 
most common structural motifs in the cell and 
have a direct association with neurological 
disorders like Alzheimer’s, diabetes and chronic 
inflammatory disorders. Other family members 







Supplementary figure 1. Examples of DRG cultures. DRG sensory neurons were purified from Thy1-YFP mice 





Supplementary table 2. Summary statistics for relative luciferase activity values in reporter gene assays 






Supplementary table 3. Summary TRPV1 and TRPV3 expression differences in CRISPR modified HEK293 cell lines. 
Sample Mean Ct TRPV1 ddCt TRPV3 ddCt 
ACTB TRPV1 TRPV3 dCt Control 
dCt 
ddCt 2-∆∆Ct Mean SEM dCt Control 
dCt 
ddCt 2-∆∆Ct Mean SEM 
Unedited 21.04 31.85 32.81 -10.81 -10.89 0.41 0.75 0.80 0.03 -
11.77 
-11.85 0.10 0.93 0.97 0.05 
Unedited 21.68 32.68 33.65 -11.00 0.22 0.86 -
11.97 
-0.10 1.08 
Unedited 21.87 32.73 33.60 -10.87 0.35 0.78 -
11.74 
0.13 0.91 
ntgRNA control 21.49 32.52 33.17 -11.03 -11.22 0.19 0.88 1.01 0.09 -
11.67 
-11.87 0.19 0.88 1.02 0.14 
ntgRNA control 21.51 32.98 33.74 -11.46 -0.25 1.19 -
12.23 
-0.36 1.29 





22.83 33.68 35.78 -10.84 
 
0.37 0.77 1.18 0.51 -
12.94 
 
-1.08 2.11 4.56 2.87 
Edited 
(heterozygous) 










23.25 34.89 27.57 -11.64 -0.43 1.34 1.12 0.12 -4.33 7.54 0.01 0.66 0.39 
Edited 
(homozygous) 











Supplementary table 4. Summary statistics (Mann-Whitney U tests) for relative expression analysis of L1 
mRNA in ageing DRG Thy1-YFP mouse model. Data assessed was 2-∆∆Ct values. Data assessed separately for 






Supplementary table 5. Summary statistics for relative L1 and TDP-43 expression values in ageing brain 






Supplementary figure 2. Screenshot of SNPs in 3'UTR of TRPV1 associated with changes in TRPV1 mRNA expression. Screenshot of UCSC genome browser hg38 showing SNPs at the 3’ UTR 

































Supplementary table 6. QGRS sequences identified and used to predict G4 formation in full length SVA.  





213 241 28 GGAGACGGGTTTCGCTGTGTTGGCCGGG 12 
281 311 30 GGCCTCCCGAGGTGCCGGGATTGCAGACGG 17 
335 359 24 GGTGCCCAGGCTGGAGTGCAGTGG 15 
592 619 27 GGCCACGACCCCGTCTGGGAGGTGAGG 9 
730 741 11 GGAGGTGGGGG 21 
772 784 12 GGAGGTGAGGGG 18 
879 907 28 GGCCATGATGACAATGGCGGTTTTGTGG 9 
916 929 13 GGGGGAAAGGTGG 19 
1098 1119 21 GGTTAAATGGATTAAGGGCGG 17 
1218 1245 27 GGAAGGCCGCAGGGTCCTCTGCCTAGG 12 
Sense (3’-
5’) 
10 31 21 GGGAGAGGGAGAGGGAGAGGG 42 
46 76 30 GGAGAGAAAGGTGCCAGAGGGAGAGTACGG 20 
120 139 19 GGAGGGACGGACTAAGAGG 16 
141 160 19 GGAGTCGGACGGGTCACGG 20 
248 272 24 GGTCGAGGATTGGCGCTCACTAGG 15 
273 289 16 GGTCGGAGCCGGAGGG 19 
380 391 11 GGAGGTGGAGG 21 
397 413 16 GGACGGAACCGGAGGG 19 
431 448 17 GGAGACGGACCGGCGGG 19 
469 488 19 GGGAGACGGACCGACGGGG 15 
510 524 14 GGCGGGCCGGCGGG 21 
554 564 10 GGCGGCGGGG 20 
583 602 19 GGAGACGGGCCGGTGCTGG 20 
630 641 11 GGTCGGCGGGG 19 
658 668 10 GGGGAGGTGG 20 
714 725 11 GGTGGGGCAGG 19 
756 771 15 GGTCGGCGGGGCAGG 20 
786 804 18 GGAGACGGACCGGCGGGG 20 
830 842 12 GGCCGGTGGTGG 20 
1049 1063 14 GGAATGGGGGTTGG 19 
1224 1251 27 GGCGTCCCAGGAGACGGATCCTTTTGG 17 
1282 1310 28 GGAAGGGAGGTGATAGCAGGATACTGGG 19 
1312 1338 26 GGTTTAGGGGGAGACACTCTTTGTGG 9 
Supplementary table 7. QGRS sequences identified and used to predict G4 formation in CT-rich alleles.  
Allele Start Length QGRS G-Score 
a 
4 21 GGGAGAGGGAGAGGGAGAGGG 72 
29 38 GGGTACCAGAGGGAGAGGGAGAGAAAGGTGCCAGAGGG 59 
b 
10 21 GGGAGAGGGAGAGGGAGAGGG 72 
34 26 GGGAGAGGGGTACCAGAGGGAGAGGG 68 
68 27 GGGAGAGGGAGAGAAAGGTGCCAGAGG 34 
c 
4 21 GGGAGAGGGAGAGGGAGAGGG 72 
33 26 GGGAGAGGGGTACCAGAGGGAGAGGG 68 




Appendix A: Oligonucleotides and PCR cycling conditions 








Amplification of full 




SVA (full length) at TRPV1 
and TRPV3 locus 
GATACTCTACTCTGCTCTCCCT AGATACTAACACAACCTGCCCA 1511 n/a 
Touchdown PCR 
95 °C 5m 
 95 °C 30s 
65-55°c* 30s 
72 °C 1m 
 
35 cycles 
 *decreases by 1 °C 
across first ten 
cycles 
2 
Amplification of ECR 
for cloning 
hg19 
ECR adjacent to SVA at 
TRPV1 and TRPV3 locus 
ATTGAGCCATGACCACACC  AGGTTGTGTTAGTATCTGCGG 1196 n/a 
3 





hg19 SVA (CT-rich domain) GCTTGTGGATGCGTGTGTAT CAGTACAGTCCAGCTTCGG 424 n/a 
PCR 
95 °C 5m 
95 °C 30s 
63.6 °C 30s 
72 °C 30s 




Amplification of SVA 
VNTR 
hg19 SVA (VNTR) CCTCCCAAAGTGCAAAGC CGTTCTCAATGAGCTGTTGG 472 n/a 
PCR 
95 °C 5m 
95 °C 30s 
55 °C 30s 
72 °C 30s 




Amplification of SVA 
poly A region 
hg19 SVA (poly A region) CCTATGACCCTGCCAAATCC AGAGAACAGGGAGGAGGGAT 312 n/a 
PCR 
95 °C 5m 




65 °C 30s 
72 °C 30s 




inserts in pGL3-P 
n/a 
RV3 (forward read) 
GL2 (reverse read) 
(RV3) CTAGCAAAATAGGCTGTCCC  
(GL2) 
CTTTATGTTTTTGGCGTCTTCCA 
n/a n/a n/a 
7 CRISPR gRNAs  hg19 
gRNA1 TTTTGCAAAAGTACAACCACAGG n/a n/a n/a n/a 
gRNA2 CAAATTTACTCAGAGCTGGAAGG n/a n/a n/a n/a 
gRNA3 CTTTCAAATTTACTCAGAGCTGG n/a n/a n/a n/a 
gRNA4 AGCTGCAAACTTCTGCAAATTGG n/a n/a n/a n/a 
gRNA5 CCAAAACACCTCTCCTGGTAGGG n/a n/a n/a n/a 
gRNA6 CCAAAACACCTCTCCTGGTAGGG n/a n/a n/a n/a 
gRNA7 CTAACACAACCTGCCCAGTCTGG n/a n/a n/a n/a 
gRNA8 CCCAAAACACCTCTCCTGGTAGG n/a n/a n/a n/a 
gRNA9 AATGGGCTGGCATAGCTAATTGG n/a n/a n/a n/a 
gRNA10 TACGTGTGTGTACATTCCTATGG n/a n/a n/a n/a 










cell lines in CRISPR 
to assess SVA/ECR 
deletion 
hg19 SVA presence/absence AACGTGTTTACTGGCTGTGC AGCAGTGCCTTCTTCATCCT n/a n/a 
PCR 
95 °C 5m 
95 °C 30s 
60 °C 30s 
72 °C 1m 
72 °C 5m 
35 cycles 
10 
qPCR of total TRPV1 
and total TRPV3 
mRNA expression in 
CRISPR modified cell 
lines 
hg19 TRPV1 (cDNA) AGCAGTCGATTCTCTCTCTCTC GCTCCATTTCTTCATCCTTGCT 17026 240 qPCR 
95 °C 30s 
95 °C 10s 
60 °C 30s 
72 °C 15s 
hg19 TRPV3 (cDNA) ACGCACGTCTCCTTCCTTAA CTCTGGGTTCCGCTTCTACA 740 159 










RT-PCR of TRPV1 
and TRPV3 
transcript variants in 
CRISPR modified 




AGCAGTCGTATTCTCTCTCTCTC GCTCCATTTCTTCATCCTTGCT 17026 240 
Touchdown PCR 
95 °C 5m 
 95 °C 30s 
65-55°c* 30s 




 *decreases by 1 °C 









































ACGCACGTCTCCTTCCTTAA CAGGCTGGTCTCAAACTCCT 355 355 
12 
qPCR in mouse 
tissues 
mm10 LINE-1 (cDNA) CGTGATCCTAAGACCTCTAGTG CAGTGGGCAGAGTATTCTC 124 124 
qPCR 
95 °C 30s 
95 °C 10s 
60 °C 30s 
72 °C 15s 
 
40 cycles 
mm10 TDP-43 (cDNA) GCGATGGTGTGACTGTAAACT TCTACCACTTCTCCATACTGAC 1384 147 
mm10 ACTB (cDNA) GCCAACCGTGAAAAGATGAC GTACGACCAGAGGCATACAG 558 104 
mm10 B2M (cDNA) CATGGCTCGCTCGGTGAC CAGTTCAGTATGTTCGGCTTCC 3203 135 
mm10 GAPDH (cDNA) AGGTCGGTGTGAACGGATTTG TGACCTCAACTACATGGTCTACA 617 123 
mm10 GUSB (cDNA) CCGACCTCTCGAACAACCG GCTTCCCGTTCATACCACACC 1833 169 
mm10 HMBS (cDNA) ATGAGGGTGATTCGAGTGGG TTGTCTCCCGTGGTGGACATA 814 134 
mm10 HPRT (cDNA) TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 3769 95 




Appendix B: vector maps 
Vector map for pCRII 





Vector map for pGL3-Basic 






Vector map for pGL3-Promoter 







Vector map for pRL-TK 







Vector map for and pSpCas9(BB)-2A-GFP 
Sequence available at https://www.addgene.org/48138/sequences/  
 
 
